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Abstract 
 
T-cell mediated hypersensitivity reactions (HSRs) to carbamazepine (CBZ), a 
commonly used anti-epileptic drug, occur only in a small proportion of patients, 
but can often be severe in nature. As the underlying pathomechanisms are not 
fully understood, it has proven difficult to predict who may be at risk of 
developing CBZ-induced HSRs. Recently, specific human leukocyte antigen 
(HLA) alleles have been identified as susceptibility factors for CBZ 
hypersensitivity in diverse populations, indicating that HLA molecules may be 
functionally involved in CBZ-induced T-cell activation. HLA-A*31:01 represents 
the latest example and has been implicated in CBZ-induced HSRs in Caucasian 
patients. Thus, the aim of this work was to explore the molecular interactions of 
CBZ with HLA-A*31:01 and drug-specific T-cells. 
The HLA restriction pattern of CBZ-reactive T-cells from a patient expressing 
HLA-A*31:01 was investigated. It was shown that CD8+ T-cells were activated in 
a HLA-A*31:01 dependent way. Further, HLA-DRB1*04:04 was found to be 
responsible for the stimulation of CD4+ T-cells, suggesting a common HLA 
haplotype may be involved in mediating T-cell responses to CBZ in Europeans. 
Next, in vitro priming of drug-naïve T-cells from HLA-A*31:01+ healthy 
volunteers against CBZ was attempted. Weak responses to CBZ could be 
detected in some but not all volunteers, indicating factors additional to HLA-
A*31:01 are required to induce a primary stimulation of T-cells to CBZ. Besides, 
the removal of T-regulatory cells and use of dendritic cells as antigen-
presenting cells seemed to generally improve priming conditions. 
In order to investigate whether CBZ affected the peptide-binding specificity of 
HLA-A*31:01, in silico and in vitro analysis were performed. In silico modelling 
provided a possible binding site for CBZ within the HLA peptide-binding cleft. A 
peptide elution study provided a preliminary indication that binding of CBZ to 
HLA-A*31:01 may alter the peptide repertoire presented by the allele, which 
could potentially result in T-cell activation. 
Most recently, it has been suggested that the T-cell receptor (TCR) may 
represent an additional predisposing factor for CBZ-induced HSRs. Accordingly, 
a protocol for the analysis of the TCR Vβ repertoire of drug-reactive T-cells by 
flow cytometry as well as CDR3 spectratyping was set up using T-cells from 
healthy donors primed against the model antigen SMX-NO. Both methods 
showed that antigen stimulation resulted in skewing of common TCR Vβ 
subtypes among the donors. Combined, the optimised methods will allow 
assessment of whether specific TCR clonotypes may be implicated in HLA-
A*31:01 associated HSRs to CBZ. 
In summary, the data presented in this thesis provide initial evidence that CBZ 
is able to interact directly, through a non-covalent binding mechanism, with 
HLA-A*31:01 causing T-cell activation. However, it cannot be excluded that the 
stimulation of T-cells in vivo requires the formation of a hapten complex. 
Further work is needed to define other factors that are involved in predisposing 
an individual to CBZ hypersensitivity. 
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1.1 Introduction 
 
Hypersensitivity reactions (HSRs) to drugs occur only in a few susceptible 
patients but can often be severe in nature. Specific human leukocyte antigen 
(HLA) alleles have recently been identified as risk factors in some forms of 
drug-induced hypersensitivity. It is known that drug-specific T-cells are 
involved in many of these reactions. However, the contribution of HLA to the 
development of drug-specific T-cell responses has not been fully understood. 
 
 
1.2 Adverse Drug Reactions 
 
1.2.1 Definitions 
Besides producing a therapeutic effect, any drug that is administered to a 
patient can cause adverse reactions. The World Health Organisation (WHO) has 
defined an adverse drug reaction (ADR) as “a response to a drug which is 
noxious and unintended, and which occurs at doses normally used in man for 
the prophylaxis, diagnosis, or therapy of disease, or for the modification of 
physiological function” (WHO 1972). Another commonly used definition for 
ADRs was proposed by Edwards and Aronson: “An appreciably harmful or 
unpleasant reaction, resulting from an intervention related to the use of a 
medicinal product, which predicts hazard from future administration and 
warrants prevention or specific treatment, or alteration of the dosage regimen, 
or withdrawal of the product” (Edwards, I. R. and Aronson 2000). This clearly 
separates ADRs from adverse events, which comprehend any harmful event 
that happens to a patient during drug therapy but does not have to be caused by 
the drug itself. 
Adverse drug reactions are a major burden to health care systems and 
considerably increase patients’ morbidity and mortality. They also present a 
significant problem for drug development in the pharmaceutical industry, as 
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potentially effective drugs might have to be withdrawn from the market due to 
unforeseen ADRs arising during the post-marketing period (Lasser et al. 2002). 
 
1.2.2 Incidence 
A study by Pirmohamed et al. (2004) investigated the percentage of hospital 
admissions attributed to ADRs in two UK hospitals and found this to be as high 
as 6.5%. ADRs led to death in 0.15% of all patients admitted to hospital during 
the monitoring period and the costs of ADR treatment were estimated to 
amount to approximately £466m per year for the UK National Health Service 
(NHS). ADRs leading to hospital admission were seen more often in elderly 
patients and were more prevalent in women (Pirmohamed et al. 2004). This is 
in line with a meta-analysis performed by Lazarou and colleagues, which 
estimated the incidence of ADRs in the United States was 6.7% of all patients 
hospitalized and a rate of fatal ADRs of up to 0.32% of all patients admitted to 
hospital (Lazarou et al. 1998). A more recent study by Miguel et al. (2012) 
stated ADRs could occur in up to 16% of hospitalized patients, but significant 
heterogeneity between the studies analysed hampered the authors in drawing 
firm conclusions. The true proportion of ADRs within a population will most 
likely remain unknown until the definition of ADRs has been standardised as 
well as the methods used for ADR monitoring (Miguel et al. 2012). Determining 
the incidence of ADRs in outpatients is even more difficult as there are only 
limited reporting systems in place and most ADRs therefore remain undetected. 
 
1.2.3 Classification 
ADRs can be classified according to their severity, time to reaction, or 
localisation. But most frequently ADR are classified by their pharmacological 
characteristics. 
Initially, ADRs were grouped into either type A or type B reactions based on the 
classification proposed by Rawlins and Thompson (Rawlins 1981). 
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Type A reactions, also known as augmented reactions, can be predicted from 
the known pharmacological action of the drug. They often represent an 
exaggerated effect of the drug and are generally dose-dependent. The majority 
of ADRs are type A reactions. 
Type B reactions, referred to as bizarre or idiosyncratic reactions, are not 
related to the known pharmacology of the drug and are usually not directly 
dose-dependent. Type B reactions are rare, but often more severe in nature 
than type A reactions. Reactions of this type occur only in susceptible patients 
and the predisposing risk factors are mostly still unknown. 
In order to allow a more distinguished classification of the different types of 
ADRs, more types were introduced accordingly (Edwards, I. R. and Aronson 
2000). An overview of the types of ADR proposed in the literature is given in 
Table 1.1. 
A more comprehensive system to classify ADRs has been introduced by 
Aronson and Ferner (2003) which takes into consideration the dose 
relatedness, timing and patient susceptibility (DoTS) of an adverse reaction. It 
has been proposed that the three-dimensional DoTS classification could 
improve the monitoring and treatment of ADRs and assist drug development 
and regulation (Aronson and Ferner 2003). 
 
The focus of this thesis will be on type B reactions, particularly hypersensitivity 
reactions, which are covered later in the chapter. Initially, I will give an 
overview of the immune system and its principal cellular and molecular 
components. 
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Table 1.1: Classification of adverse drug reactions (adapted from (Park et al. 
1998; Edwards, I. R. and Aronson 2000). 
Type of reaction Mechanism Example 
A 
(augmented) 
Predictable from the known 
pharmacology of the drug; 
dose-dependent effect 
Haemorrhage with 
anticoagulants 
B 
(bizarre or 
idiosyncratic) 
Not predictable from 
pharmacological action of 
the drug; no direct dose 
relationship 
Penicillin 
hypersensitivity 
C 
(chemical or 
chronic) 
Related to the chemical 
structure or a metabolite of 
the drug 
Paracetamol 
hepatotoxicity 
D 
(delayed) 
Develop years after drug 
therapy 
Secondary tumour after 
chemotherapy 
E 
(end of treatment) 
Appear after drug 
withdrawal, especially when 
stopped abruptly 
Withdrawal syndrome 
after opiate therapy 
F 
(failure) 
Often caused by drug 
interactions 
Reduced level of oral 
contraceptive during 
antibiotic therapy 
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1.3 The Immune System 
 
The immune system developed alongside human evolution to protect the 
human body against disease. The mechanisms involve elimination of existing 
pathogens and protection against new infections. One important aspect in this 
process is the differentiation between “foreign” and “self” molecules. 
The immune system can be divided into two main components: the innate and 
the adaptive immune systems. 
 
1.3.1 Innate immunity 
The innate immune system is thought to be the initial form of protection against 
pathogenic structures in humans, and it also exists in a lower form in all animals 
and some plants (Murphy et al. 2008). Its components are functional straight 
after birth and always present within the body to clear away infectious 
pathogens. Activation of innate responses occurs rapidly, as the recognition of 
pathogenic molecules is non-specific, and no immunological memory is formed. 
The main purpose of innate immunity is the prevention of an infection or to 
reduce its spreading. 
Epithelial membranes are considered a first barrier displaying a physical and 
chemical impediment to entering pathogens. If infectious agents circumvent 
these barriers, phagocytic cells, i.e. macrophages, monocytes and neutrophils, 
come into effect. These cells can recognise pathogen-specific molecules not 
expressed on human cells, e.g. mannose; and this results in the uptake and 
subsequent digestion of pathogens. The most important phagocytic cells are 
dendritic cells (DCs), which constantly ingest extracellular antigens. When 
immature DCs encounter pathogens they are activated and turn into so called 
antigen-presenting cells (APCs)(Delves and Roitt 2000). APCs are important for 
the initiation of the adaptive immune response, and DCs therefore form a 
crucial link between the innate and adaptive immunity. 
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Other cellular components of innate immunity include cells releasing 
inflammatory mediators, such as mast cells, basophils and eosinophils, and 
Natural Killer (NK) cells (Delves and Roitt 2000). NK cells recognise abnormal 
cells, such as those infected by viruses or malignant cells, and kill these through 
induction of apoptosis. 
Protein components of the innate immune response include cytokines and 
acute-phase proteins. These cause local inflammation at the site of infection 
which attracts phagocytic cells and also recruits cells of the adaptive immune 
system (Murphy et al. 2008). The complement system, a group of soluble 
plasma proteins, works as an additional pathway in the early and unspecific 
removal of infections. Complement can envelop infectious agents and these 
complexes are recognised by phagocytes and eliminated (Murphy et al. 2008). 
 
1.3.2 Adaptive immunity 
The adaptive immune system recognises pathogens in an antigen specific 
manner through the use of specialised receptors (Murphy et al. 2008). Key 
components of adaptive immunity are B- and T-lymphocytes, which carry 
specific receptors on their surface each recognising different antigenic 
structures. Binding of antigens to these receptors results in lymphocyte 
activation. 
B-cells encounter native antigens via their B-cell receptors, which are 
membrane-bound antibody molecules. Following antigen recognition, B-cells 
differentiate into plasma cells and start to secrete soluble antibodies. The 
secreted antibodies are specific for the encountered antigen and antibody-
labelled antigens are taken up by phagocytic cells and destroyed. This is known 
as the humoral immune response. 
T-cells are unable to recognise antigens directly but require the help of APCs. 
APCs can cleave antigens through proteolysis into short peptide fragments, also 
known as epitopes, and present these on human leukocyte antigen (HLA) 
molecules on their surface. T-cells recognise antigenic epitopes through T-cell 
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receptors (TCRs) expressed on their surface. After an interaction between APC, 
epitope and TCR takes place, T-cells differentiate into effector T-lymphocytes. 
This pathway is called the cell-mediated immune response. 
An important feature of the adaptive immune response is the generation of an 
immunological memory population. After an infection has been successfully 
eliminated, most activated B- and T-cells die. However, a few B- and T-cells with 
high affinity to their specific antigens are transformed into memory cells. Upon 
re-exposure to a pathogen, these cells can be rapidly activated allowing a faster 
and more effective immune response (Murphy et al. 2008). 
 
1.3.3 Antigen processing and presentation 
The main role of APCs is the uptake and processing of antigens at the site of 
infection followed by the migration of the cells to draining lymph nodes, where 
they display antigenic peptides to T-cells. The most specialised APCs are DCs, 
but to a lesser extent macrophages and B-cells can also function as APCs. 
Antigenic peptides generated within APCs generally originate from two 
different sources, extracellular or intracellular proteins. The process of antigen 
degradation into peptide fragments is called antigen processing and is depicted 
in Figure 1.1. 
Antigenic proteins formed in the cell cytosol get digested by the proteasome. 
The resulting peptide fractions are transferred into the endoplasmic reticulum 
(ER) by the transporter associated with antigen processing (TAP). In the ER, 
peptides get loaded onto newly synthesized HLA class I molecules by the 
peptide loading complex (PLC). The stable complexes of peptide and HLA I 
molecules are released from the ER and travel through the Golgi apparatus to 
the cell surface (Blum et al. 2013). 
 
 
  
 
1
0
 
Figure 1.1: Antigen processing 
pathways(adapted from (Blum et al. 
2013)): 
Cytosolic antigens are degraded by the 
proteasome. The peptides are 
transported into the ER by TAP where 
they bind to HLA class I molecules. 
Extracellular antigens are internalised 
by endocytosis. In late endosomes, 
antigens are lysed into peptides and 
loaded onto HLA class II molecules. The 
resulting peptide-HLA complexes are 
transported to the cell surface for 
presentation to T-lymphocytes. 
(CLIP= Class II-associated invariant 
chain peptide; ER= Endoplasmic 
reticulum; PLC= Peptide-loading 
complex; TAP= Transporter associated 
with antigen processing) 
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Extracellular antigens are taken up by phagocytic cells and captured in 
endosomes. Over time the endosomes become increasingly acidic which induces 
proteases to lyse the contained proteins into peptide fragments. These late 
endosomes fuse with vesicles containing HLA class II molecules, and the 
peptides are loaded onto HLA II proteins (Blum et al. 2013). The resulting 
peptide-HLA complexes are then transported to the cell surface. HLA class II 
molecules are formed in the ER and combined with an invariant chain. The 
invariant chain protects the HLA binding grove and guides the HLA class II 
molecules to endosomes. The proteolytic conditions in the endosomes degrade 
the invariant chain until only the short peptide CLIP, class II-associated 
invariant chain peptide, is left. CLIP is removed by HLA-DM, which enables 
binding of antigenic peptides to HLA class II molecules (Blum et al. 2013). 
The display of peptide-HLA complexes on the surface of APCs is known as 
antigen presentation, and they are recognised by the corresponding TCRs on T-
cells. 
T-lymphocytes can be grouped into two subtypes according to their cluster of 
differentiation (CD) markers, CD4 and CD8. These cell-surface proteins are able 
to specifically recognise HLA molecules and assist in stabilising peptide-HLA 
complexes; they are therefore also termed co-receptors (Murphy et al. 2008). T-
cells expressing the CD4 co-receptor will only interact with HLA class II 
complexes. CD8+ T-cells will only recognize peptides presented on HLA class I 
molecules (Murphy et al. 2008). Interactions occurring between APCs and T-
cells during antigen presentation and recognition are illustrated in Figure 1.2. 
When a TCR engages an antigenic peptide, it forms contact with both the HLA 
molecule and the peptide. However, for T-lymphocytes to become fully 
activated additional co-stimulatory signals are needed. This includes the 
interaction between the co-receptors CD28 on T-cells, CD80/CD86 on APCs and 
the secretion of co-stimulatory cytokines (Murphy et al. 2008). Once T-cells are 
successfully activated they turn into effector T-cells. 
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Figure 1.2: Interactions between APC and T-cell during antigen recognition (adapted 
from Janeway’s Immunobiology (Murphy et al. 2008)). 
 
There are three main types of effector T-lymphocytes: cytotoxic T-cells, helper 
T-cells and regulatory T-cells (Murphy et al. 2008). Cytotoxic T-cells are able to 
directly kill infected cells through the secretion of cytolytic molecules, which 
induce apoptosis in the target cells. Helper T-cells (Th cells) aid the activation of 
other immune cells through the release of cytokines. Depending on the 
cytokines secreted, they can be further divided into Th1, Th2 and Th17 cells. 
Th1 cells release mainly interferon (IFN) γ and tumour necrosis factor (TNF) α 
which promote macrophage activity. Th2 cells enhance the activation of B-cells 
by release of interleukin (IL) 4, IL-5 and IL-13. Th17 cells assist in neutrophil 
recruitment through secretion of IL-17 and IL-6. Regulatory T-cells help control 
immune responses through the release of inhibitory cytokines, such as IL-10 
and transforming growth factor (TGF) β, which suppress T-cell activation and 
thereby limit immune responses. The effector T-cell subtypes and their 
phenotypic characteristics are summarised in Table 1.2. 
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Table 1.2: Effector T-cell subsets and their secreted effector molecules (taken 
from Janeway’s Immunobiology (Murphy et al. 2008)). 
 
 
 
 
1.4 Major Histocompatibility Complex 
 
The major histocompatibility complex (MHC) was first discovered in mice by 
Peter Gorer (Gorer 1936); he identified antigenic molecules in the blood of the 
animals to be responsible for the rejection of transplanted tumours. In the 
1950s, Jean Dausset was able to prove that a similar antigenic system is 
expressed on the cell surface of human leukocytes (Dausset 1958). The gene 
products of the human MHC are therefore also referred to as human leukocyte 
antigens. Initially, HLA molecules were studied because of their clinical 
relevance in transplant medicine (Chinen and Buckley 2010). But their main 
biological role in the human immune system is the presentation of pathogen-
derived peptide antigens to T-lymphocytes. 
In the last decades extensive research of the MHC determined this genetic 
region to be the most polymorphic in the human genome; and its genetic 
variation has been shown to contribute to various diseases, especially 
autoimmune disorders (Trowsdale 2011). 
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1.4.1 Genetic organisation 
In humans, the MHC is located on the short arm of chromosome 6 (6p21). 
Through the joint efforts of the MHC sequencing consortium, it was one of the 
first genomic regions to be fully sequenced. It spans a region of 3.6 megabase 
pairs (Mb) containing 224 gene loci of which about 60% are thought to be 
expressed and about 40% proposed to be implicated in immunity (The MHC 
sequencing consortium 1999). 
The MHC can be divided into three major regions: MHC class I at the telomeric 
end, MHC class III, and MHC class II at the centromere. MHC class I genes encode 
the heavy chain of the glycoproteins HLA-A, -B and –C, also known as classical 
HLA class I molecules. These molecules present peptide antigens to CD8+ T-
cells. The non-classical HLA molecules (HLA-E, -F and –G) and the MHC class I 
chain like (MIC) proteins complete this gene cluster. The MHC class II cluster 
contains the genes coding for the α- and β-chain of the classical HLA-DR, -DQ 
and -DP heterodimer proteins, which present antigens to CD4+ T-cells. Also 
encoded in this region are the non-classical HLA class II molecules, HLA-DM and 
-DO, which assist in antigen loading of HLA class II molecules. The genes 
encoding TAP and tapasin, proteins important for loading of HLA class I 
molecules, are also located in this cluster. Genes of the MHC class III region 
cover proteins of the complement system, heat shock proteins (HSP), and many 
cytokines (e.g. TNF-α). A schematic gene map of the three MHC gene clusters is 
shown in Figure 1.3. 
 
 
Figure 1.3: Gene organisation of the classical major histocompatibility complex 
(adapted from (Klein and Sato 2000)). 
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Further research in the field and advances in sequencing techniques have 
shown that genes related to the MHC extend beyond the region originally 
defined as MHC and the term extended MHC was coined, which covers about 7.6 
Mb and comprises around 421 gene loci (Horton et al. 2004). 
 
1.4.2 Polymorphisms 
HLA genes are highly polymorphic with the HLA-B locus being the most 
polymorphic gene in the human genome (Vandiedonck and Knight 2009). It is 
believed that HLA polymorphisms evolved as a result of a constant evolutionary 
pressure to fight infections and protect the human body against diverse 
pathogens. Single nucleotide polymorphisms (SNPs) are the most common form 
of genetic variation found in HLA genes (Vandiedonck and Knight 2009). For 
HLA class I alleles, the majority of SNPs are located in exon two and three of the 
genes, forming the antigen-binding groove. Similarly, most SNPs in HLA class II 
alleles are found in the second exon. The only exception is the HLA-DRA locus, 
which shows no functional polymorphisms in the peptide-binding region. Many 
SNPs in the MHC region are non-synonymous leading to changes in the amino 
acid sequence of the peptide-binding groove. This in turn increases the 
likelihood of pathogenic antigens being recognised and eliminated 
(Vandiedonck and Knight 2009). Until today, more than 9,000 HLA alleles have 
been discovered and the numbers are growing continually. A complete list can 
be found on the IMGT/HLA database (www.ebi.ac.uk/ipd/imgt/hla) (Robinson 
et al. 2013). 
A high degree of linkage disequilibrium (LD) is seen across the entire MHC 
region and HLA alleles are generally inherited in haplotype blocks. The 
frequency of HLA haplotypes are highly variable between different ethnic 
populations; and this has partly been attributed to differences in pathogen 
exposure in different geographic environments (Choo 2007). 
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1.4.3 Nomenclature 
The numerous HLA polymorphisms and resulting high number of HLA 
molecules called for a systematic nomenclature. 
Initially, HLA typing was only possible at the serological level using 
alloantibodies directed against HLA expressed on the cell surface (McCluskey et 
al. 2003). The HLA alleles defined through this process were numbered, but in a 
non-systematic way. When molecular DNA-based typing methods became 
available, the number of detectable HLA alleles grew exponentially. At the same 
time, different genotyping methods used different nomenclature systems for the 
HLA alleles detected. A standardised nomenclature was established through the 
work of the International Histocompatibility Working Group (IHW) (Gourraud 
et al. 2007), and this system is used today. The nomenclature is maintained and 
regularly updated by the WHO HLA Nomenclature Committee for Factors of the 
HLA system (Marsh et al. 2010). 
The naming of individual HLA alleles follows a general structure: the name of 
the gene locus, e.g. HLA-A, is succeeded by an asterisk, and a number identifying 
the gene variant. An example is given in Figure 1.4. 
The numbering system used to determine each HLA variant consists of up to 
four fields, and each field is separated by a colon. The first two digits identify 
the type, which in most cases corresponds to the serological phenotype. The 
next numeric field signifies the subtype representing the DNA genotype. These 
numbers are assigned in sequential order to allow newly discovered alleles to 
be integrated at any time. The third and fourth set of numbers can be included 
to describe synonymous mutations and mutations in non-coding regions 
respectively. Optional letters may be added at the end to indicate the expression 
status of the allele: 
 N =“null” allele (not expressed at the cell surface) 
 L =allele is expressed at low levels 
 S = “soluble” allele (protein is secreted) 
 C = allele is only expressed in the cytosol 
 A = “aberrant” allele (doubts to whether the allele is expressed) 
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 Q =expression of the allele is “questionable” (mutation known to affect 
expression levels) 
 
 
Figure 1.4: Nomenclature of HLA alleles. 
 
Regular meetings are held to collect information on confirmed new HLA alleles, 
and any errors or corrections needed concerning already published sequences. 
The reports are published on a monthly basis in the journals Tissue Antigens, 
Human Immunology and the International Journal of Immunogenetics. 
 
1.4.4 Structure and function 
Although HLA class I and class II alleles play a similar role in the immune 
system, their structures are quite different. 
HLA class I proteins consist of a heavy α chain encoded by the HLA class I genes 
and a non-covalently bound β2-microglobulin (β2m) chain (see Figure 1.5). 
Human β2m is encoded by a gene located on chromosome 15 and its protein 
product is invariant. The glycosylated α chain is built up of five domains: the 
peptide-binding region (α1 and α2), an immunoglobulin-like constant domain 
(α3), a transmembrane region and a cytoplasmic tail (Klein and Sato 2000). The 
α1 and α2 domains create a distinct structure forming the peptide-binding 
groove. It comprises a platform of eight antiparallel β strands and two walls of 
antiparallel α-helices. The two α-helices assemble closely, which allows only 
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short peptide fragments between seven to fifteen amino acids to be bound 
(Klein and Sato 2000). The α3 domain assembles with β2m to form a structure 
resembling the constant region of immunoglobulins. 
HLA class I molecules are expressed on almost all nucleated cells and antigens 
presented in the peptide-binding groove are recognised by the TCR of CD8+ T-
lymphocytes. 
 
 
Figure 1.5: Schematic structure of HLA class I and class II molecules (adapted from 
(Klein and Sato 2000)). 
 
The HLA class II genes encode the α- and β-chain of HLA class II proteins. The 
two polypeptide chains form heterodimers through non-covalent binding and 
consist of four domains each (Klein and Sato 2000). The α1 and β1 domain form 
the peptide-binding region. The α2 domain together with the β2 domain makes 
up the immunoglobulin-like region. Both chains are anchored in the cell 
membrane through a short transmembrane domain and a cytoplasmic tail. A 
schematic structure is depicted in Figure 1.5. Due to the heterodimer structure, 
the peptide-binding groove of HLA class II molecules is open, and longer 
peptides of up to twenty-five amino acid length can be presented (Rammensee, 
Hans-Georg 1995). 
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In contrast to HLA class I, HLA class II molecules are normally only expressed 
on antigen-presenting cells. However, when T-cells become activated, this can 
induce the expression of class II molecules on their cell surface. The secretion of 
IFN-γ can also lead to expression of HLA class II on other cells (Murphy et al. 
2008). Peptides presented by HLA class II molecules are usually recognised by 
the TCR of CD4+ T-cells. 
 
1.4.5 HLA associated diseases 
Due to their key function in initiating T-cell mediated immune responses, many 
HLA alleles have been linked to autoimmunity, infectious diseases and cancer 
(Trowsdale 2011). In most cases it is not yet known how the HLA protein 
contributes to the development of the disease. It is generally difficult to prove 
whether the reported genes are causal variants or merely an effect of extensive 
LD across the MHC (Trowsdale 2011). This is further complicated by the fact 
that most diseases are multifactorial, involving both environmental and genetic 
factors. A summary of diseases associated with specific HLA alleles or 
haplotypes are presented in Table 1.3. 
Furthermore, some forms of drug-induced hypersensitivity reactions have been 
linked to specific HLA class I and class II alleles. These will be discussed 
separately in sections 1.6.4 and 1.6.5 of this chapter. 
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Table 1.3: Examples of HLA-associated diseases reported in the literature. 
Disease HLA association(s) Reference 
Infectious diseases 
HIV 
B*27, B*57→ improved HIV control; 
B*35→ lack of HIV control 
(Kaslow et al. 1996); 
(Carrington et al. 
1999) 
Malaria 
B*35, DRB1*13:02-DQB1*05:01 
→ reduced malaria risk 
(Hill et al. 1991) 
Hepatitis C 
C*04→ virus persistence; 
DRB1*11:01-DQB1*03:01 
→ spontaneous virus clearance 
(Thio et al. 2002); 
(Hong et al. 2005) 
Cancer 
Cervical 
carcinoma 
DRB1*15:01-DQB1*06:02 (risk alleles 
in Hispanics); 
B*07 (risk allele in Chinese) 
(Apple et al. 1994); 
(Qiu et al. 2011) 
Hodgkin’s 
lymphoma 
HLA-DPB1*03:01 (risk allele in 
Caucasians) 
(Oza et al. 1994) 
Autoimmune diseases 
Ankylosing 
spondylitis 
B27 
(Brewerton et al. 
1973) 
Celiac disease 
DQ2 (DQA1*05-DQB1*02) and DQ8 
(DQA*03-DQB1*03:02) haplotypes 
(Megiorni and Pizzuti 
2012) 
Multiple 
sclerosis 
DRB5*01:01-DRB1*15:01-
DQA1*01:02-DQB1*06:02 haplotype 
(Fogdell et al. 1995) 
Narcolepsy 
DRB1*15:01-DQA1*01:02- DQB1*06:02 
haplotype 
(Mignot et al. 2001) 
Rheumatoid 
arthritis 
DRB1*04 and DRB1*01 subtypes 
(Wordsworth et al. 
1989) 
Systemic lupus 
erythematosus 
DRB1*15:01-DQB1*06:02 haplotype, 
DRB1*03:01-DQB1*02:01 haplotype 
(Graham et al. 2007) 
Type 1 
diabetes 
DRB1*03:01-DQA1*05:01-
DQB1*02:01 (“DR3” haplotype), 
DRB1*04-DQA1*03:01-DQB1*03:02 
(“DR4” haplotype) → strongly 
predisposing; B*3906→ risk allele, 
DRB1*15:01-DQA1*01:02-
DQB1*06:02 (“DR2” haplotype) 
→ highly protective 
(Erlich et al. 2008); 
(Noble et al. 2010) 
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1.5 T-cell Receptor 
 
The T-cell receptor (TCR) is a highly variable polypeptide on the cell surface of 
T-lymphocytes which specifically recognises antigenic peptides in complex with 
an MHC molecule. As each TCR is restricted to recognise only a few structurally 
similar antigens, a broad TCR repertoire is needed to guarantee recognition of 
any invading pathogen. After binding of the TCR to a specific peptide-MHC 
(pMHC) complex, intracellular signalling cascades are induced which lead to T-
cell proliferation and activation of their effector functions. 
 
1.5.1 Structure and function 
The TCR protein is composed of two polypeptide chains, either α and β, or γ and 
δ, which form disulphide-linked heterodimers. The vast majority of T-cells 
express α:β heterodimers, whereas only a minority are γ:δ T-cells. Only little is 
known so far about the functions and antigen-binding mode of γ:δ TCRs. It has 
been suggested that γ:δ TCRs specialise on infections caused by parasites and 
mycobacteria (Rudolph et al. 2006). They are able to especially recognise small 
non-peptide antigens that contain phosphate (Rudolph et al. 2006). Although 
structurally similar to α:β TCRs, it appears that γ:δ TCRs are not restricted by 
classical MHC class I or class II molecules. For reasons of simplification this 
chapter will focus on α:β TCRs. 
The general molecular structure of TCRs resembles the antigen-binding 
fragment of immunoglobulins and is illustrated in Figure 1.6. Each TCR chain 
consists of four domains: an N-terminal variable region, a constant region 
followed by a short cysteine-containing stalk segment which forms the 
interchain bond, a hydrophobic transmembrane region and a cytoplasmic tail 
(Rudolph et al. 2006). The variable (V) region forms three loops which are 
known as the complementarity determining regions (CDRs). The CDR regions of 
the α- and β-chain together form the TCR binding site and are responsible for 
antigen recognition. The CDR1 and CDR2 regions each contact the side chains of 
the MHC binding groove, while the CDR3 loops interact with the peptide ligand 
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and therefore determine the TCR specificity (Garcia and Adams 2005). The 
constant (C) region associates with the CD3 co-receptors, and this complex 
transmits any signal generated at the antigen-recognition site into the cell, 
leading to the activation of downstream signalling pathways. The crystal 
structures solved to date demonstrate that the docking mode of TCRs with a 
pMHC complex is largely preserved. The TCR heterodimer binds diagonally to 
the long side of the pMHC complex (Morris and Allen 2012). The Vα domain is 
hereby located above the N-terminal peptide half and the Vβ domain comes to 
lie above the C-terminus of the peptide (Gras et al. 2008). 
 
 
Figure 1.6: Schematic structure of the T-cell receptor (adapted from Janeway’s 
Immunobiology (Murphy et al. 2008)). 
 
1.5.2 Generation of the TCR repertoire 
The variety of antigens that can be recognised by the TCR repertoire is 
determined by the V region, especially the CDR3 loops. As it would not be 
possible to encode all receptor chains present in an individual at full length in 
the genome, a complex genetic mechanism for generating the TCR repertoire 
evolved. This mechanism is termed gene rearrangement. 
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The TCR genes are divided into a multitude of interchangeable gene segments 
and spread over a large DNA section. The human TCR α genes are located on 
chromosome 14 and comprise 43 variable (Vα), 58 junctional (Jα) gene 
segments and a single Cα gene. The human TCR β genes are located on 
chromosome 7 and consist of 42 variable (Vβ), 2 diversity (Dβ) and 12 
junctional (Jβ) gene segments, as well as two Cβ genes (Gras et al. 2008). The V, 
D and J gene segments are randomly rearranged by events of somatic 
recombination to form a complete TCR-V region. The TCR-V region is then 
spliced together with a particular C region and together they shape a TCR α- or 
β-chain (Murphy et al. 2008). The two chains are then paired to form an α:β 
heterodimer expressed on the cell surface. The genetic processes involved in 
the formation of T-cell receptors are illustrated in Figure 1.7. 
The CDR3 loops, as the site of antigen recognition, are shaped by the D and J 
segments of the α- and β-chains. The variation in the CDR3 region is formed 
through juxtaposition of the different V, D and J segments after somatic 
recombination (Turner et al. 2006). And the TCR repertoire is further 
diversified through the addition of non-template encoded nucleotides at the 
junctions of V, D and J segments. 
The range of TCRs generated through the above described mechanism 
represents the TCR repertoire of immature T-cells. Selection processes in the 
thymus guarantee that only T-cells expressing TCRs which are able to interact 
with self-MHC molecules but are not autoreactive undergo maturation (Delves 
and Roitt 2000). During positive selection, early T-lymphocytes, expressing 
both co-receptors CD4 and CD8, get to screen self-peptides presented on self-
MHC molecules. Those T-cells able to engage a self-pMHC complex are rescued 
from programmed cell death and mature into single-positive CD4+ or CD8+ T-
cells. To avoid autoimmune reactions, T-cells interacting too strongly with self-
peptides get deleted through induction of apoptosis. This process is known as 
negative selection. Through this process the TCR repertoire is shaped to 
encompass receptors that recognise foreign antigens in a self-MHC restricted 
manner. At the same time, T-cells that could induce autoimmune reactions are 
removed (Turner et al. 2006). 
  
 
2
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Figure 1.7: Gene rearrangement and assembly of T-cell receptors (taken from Janeway’s Immunobiology (Murphy et al. 2008)). 
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1.5.3 T-cell receptor signalling 
T-cell receptors do not have the ability to activate intrinsic signalling cascades 
on their own. In order to gain full functionality, the TCR associates with CD3 
receptors to what is known as the TCR complex. CD3 proteins consist of γ, δ and 
ε chains forming heterodimers or ζ:ζ homodimers. In the TCR complex, the TCR 
α-chain associates with a CD3ζ homodimer and a CD3δ:CD3ε heterodimer, 
whereas the TCR β-chain is thought to interact with a CD3γ:CD3ε heterodimer 
(Murphy et al. 2008). The complex is maintained through hydrophobic 
interactions between the receptor chains. In addition to enabling intracellular 
signalling, the CD3 proteins assist in transporting the TCR to the cell membrane 
and stabilise the TCR at the cell surface. The CD3 receptors have an 
immunoglobulin-like extracellular domain, with the exception of the CD3ζ 
homodimer, and a cytosolic domain containing immunoreceptor tyrosine-based 
activation motifs (ITAMs). ITAMs are the elements responsible for transforming 
extracellular signals received from the TCR into intracellular signalling events. 
Signalling cascades within T-cells are activated by phosphorylation of the 
ITAMs following TCR engagement. The pathways involved in TCR signalling are 
summarised in Figure 1.8. 
Phosphorylated ITAMs at the CD3ζ chain recruit ZAP-70 (Zeta-chain-associated 
protein kinase 70), which in turn gets phosphorylated by Lck (lymphocyte-
specific protein tyrosine kinase). Phosphorylated ZAP-70 can then activate 
adaptor proteins, such as the linker for the activation of T-cells (LAT) (Gorentla 
and Zhong 2012). Phosphorylated LAT leads to the recruitment of 
phospholipase C-γ (PLC-γ). Activation of PLC-γ enables hydrolysis of PIP2 
(phosphatidylinositol-4,5-bisphospahte) into two second messenger molecules, 
diacylglycerol (DAG) and inositol triphosphate (IP3). 
IP3 triggers an increase in intracellular Ca2+ levels, and this leads to the 
activation of the transcription factor NFAT (nuclear factor of activated T-cells). 
NFAT translocates to the nucleus and induces gene transcription leading to cell 
proliferation and differentiation. 
  Chapter 1 
26 
 
DAG can activate the transcription factor NFϰB (nuclear factor kappa-light-
chain-enhancer of activated B cells), and at the same time induce the Ras-MAP 
kinase pathway, both causing transcription of target genes related to T-cell 
proliferation and effector function. 
 
 
Figure 1.8: Summary of the intracellular TCR signalling pathways (adapted from 
(Morris and Allen 2012)). 
Recognition of an antigen by the TCR leads to phosphorylation of the TCR complex and 
activation of downstream signalling cascades. These involve Ca2+ influx, activation of Ras-MAP 
kinase pathway and recruitment of transcription factors like NFϰB. The activated transcription 
factors induce T-cell development and effector functions. 
(Lck= Lymphocyte-specific protein tyrosine kinase; ZAP-70= Zeta-chain-associated protein 
kinase 70; LAT= Linker for the activation of T-cells; PLC= Phospholipase C; PIP2= 
Phosphatidylinositol-4,5-bisphospahte; IP3= Inositol triphosphate; DAG= Diacylglycerol; NFAT= 
Nuclear factor of activated T-cells; NFϰB= Nuclear factor kappa-light-chain-enhancer of 
activated B cells; MAP kinase= mitogen-activated protein kinase)   
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1.6 Drug Hypersensitivity Reactions 
 
Hypersensitivity reactions (HSRs) to drugs are a form of idiosyncratic adverse 
drug reaction (iADR) that involves one or more immunological mechanisms 
(Pichler 2003). In most cases, however, the exact process through which a drug 
causes an immune response is not known. These reactions are also commonly 
referred to as drug allergy. 
Drug-induced HSRs are thought to make up about one third of all ADRs (Gomes 
and Demoly 2005). But the exact percentage is hard to determine as there are 
currently no epidemiological studies focusing on HSRs. Also, definitions of 
iADRs and HSRs are not clear cut and are often used interchangeably (Uetrecht 
2007). 
Hypersensitivity reactions can manifest themselves in a diverse range of 
diseases, affecting almost any organ of the human body. The most commonly 
affected organ is the skin, followed by the liver and haematological system 
(Uetrecht and Naisbitt 2013). Some HSRs are limited to one organ, but often 
drug allergies show multi-organ involvement. Antibiotics and anticonvulsants 
are drugs known to cause hypersensitivity reactions most frequently. 
Clinical characteristics of most HSRs include a delayed onset of disease 
symptoms, ranging from days to several weeks or even months after the start of 
drug therapy (Uetrecht 2007). Upon rechallenge symptoms usually appear 
more quickly. Both factors strengthen the assumption of an underlying 
immune-mediated mechanism. Also, the risk of developing drug-induced HSRs 
does not seem to be correlated with the therapeutic dose of the drug received, 
but in general are rarely seen at doses below 10mg per day (Uetrecht 2007). 
 
1.6.1 Classification 
HSRs are generally classified into four subtypes following the system described 
by Gell and Coombs. This classification system has proven useful in clinical 
practice to relate the clinical symptoms to the fundamental immune response 
  Chapter 1 
28 
 
(Pichler 2003). However, many drugs are able to elicit several forms of 
hypersensitivity, suggesting different immune mechanisms can be activated by 
a single drug (Park et al. 1998). 
Type I reactions, also known as immediate-type hypersensitivity, are caused by 
the formation of immunoglobulin (Ig) E against drug hapten complexes leading 
to mast cell activation. Type-I reactions depend on covalent binding of a drug 
hapten to an endogenous protein and recognition of the antigenic structure by 
the humoral immune system. A typical example is anaphylaxis as a form of 
penicillin hypersensitivity. 
Type II hypersensitivity is a result of a drug binding to the surface of mainly 
blood cells (e.g. erythrocytes or platelets), and subsequent generation of anti-
drug IgG antibodies which cause cellular lysis. Haemolytic anaemia caused by 
cephalosporins falls into this subgroup. 
Type III reactions are mediated though excess formation of immune complexes 
of soluble drug antigen and IgG antibodies. Serum sickness is a classic example 
of this type of reaction. 
Type IV hypersensitivity reactions are also referred to as delayed-type 
hypersensitivity and are mediated by antigen-specific T-cells. Effector T-cells 
involved in delayed-type HSRs have been shown to be rather heterogeneous. 
Type IV reactions have therefore been divided further into Type IVa- IVd 
reactions (Posadas and Pichler 2007). Table 1.4 summarizes the different 
effector T-cells of Type IV reactions and their functions. Most delayed-type 
hypersensitivity reactions show an overlap in effector T-cells and the resulting 
inflammatory response.  
Delayed-type hypersensitivity reactions will be the focus of the following 
chapters and this thesis. 
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Table 1.4: Characteristics of Type IV hypersensitivity reactions (adapted from 
(Posadas and Pichler 2007)). 
 Type IV a Type IV b Type IV c Type IV d 
T-cell type 
Th1-type 
reaction 
Th2-type 
reaction 
Cytotoxic T-
cells 
T-cells 
Secreted 
cytokines 
IFN-γ, 
TNF-α 
IL-4, IL-13, 
IL-5 
Perforin, 
granzyme B, 
FasL 
IL-8 
Effector 
mechanism 
Macrophage 
activation; 
Stimulation of 
proinflammatory 
responses 
B-cell 
production; 
macrophage 
deactivation; 
eosinophilic 
inflammation 
Killing of 
tissue cells 
(keratinocytes, 
hepatocytes) 
Neutrophilic 
inflammation 
Clinical 
phenotype 
Eczema 
Maculopapular 
exanthema 
(MPE) 
Bullous 
exanthema 
(SJS, TEN), 
MPE 
Pustular 
exanthema 
(e.g. AGEP) 
 
 
1.6.2 Clinical phenotypes 
The most frequent delayed-type HSRs are cutaneous manifestations, some of 
which include systemic organ involvement. The different syndromes each bear 
distinct clinical and histopathological characteristics (Hausmann et al. 2010). 
 
Maculopapular rash 
Maculopapular exanthema (MPE) is the most common form of delayed HSRs, 
making up over 90% of all drug-induced skin rashes. Among the drugs most 
commonly causing MPE are β-lactam antibiotics, sulfamethoxazole, quinolones, 
antiepileptic drugs and diuretics (Hausmann et al. 2010). Symptoms typically 
arise one to two weeks after start of drug treatment and often resolve 
spontaneously despite continuation of drug therapy (Uetrecht and Naisbitt 
2013). 
CD4+ cytotoxic T-cells have been found to be the dominant cell type in these 
reactions, present in both the dermis and blood of patients. The CD4+ T-cells can 
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kill activated keratinocytes through the release of perforin and granzyme B 
(Pichler 2003). Apoptosis of keratinocytes might be less severe due to the 
limited expression of HLA class II on normal skin cells. Cytokines released by 
the drug-specific CD4+ T-cells include type 1 as well as type 2 cytokines 
(Hausmann et al. 2010). 
 
Hypersensitivity syndrome 
Hypersensitivity syndrome (HSS) was initially associated with aromatic 
anticonvulsants, but it is also with other drugs, such as allopurinol, 
sulfonamides, and anti-retrovirals, including nevirapine and abacavir (Uetrecht 
and Naisbitt 2013). Other terms used to describe this phenotype are drug-
induced hypersensitivity syndrome (DIHS) or drug reaction with eosinophilia 
and systemic symptoms (DRESS) (Pirmohamed et al. 2011). Clinical symptoms 
usually occur two to six weeks after commencement of drug therapy and 
comprise rash, fever and internal organ involvement, such as hepatitis, 
nephritis, carditis, pneumonitis and lymphadenopathy (Uetrecht and Naisbitt 
2013). Hematologic abnormalities are common, with eosinophilia seen most 
frequently. It should be noted that the symptoms can persist for several weeks 
or even reoccur despite drug withdrawal (Hausmann et al. 2010). Mortality has 
been estimated to be around 10% and is most often due to liver failure. 
In patients with HSS, a high number of activated T-cells, secreting large 
amounts of IFN-γ and IL-5, can be detected in the circulation (Hausmann et al. 
2010). It has also been shown that many patients experience a reactivation of 
herpes viruses during HSS, but the implication of this association has not yet 
been clarified (Descamps et al. 2001; Picard et al. 2010). 
 
Acute Generalized Exanthematous Pustulosis 
Acute generalized exanthematous pustulosis (AGEP) is a rare disease estimated 
to occur in approximately 1: 100,000 patients with a mortality rate of 2-4% 
(Hausmann et al. 2010). The typical symptoms include a non-infectious pustular 
skin rash, fever and leucocytosis (Pichler 2003). The time to onset is a relatively 
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short period of three to five days after treatment (Hausmann et al. 2010). The 
pustules are infiltrated by neutrophilic granulocytes and activated CD4+ and 
CD8+ T-cells (Pichler 2003). Antibiotics are the causative drugs in most cases of 
AGEP (Uetrecht and Naisbitt 2013). 
 
Stevens-Johnson syndrome and Toxic Epidermal Necrolysis 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the 
most severe types of delayed-type HSRs with an estimated incidence of 1: 
100,000 and 1:1,000,000 patients, respectively (Hausmann et al. 2010). The 
syndromes are considered to be variants of the same disease and are classified 
by the extent of skin detachment. SJS involves less than 10%, TEN more than 
30%, and SJS/TEN overlap 10- 30% of skin detachment. Both conditions are 
associated with high mortality rates of about 10% and 30%, respectively 
(Hausmann et al. 2010). The reactions usually occur after two weeks of 
treatment with the first signs being a sudden onset of fever and malaise. This is 
followed by a quickly spreading, painful rash and the development of blisters 
(Uetrecht and Naisbitt 2013). Mucous membranes of the mouth, eyes, genitals 
and intestine can also be affected. 
Immunohistology shows widespread apoptosis of keratinocytes which is 
mediated by CD8+ T-cells secreting cytolytic molecules, such as Fas Ligand 
(FasL) and granulysin (Nassif et al. 2004; Chung and Hung 2010). 
 
Drug-induced liver injury 
The liver is the most frequently involved extra-cutaneous organ in drug-
induced HSRs, either in combination with other organs or as an isolated 
syndrome in form of drug-induced liver injury (DILI) (Zhang, X. et al. 2011a). 
Most drugs that cause DILI can be metabolised in the liver to reactive 
metabolites, which are thought to induce liver injury. The mechanisms through 
which DILI is caused are largely unknown, but for many drugs there is evidence 
that the immune system is involved (Zhang, X. et al. 2011a). In general, 
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symptoms occur with a delay of one to three months after the start of 
treatment. Anti-drug antibodies or autoantibodies have been detected in 
several cases of DILI, but their function in the pathogenesis of liver injury has 
not yet been elucidated. Liver histology frequently shows infiltration of 
lymphocytes and eosinophils, similar to viral hepatitis. Recently, strong HLA 
associations have been found with several drugs causing DILI, the prime 
example being flucloxacillin-induced liver injury and HLA-B*57:01 (Daly et al. 
2009). 
 
1.6.3 Mechanistic hypotheses 
The involvement of T-cells in delayed-type HSRs was clearly demonstrated by 
the successful isolation of drug-specific T-cells from blood and tissue cells of 
patients suffering from a diverse range of drug-induced HSRs (Mauri-Hellweg et 
al. 1995; Hashizume et al. 2002; Naisbitt et al. 2003b). This strengthened the 
presumption of an underlying T-cell mediated pathomechanism. Due to the 
heterogeneity of the clinical syndromes of HSRs and the lack of adequate animal 
models, studies trying to unravel the mechanisms behind drug-induced T-cell 
activation focused on in vitro analysis of drug-specific T-cells isolated from 
hypersensitive patients. Several hypotheses have been put forward to explain 
how drugs might stimulate an immune response. 
 
Hapten hypothesis 
Initial models were built on the hapten hypothesis, first introduced by 
Landsteiner and Jacobs in 1935. It is based on the fact that drugs of low 
molecular weight as such are not immunogenic, but have to covalently bind to 
endogenous proteins in order to elicit an immune response (Landsteiner and 
Jacobs 1935). Such chemically reactive molecules are referred to as haptens. 
Haptenization of different proteins can lead to the formation of diverse 
immunogenic structures resulting in a broad range of immune responses (Adam 
et al. 2011). Modification of soluble or cell-bound proteins can lead to the 
formation of anti-drug antibodies. On the other hand, haptenized proteins can 
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be taken up by antigen-presenting cells (APCs), processed into drug-modified 
peptides and presented on HLA molecules to naïve T-cells (Adam et al. 2011). A 
classic example are penicillins, which are known to irreversibly bind to lysine 
residues on serum albumin (Uetrecht and Naisbitt 2013), and both anti-
penicillin antibodies and T-cells specific to penicillin-conjugates can be detected 
in hypersensitive patients. The hapten hypothesis is illustrated in Figure 1.9. 
 
 
Figure 1.9: Hapten hypothesis (adapted from (Uetrecht 2007)). 
The drug or its reactive metabolite binds to an endogenous protein. APCs take up the modified 
protein, process it and display drug-modified peptides in complex with HLA to T-cells. 
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Drugs that are chemically inert may become reactive through metabolism, and 
lead to metabolites acting as haptens. In this case the parent drug is referred to 
as a pro-hapten. Bioactivation predominantly takes place in the liver through 
cytochrome P450 (CYP) enzymes, but it can also occur in the skin, albeit at a 
lower rate (Posadas and Pichler 2007). If not eliminated from the body, reactive 
metabolites can cause direct cellular damage, activating the innate immune 
system, and at the same time form protein adducts that are able to elicit an 
adaptive immune response (Uetrecht and Naisbitt 2013). Sulfamethoxazole 
(SMX) is a typical example of a pro-hapten. SMX is metabolised to a 
hydroxylamine intermediate which can be spontaneously oxidized to nitroso-
SMX. The nitroso metabolite is highly reactive and able to modify cysteine 
residues of various proteins (Uetrecht and Naisbitt 2013). 
 
Danger hypothesis 
The danger hypothesis takes into account that activation of T-cells only occurs if 
at least two signals are present. Signal one represents the interaction between 
TCR and peptide-HLA complex. Signal two refers to the expression of 
costimulatory molecules on APCs interacting with CD28 receptors on T-cells 
(see Figure 1.2). Polly Matzinger proposed that T-cell mediated immune 
responses are initiated by so called danger signals rather than recognition of 
non-self epitopes (Matzinger 1994). These “danger signals” are released upon 
cellular damage leading to the activation of APCs and upregulation of 
costimulatory molecules on the cell surface. In case of HSRs, reactive drugs or 
metabolites could induce cellular stress causing the release of danger signals, 
and at the same time function as antigenic stimuli (Pirmohamed et al. 2002). 
Depending on the affected tissue, this could determine the localisation and 
nature of the hypersensitivity reaction seen in vivo (Uetrecht 2007). Figure 1.10 
represents a schematic model of the danger hypothesis. 
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Figure 1.10: Danger hypothesis (adapted from (Uetrecht 2007)). 
Danger signals are produced by stressed cells, which activate APCs and lead to the up-
regulation of costimulatory molecules. This signal, in addition to the interaction between HLA 
and TCR, is required for the initiation of a T-cell response. The absence of this signal results in 
tolerance. 
 
The danger hypothesis may explain why some chemically reactive drugs or 
metabolites do not cause hypersensitivity, as these might not cause cellular 
damage (Uetrecht 2007). Other factors such as viral infections could also trigger 
the release of danger signals and thereby increase the risk of HSRs, as seen for 
some drugs. On the other hand, not every drug known to cause cell damage is 
associated with hypersensitivity (Pirmohamed et al. 2002). 
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Pharmacological interaction of drugs with immune receptors (p-i concept) 
Based on the observation that T-cell clones generated from SMX hypersensitive 
patients could be stimulated by SMX in the absence of metabolism, Pichler 
developed the so called p-i concept (Pichler 2002). According to this hypothesis, 
drugs that are chemically inert can activate T-cells through direct interaction 
with either the TCR or HLA molecule given that a sufficient binding affinity is 
generated (Adam et al. 2011). The interaction is reversible and seems to be 
independent of a specific peptide ligand present in the HLA binding groove. This 
resembles the binding of superantigens to HLA-TCR complexes (Uetrecht 2007). 
T-cells stimulated by drugs through the p-i mechanism are thought to derive 
from previously primed effector cells and memory T-cells (Adam et al. 2011). In 
comparison to naïve T-cells, these cells have a lower activation threshold and 
therefore may not require co-stimulatory signals from APCs (Adam et al. 2011). 
Drugs reported to stimulate T-cell clones in vitro via a p-i mechanism include 
lamotrigine, lidocaine and carbamazepine (Zanni et al. 1999; Naisbitt et al. 
2003b; Wu et al. 2007). The p-i concept is illustrated in Figure 1.11 A. 
 
Altered peptide hypothesis 
A novel mechanism of drug-induced T-cell activation has been proposed 
recently for HSRs displaying strong associations with specific HLA alleles. 
Several independent research groups were able to show that abacavir can bind 
non-covalently to specific residues within the HLA binding groove of HLA-
B*57:01 which leads to changes in the peptide repertoire presented by the HLA 
allele. The novel self-peptides displayed by HLA-B*57:01 could subsequently 
trigger T-cell activation (Illing et al. 2012; Norcross et al. 2012; Ostrov et al. 
2012). This new concept became known as the altered peptide repertoire 
model and is depicted in Figure 1.11 B. 
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Figure 1.11: Schematic representation of the p-i concept (A) and altered peptide 
model (B) (adapted from (Bharadwaj et al. 2012)) 
The p-i concept states that a drug (in green) can bind directly to either HLA or TCR molecule 
and is not dependent on the presence of a specific peptide (in purple) in the HLA binding-
groove. In the altered peptide model, a drug (green shape) binds to the empty HLA molecule 
changing its physicochemical properties and allowing novel self-peptides (purple shape) to be 
presented to T-cells. 
 
1.6.4 Risk factors 
Hypersensitivity reactions are known to be multi-factorial diseases, involving 
both environmental and genetic risk factors. 
Genetic factors have been hypothesised to play a role in predisposing 
individuals to HSRs for a long time. Family case studies describing similar 
reactions to a drug given to members of the same family have provided some 
early evidence (Pirmohamed 2006). In the past, most genetic studies focused on 
two main aspects, genes involved in drug metabolism and immune-related 
genes, especially the MHC region due to its essential functions in the immune 
system. 
To date, genetic polymorphisms in drug metabolising enzymes were found to 
contribute only a minor relative risk to HSRs and most studies proved negative 
(Uetrecht 2007). One example is hydralazine-induced systemic lupus 
erythematosus which occurs more frequently in patients who are slow 
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acetylators due to a deficiency in the N-acetyl-transferase 2 enzyme (Naisbitt et 
al. 2003c). 
Early studies looking into polymorphisms of MHC genes turned out negative, 
and this was mainly a result of small sample sizes, ill-defined clinical 
phenotypes and insensitive serotyping methods (Pirmohamed 2006). This 
changed when high-resolution HLA genotyping became available, and several 
strong associations between specific HLA alleles and certain drug 
hypersensitivity phenotypes have already been identified. Recent genome-wide 
association studies (GWAS) have added further evidence for the involvement of 
HLA alleles in drug hypersensitivity. An overview of drug-induced HSRs known 
to be associated with specific HLA alleles is presented in Table 1.5. Three 
examples of HLA-associated HSRs are described in more detail below. 
Environmental factors predisposing individuals to HSRs include viral infections. 
For example patients suffering from Epstein-Barr virus-induced infectious 
mononucleosis and treated with amoxicillin have a strongly increased risk of 
developing skin rash (Pirmohamed 2006). Another example is the increased 
frequency of hypersensitivity to SMX among HIV patients, which increases from 
3% in HIV-negative to 30% in HIV-positive patients (Pirmohamed 2006). 
Other risk factors predisposing individuals are related to the treatment 
regimen. For instance intermittent or repeated drug administration has been 
shown to increase the frequency of HSRs (Gomes and Demoly 2005). Also, 
parenteral administration of a drug appears to be more immunogenic than oral 
administration of the same drug (Gomes and Demoly 2005). Host-related 
factors, such as age, sex and weight, have been found to be risk factors in a few 
forms of HSRs. Women for instance have an increased risk of developing 
halothane-induced hepatitis or clozapine-induced agranulocytosis compared to 
men (Uetrecht 2007). 
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Table 1.5: Summary of well-characterised HLA-associated drug hypersensitivity reactions. 
Drug  
(Indication) 
HLA allele Syndrome Odds ratio Reference 
Abacavir 
(Antiretroviral) 
B*57:01 HSS 23.4; 117 (Hetherington et al. 2002; 
Mallal et al. 2002) 
Allopurinol 
(Gout) 
B*58:01 SJS/TEN, HSS 580.3; 96.6 (Hung et al. 2005b; Somkrua 
et al. 2011) 
Carbamazepine 
(Antiepileptic) 
B*15:02 (Han Chinese) 
 
A*31:01 (Caucasian, Japanese) 
SJS/TEN 
 
MPE, HSS, SJS/TEN 
2504 
 
12.1; 9.5 
(Chung et al. 2004) 
 
(McCormack et al. 2011; Ozeki 
et al. 2011) 
Co-amoxiclav 
(Antibiotic) 
A*02:01-B*07:02- 
DRB1*15:01-DQB1*06:02, 
A*02:01-B*18:01 (Spanish) 
DILI 13.0 
 
6.4 
(Lucena et al. 2011) 
Dapsone 
(Antibiotic) 
B*13:01 HSS 20.5 (Zhang, F. R. et al. 2013) 
Efavirenz 
(Antiretroviral) 
DRB1*01 (French) Skin rash (p= 0.004) (Vitezica et al. 2008) 
Flucloxacillin 
(Antibiotic) 
B*57:01 DILI 80.6 (Daly et al. 2009) 
Lamotrigine 
(Antiepileptic) 
B*15:02 (Han Chinese) 
 
A*30:01, B*13:02 (Han Chinese) 
 
SJS/TEN 
 
MPE 
5.1 
 
(p= 0.013) 
(Hung et al. 2010) 
 
(Li, Li-Juan et al. 2013) 
DILI= Drug-induced liver injury; HSS= Hypersensitivity syndrome; MPE= Maculopapular exanthema; NSAID= Non-steroidal anti-inflammatory drug; SJS= Stevens-
Johnson syndrome; TEN= Toxic epidermal necrolysis 
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Table 1.5 (continued): Summary of well-characterised HLA-associated drug hypersensitivity reactions. 
Drug 
(Indication) 
HLA allele Syndrome Odds ratio Reference 
Lapatinib 
(Breast cancer) 
DRB1*07:01-DQA1*02:01-DQB1*02:02 DILI 2.2 (Spraggs et al. 2011) 
Lumiracoxib 
(NSAID) 
DRB1*15:01-DQB1*06:02-
DRB5*01:01-DQA1*0102 
DILI 5.0 (Singer et al. 2010) 
Methazolamide 
(Glaucoma) 
B*59:01, C*02:01 (Korean) SJS/TEN 249.8 and 
22.1 
(Kim et al. 2010) 
Nevirapine 
(Antiretroviral) 
DRB1*01:01 
 
B*58:01, DRB1*01:02 (South Africans) 
 
C*04:01 (Malawian) 
 
C*8-B*14 (Sardinians) 
C*8 (Japanese) 
DRB1*01 (French) 
C*4-B*35:05 (Thai) 
C*4-DRB1*15 (Han Chinese) 
Hepatitis with rash 
 
Hepatotoxicity 
 
SJS/TEN 
 
Cutaneous reactions 
 
4.8 
 
(p= 0.03) 
 
17.5 
 
(p= 0.004) 
(p= 0.03) 
(p= 0.004) 
18.9 
3.6 
(Martin et al. 2005) 
 
(Phillips, E. et al. 2013) 
 
(Carr et al. 2013) 
 
(Littera et al. 2006; Gatanaga et 
al. 2007; Vitezica et al. 2008; 
Chantarangsu et al. 2009; Gao et 
al. 2012) 
Phenytoin 
(Antiepileptic) 
B*15:02 (Thai and Han Chinese) SJS/TEN (p= 0.005); 
5.1 
(Locharernkul et al. 2008; Hung 
et al. 2010) 
Ticlopidine 
(Antiplatelet) 
A*33:03 (Japanese) DILI 13.0 (Hirata et al. 2008) 
Ximelagatran 
(Anticoagulant) 
DRB1*07-DQA1*02 DILI 4.4 (Kindmark et al. 2008) 
DILI= Drug-induced liver injury; SJS= Stevens-Johnson syndrome; TEN= Toxic epidermal necrolysis 
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1.6.5 HLA associated drug hypersensitivity reactions 
The growing number of HLA associations with various drug hypersensitivity 
reactions implies that a causal relationship between the HLA molecules and 
hypersensitivity might exist (Wei, C. Y. et al. 2012b). However, the underlying 
mechanism for most HLA-associated reactions has not been resolved yet. This is 
further complicated by the fact that the majority of HLA associations are 
phenotype specific and the association can vary between populations of 
different ethnicity (Wei, C. Y. et al. 2012b). 
Three examples of HLA-associated hypersensitivity reactions will be discussed 
here in more detail: abacavir hypersensitivity and HLA-B*57:01, flucloxacillin-
induced liver injury and HLA-B*57:01, and allopurinol and HLA-B*58:01. 
 
Abacavir and HLA-B*57:01 
Abacavir (ABC) is an antiretroviral drug used to treat human immunodeficiency 
virus (HIV) infections. ABC can cause hypersensitivity syndrome in 5-8% of 
patients, with symptoms of fever, gastrointestinal manifestations and internal 
organ involvement (Pavlos et al. 2012). In up to 70% of hypersensitive patients 
a mild to moderate skin rash can develop. In 2002, two independent research 
groups reported a strong association between HLA-B*57:01 and ABC 
hypersensitivity (Hetherington et al. 2002; Mallal et al. 2002). Subsequent 
clinical trials showed that 100% of patch-test positive patients carried HLA-
B*57:01 and demonstrated a 100% negative-predictive value of HLA-B*57:01 
for ABC hypersensitivity (Pavlos et al. 2012). CD8+ T-cells have been found in 
the skin of ABC hypersensitive patients (Phillips, E. J. et al. 2002) and drug-
specific T-cell responses could be induced in patients as well as ABC-naïve, 
HLA-B*57:01+ healthy donors (Chessman et al. 2008). T-cell responses were 
restricted by HLA-B*57:01 and closely related HLA allotypes were unable to 
elicit a response (Chessman et al. 2008). Most recently, three individual studies 
showed that ABC can bind non-covalently within the F-pocket of HLA-B*57:01 
and thereby change the properties of the peptide-binding cleft, allowing an 
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altered set of self-peptides to be presented by HLA-B*57:01 (Illing et al. 2012; 
Norcross et al. 2012; Ostrov et al. 2012). 
It is important to note that 45% of HLA-B*57:01 positive patients are able to 
tolerate ABC, indicating additional factors are required for the development of a 
reaction (Pavlos et al. 2012). However, screening for HLA-B*57:01 prior to ABC 
therapy has been recommended by both the US Food and Drug Administration 
(FDA) and European Medicines Agency (EMA). Pharmacogenetic testing has 
strongly reduced the incidence of ABC hypersensitivity and has proven to be 
cost effective (Phillips, E. and Mallal 2009). 
 
Flucloxacillin and HLA-B*57:01 
Flucloxacillin is a β-lactam antibiotic used in the treatment of staphylococcal 
infections. The drug is associated with a risk of cholestatic hepatitis occurring in 
about 8 out of 100,000 patients (Russmann et al. 2005). A GWAS has recently 
identified HLA-B*57:01 as a risk factor for flucloxacillin-induced liver injury 
(Daly et al. 2009). The HLA allele was present in 85% of patients compared to 
5% of the general population. The detection of drug-specific T-cells in patients 
together with the HLA association suggests an underlying immune-mediated 
mechanism. Recently, two separate groups of researchers were able to generate 
drug-specific T-cells from HLA-B*57:01 positive patients and healthy 
volunteers. In the study by Monshi et al., drug-responsive CD8+ T-cell clones 
were shown to secrete cytolytic molecules upon flucloxacillin stimulation. The 
clones were shown to express chemokine receptors linked to the migration of 
immune cells to the liver (Monshi et al. 2013). T-cell activation was observed in 
the presence of APCs expressing HLA-B*57:01 or the closely related HLA-
B*58:01 allele (Monshi et al. 2013). Wuillemin et al. reported that HLA-
B*57:01+ T-cells were able to recognise flucloxacillin as a hapten complex, but 
the majority of T-cells were stimulated via a direct interaction as explained by 
the p-i concept (Wuillemin et al. 2013). In contrast to abacavir, no changes in 
the peptide repertoire of a HLA-B*57:01 expressing cell lines were seen 
following flucloxacillin treatment (Norcross et al. 2012). 
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It remains unclear why HLA-B*57:01 is only associated with flucloxacillin-
induced liver injury. The molecular pathomechanism through which 
flucloxacillin is able to specifically kill liver cells has yet to be resolved. 
 
Allopurinol and HLA-B*58:01 
Allopurinol is used for the prevention of gout and hyperuricemia, and is 
associated with the occurrence of HSS and SJS/TEN syndromes. The first study 
linking HLA-B*58:01 with allopurinol-induced serious cutaneous reactions was 
conducted in Han Chinese patients, showing that HLA-B*58:01 was present in 
100% of patients and only 15% of tolerant controls (Hung et al. 2005b). This 
has meanwhile been replicated in several Asian populations, including 
Japanese, Thai and Koreans (Pavlos et al. 2012). In Caucasians the association 
between HLA-B*58:01 and allopurinol hypersensitivity was found to be lower 
but still present with about 50% of patients carrying the risk allele (Lonjou et al. 
2008). This might be due to the lower allele frequency of HLA-B*58:01 in 
Caucasians compared to Asians (Pavlos et al. 2012). The mechanism through 
which this HLA allele might contribute to the development of allopurinol HSRs 
remains to be elucidated. Additional risk factors have been found to influence 
the occurrence of allopurinol hypersensitivity, namely renal failure and 
administered daily dose (Yun et al. 2012). Yun et al. hypothesized that both 
factors could lead to the accumulation of allopurinol, or its metabolite 
oxypurinol, which may be presented by HLA-B*58:01 to drug-specific T-cells; 
and if the TCR avidity is high enough this might result in T-cell activation (Yun 
et al. 2012). 
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1.7 Carbamazepine 
 
1.7.1 Indication 
Carbamazepine (CBZ) is an anticonvulsant which is primarily used in the 
treatment of epilepsy for the prevention of partial and secondarily generalized 
tonic-clonic seizures (Engel and Pedley 2008). It was first introduced to the 
market in the 1960s, and has since then become one of the most often 
prescribed drugs in neurologic disorders due to its proven clinical efficacy, 
inexpensiveness and wide availability (Engel and Pedley 2008). CBZ is also 
effectively used in the treatment of neuropathic pain syndromes, such as 
trigeminal neuralgia and diabetic neuropathy (Spina and Perugi 2004). In 2004, 
CBZ was approved as mood stabilizer for the treatment of manic and mixed 
episodes of bipolar disorders (Ettinger and Argoff 2007). Its efficacy is 
comparable to lithium and many patients intolerant to lithium can be 
successfully treated with CBZ (Grunze 2010). 
 
1.7.2 Mechanism of action 
The mechanism of action is still not completely understood. CBZ is known to 
block voltage-dependent sodium channels in the neuronal membrane 
promoting their inactivation; and this leads to reduced firing of high-frequency 
action potentials and stabilisation of hyperexcited neurones (Rogawski and 
Loscher 2004). The inhibitory effect is voltage- and use-dependent, so that only 
hyperreactive nerves are affected. The reduced firing of action potentials is 
followed by a reduced amount of neurotransmitters being released into the 
synaptic cleft (Rogawski and Loscher 2004). 
 
1.7.3 Pharmacokinetics and Metabolism 
Carbamazepine is slowly absorbed from the gastrointestinal tract and has a 
bioavailability of about 80 to 90%. The drug is quickly distributed to various 
organs and readily transported across the blood-brain barrier (Wyllie et al. 
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2006). CBZ is metabolized extensively and almost entirely in the human liver, 
involving steps of oxidation, hydroxylation and conjugation. Only about 5% of 
the parent drug is excreted unchanged in the urine (Thorn et al. 2011), 
alongside more than 30 different metabolites (Lertratanangkoon and Horning 
1982). The main metabolic pathways are shown in Figure 1.12. 
CBZ is oxidized by cytochrome P-450 (CYP) enzymes, mainly CYP3A4 and to 
some extent CYP2C8 and CYP3A5, to CBZ-10,11-epoxide (Thorn et al. 2011). 
The epoxide is further hydrolysed by microsomal epoxide hydrolase 1 (EPHX1) 
to CBZ-10,11-trans-diol, which can be excreted in the urine directly or as a 
conjugate after glucuronidation (Maggs et al. 1997). The epoxide-diol pathway 
is the major route of metabolism. Minor metabolites include hydroxylation at 
variable sides of the aromatic rings, presumably via arene oxide intermediates. 
These reactions are catalysed by various CYP enzymes, including CYP 3A4, 
CYP2B6, CYP2E1, CYP2A6 and CYP1A2 (Pearce et al. 2002). Subsequent 
metabolism leads to the formation of reactive quinone structures. These can be 
conjugated with glucuronic acid and excreted into the urine (Lu and Uetrecht 
2008). 
CBZ can enhance the transcription of several metabolising enzymes, including 
autoinduction of CYP3A4 and CYP2B6 (Thorn et al. 2011). This can cause 
various forms of drug interactions, for example decreased plasma 
concentrations of concomitantly administered anticonvulsants. This process is 
known to appear about 2 to 6 weeks after treatment initiation and requires 
dose adjustment (Wyllie et al. 2006). 
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Figure 1.12: Metabolic pathways of carbamazepine bioactivation and detoxification 
(adapted from (Pearce et al. 2002; Lu and Uetrecht 2008; Pearce et al. 2008)). 
Structures in brackets were deduced from products. 
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1.8 Carbamazepine-induced Hypersensitivity 
 
Carbamazepine is usually well tolerated but it can cause cutaneous ADRs in up 
to 10% of patients treated with the drug (Marson et al. 2007). Most commonly, 
a mild erythematous skin rash develops several days after treatment initiation, 
which can resolve spontaneously without further intervention. More severe 
reactions include hypersensitivity syndrome (HSS) which usually occurs within 
the first eight weeks of CBZ therapy and is associated with rash, fever, 
eosinophilia and internal organ involvement, mostly hepatitis (Knowles et al. 
1999). CBZ-induced HSS occurs at an estimated frequency of 4 in 10,000 
exposures (Gogtay et al. 2005). Cases of SJS and TEN have also been reported 
but are rare in Caucasians, with an estimated prevalence of 1: 5,000 patients 
(Yip, V. et al. 2013). In contrast, CBZ-induced SJS is known to occur at an 
approximately ten-fold higher frequency in Han Chinese (Hung et al. 2005a). 
 
1.8.1 Pharmacogenetics 
Predisposition to CBZ hypersensitivity has long been thought to have a genetic 
basis. This was supported by case reports of hypersensitivity reactions in 
members of the same family, as well as monozygotic twins (Edwards, S. G. et al. 
1999). Since chemically reactive metabolites of CBZ, such as arene oxides, were 
suspected to cause direct cellular toxicity and potentially stimulate the immune 
system, early investigations concentrated on genetic defects in detoxification 
mechanisms (Knowles et al. 1999). However, studies on polymorphisms in 
genes of metabolising enzymes, such as microsomal epoxide hydroxylase 
(Green et al. 1995), failed to find any significant association. Autoantibodies 
directed against CYP isoenzymes have been detected in some patients, 
suggesting CBZ or a metabolite may form adducts with CYP enzymes leading to 
the formation of neoantigens (Leeder et al. 1992). However, whether these 
antibodies are immunogenic has not yet been demonstrated. 
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A major advancement was the discovery that specific HLA alleles are strongly 
associated with defined clinical phenotypes of CBZ hypersensitivity. In 2004, 
Chung et al. reported that HLA-B*15:02 was found to be present in 100% of Han 
Chinese patients suffering from CBZ-induced SJS/TEN, compared to 3% of CBZ-
tolerant controls (Chung et al. 2004). This association has been replicated in 
several populations of Southeast Asian ancestry, including Thai, Malaysians and 
Indians (Locharernkul et al. 2008; Mehta et al. 2009; Then et al. 2011). 
However, HLA-B*15:02 is not associated with CBZ hypersensitivity in Caucasian 
populations (Alfirevic et al. 2006; Lonjou et al. 2006) or Japanese (Kaniwa et al. 
2008). This is possibly due to the low frequency of HLA-B*15:02 in Europeans 
and Japanese (both < 1%; reported on www.allelefrequencies.net) compared to 
Chinese populations (up to 35%; see www.allelefrequencies.net). Genetic 
testing for HLA-B*15:02 prior to start of CBZ therapy has therefore been 
recommended by the FDA in patients of Asian descent only (Ferrell and McLeod 
2008). 
More recently, two independent GWAS have identified an association between 
HLA-A*31:01 and all phenotypes of CBZ hypersensitivity in Japanese (Ozeki et 
al. 2011) and in Caucasians (McCormack et al. 2011), with a prevalence of 60% 
and 26% respectively. The HLA-A*31:01 allele had previously been reported in 
association with CBZ-induced MPE in Han Chinese (Hung et al. 2006). 
 
1.8.2 Functional studies 
The clinical features of CBZ hypersensitivity suggest an immune-mediated 
aetiology, and the presence of drug-specific T-cells in hypersensitive patients 
supports this assumption (Mauri-Hellweg et al. 1995; Wu et al. 2007). The 
strong associations with specific HLA alleles indicate a direct role for HLA in the 
presentation of CBZ and subsequent initiation of a T-cell mediated immune 
response. 
In vitro studies using CBZ-specific T-cell clones have shown that T-cells are 
stimulated by CBZ in the absence of drug metabolism and antigen processing 
(Wu et al. 2006; Wu et al. 2007). These observations suggest that T-cell 
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activation occurs through direct interaction between the drug, HLA and/ or 
TCR, as proposed in the p-i concept. Peptide elution studies using HLA-B*15:02-
transfected cell lines cultured in the presence of the drug were unable to 
detected any CBZ-modified peptides (Yang et al. 2007). A study by Wei et al. 
demonstrated that CBZ binds directly to the binding groove of HLA-B*15:02 and 
subsequently presented to cytotoxic T-cells (Wei, C. Y. et al. 2012a). However, 
CBZ-specific T-cell activation was only possible if endogenous peptides were 
present to stabilize the HLA complex. Moreover, in silico modelling showed that 
CBZ preferably bound in the B-pocket of HLA-B*15:02 (Wei, C. Y. et al. 2012a). 
In a recent study by Illing et al. (2012), CBZ was found to bind non-covalently to 
HLA-B*15:02 and induce a modest shift in the peptide repertoire to slightly 
more hydrophobic peptides. These findings suggest that the altered peptide 
hypothesis might be implicated in the pathogenesis of CBZ hypersensitivity. 
Nonetheless, it is important to note that many patients who are carriers of CBZ-
associated risk alleles are able to tolerate the drug. This indicates that 
additional factors are important in predisposing individuals to develop 
hypersensitivity. Recently, Ko et al. (2011) reported that CBZ-responsive CD8+ 
T-cells isolated from HLA-B*15:02+ individuals used a common restricted TCR 
repertoire. The predominant TCR clonotypes could be detected in both blister 
fluid cells and unstimulated peripheral blood mononuclear cells (PBMCs) of 
patients suffering from SJS. The oligoclonal T-cells can also be found in HLA-
B*15:02+ healthy donors, and when stimulated with CBZ in vitro this results in 
a robust immune response to the drug (Ko et al. 2011). This study indicates that 
the expression of both the correct TCR and the predisposing HLA molecule are 
essential in eliciting hypersensitivity reactions to CBZ. 
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1.9 Sulfamethoxazole 
 
Sulfamethoxazole (SMX) is an antibiotic agent used in combination with 
trimethoprim to treat various infections. SMX is known to cause cutaneous 
HSRs in approximately 3-8% of patients (Castrejon et al. 2010). Clinical 
manifestations range from immediate-type reactions, such as anaphylaxis, to 
delayed-type reactions, including mild exanthematous rash and blistering skin 
reactions like SJS and TEN. Many studies investigating the mechanisms behind 
drug hypersensitivity have used SMX as a model drug (Pirmohamed et al. 2002; 
Engler et al. 2004), mainly because of its well characterised metabolic 
pathways. 
SMX is metabolised by N-acetyltransferases in the liver and the nontoxic 
products are quickly excreted. A fraction of the drug can be converted to a 
hydroxylamine intermediate (SMX-NHOH) via CYP 2C9 (Cribb, A. E. et al. 1995). 
The hydroxylamine is rather stable, but spontaneous oxidation can lead to the 
formation of a highly reactive nitroso metabolite (SMX-NO) (Cribb, Alastair E. 
and Spielberg 1992). SMX-NO is known to modify cysteine residues on multiple 
proteins (Naisbitt et al. 2002; Callan et al. 2009). 
SMX-NO has been shown to be highly immunogenic, stimulating the innate 
immune system by activating dendritic cells (Sanderson et al. 2007) and 
inducing an adaptive immune response through generation of drug-modified 
peptides (Castrejon et al. 2010). In animal models, treatment with SMX-NO 
stimulates the activation of T-cells, which specifically recognise SMX-NO-
modified peptides in a TCR dependent, MHC restricted manner (Naisbitt et al. 
2002; Farrell et al. 2003). However, SMX itself is unable to stimulate these T-
cells. Studies of T-cell clones (TCCs) generated from hypersensitive patients 
show a slightly more complex picture. Most TCCs are activated by SXM-NO and 
the response is dependent on covalent binding and antigen processing 
(Castrejon et al. 2010). At the same time it has been reported that TCCs can also 
recognise SMX directly, independent of covalent binding and without the need 
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for antigen processing (Schnyder et al. 1997). Whether SMX represents the 
original immunogen in these cases remains unclear. 
In vitro studies on T-cells isolated from drug-naïve individuals demonstrated 
that SMX-NO can elicit a T-cell response in nearly 100% of cases (Engler et al. 
2004). Recently, it has been shown that SMX-NO priming induces a phenotypic 
change of naïve T-cells to a memory T-cell population (Faulkner et al. 2012). 
 
 
1.10 Aims 
 
There is substantial evidence that hypersensitivity reactions to carbamazepine 
are mediated by the adaptive immune system and drug-specific T-cells have 
been identified as key players in the pathogenesis of these reactions (Mauri-
Hellweg et al. 1995; Leeder 1998; Roujeau 2006). The isolation of CBZ-reactive 
T-cells from patients and in vitro stimulation of the cells with CBZ has made it 
possible to study their phenotype and effector functions in detail (Naisbitt et al. 
2003a; Wu et al. 2006), as discussed earlier in this chapter. However, the 
molecular mechanisms through which CBZ causes T-cell activation still remain 
largely unknown. 
The numerous associations between specific HLA alleles and drug-induced 
HSRs imply that HLA alleles may have a functional role in mediating T-cell 
responses to drugs. A mechanistic basis for some HLA-associated drug 
hypersensitivity reactions, such as abacavir and HLA-B*57:01 (Chessman et al. 
2008) or carbamazepine and HLA-B*15:02 (Wei, C. Y. et al. 2012a), is beginning 
to be uncovered. At the same time, in vitro studies investigating the interaction 
between HLA-B*15:02 and CBZ-specific T-cells have demonstrated that specific 
T-cell receptors may present additional susceptibility factors in the 
development of CBZ-induced HSRs (Ko and Chen 2012). 
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HLA-A*31:01 represents the first HLA allele associated with CBZ-induced HSRs 
in Caucasian patients (McCormack et al. 2011), indicating CBZ may selectively 
bind to HLA-A*31:01 and trigger T-cell activation in this population. However, 
studies investigating whether any direct interactions between CBZ, HLA-
A*31:01 and drug-responsive T-cells occur have not yet been performed. Thus, I 
wanted to explore whether HLA-A*31:01 is functionally involved in mediating 
carbamazepine hypersensitivity in patients of European ancestry. 
The aims of this thesis were therefore to: 
1) Determine the pattern of HLA restriction of drug-specific T-cells isolated 
from a HLA-A*31:01 positive, carbamazepine hypersensitive patient. 
 
2) Generate a primary immune response to carbamazepine in vitro using T-
cells from HLA-A*31:01 positive, drug-naïve individuals. 
 
3) Characterise the peptide-binding specificity of HLA-A*31:01 in 
comparison to HLA-B*15:02 using in silico and in vitro approaches. 
 
4) Establish a method for T-cell receptor spectratyping using the model 
drug antigen nitroso sulfamethoxazole as a first step. At a later stage, this 
method will then be used to study the T-cell receptor usage in 
carbamazepine hypersensitivity. 
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2.1 Introduction 
 
Carbamazepine (CBZ) is known to cause hypersensitivity reactions of varying 
severity in a small proportion of patients treated with the drug. The reactions 
are thought to have an underlying immune-mediated aetiology, and drug-
reactive T-lymphocytes of CD4 and CD8 phenotype have been isolated from 
patients’ blood and skin (Mauri-Hellweg et al. 1995; Leyva et al. 2000). Genetic 
factors predisposing individuals to CBZ hypersensitivity have long been 
postulated to be important, and recent genetic studies revealed strong 
associations with specific human leukocyte antigen (HLA) alleles. 
HLA-B*15:02, the first CBZ-associated HLA allele reported, was detected in 
almost all cases of CBZ-induced Stevens-Johnson syndrome (SJS) in patients of 
Han Chinese or Southeast Asian ancestry (Chung et al. 2004; Tassaneeyakul et 
al. 2010; Chang et al. 2011; Zhang, Y. et al. 2011b). Its functional role in 
development of CBZ-induced SJS has been well characterised. T-cell responses 
in these patients are predominantly mediated by cytotoxic CD8+ T-cells (Nassif 
et al. 2004), which are restricted by HLA-B*15:02 (Wei, C. Y. et al. 2012a). The 
drug-specific effector T-cells have been shown to mediate cytotoxicity through 
the use of shared restricted T-cell receptors (TCRs) (Ko and Chen 2012). 
HLA-A*31:01 represents the latest example, and two independent genome-wide 
association studies (GWAS) have found it to be associated with all clinical 
phenotypes of CBZ hypersensitivity in Caucasian and Japanese populations 
(McCormack et al. 2011; Ozeki et al. 2011). A study by Niihara et al. (2012) 
aimed to determine whether lymphocyte activation was correlated to HLA-A31 
status by comparing lymphocyte responses in HLA-A31 positive to A31 negative 
CBZ hypersensitive patients, but no significant difference was detected (Niihara 
et al. 2012). However, functional studies investigating whether T-cell responses 
to CBZ are dependent on the drug interacting specifically with HLA-A*31:01 
have not been performed.  
The main aim of the work presented in this chapter was to characterise in detail 
the HLA restriction of CBZ-reactive T-cell clones (TCCs) generated from a CBZ 
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hypersensitive patient carrying HLA-A*31:01. I focused on the CD8+ as well as 
CD4+ T-cell populations, as both lymphocyte types have been shown to be 
involved in CBZ hypersensitivity (Wu et al. 2007). In contrast to SJS, CD4+ T-cell 
have been shown to be the prevalent cell type in mild maculopapular rashes 
and are also involved in the elicitation of DRESS (see chapter 1.6.2). Thus, it was 
of interest to explore whether CBZ-specific TCCs of both CD4 and CD8 
phenotypes were activated in a HLA restricted manner. 
 
 
2.2 Materials & Methods 
 
2.2.1 Patient Characteristics 
The carbamazepine hypersensitive patient was recruited retrospectively at the 
Royal Liverpool University Hospital. The study was approved by the local ethics 
committee and informed consent obtained from the patient. The patient was a 
74-year old female who had suffered a hypersensitivity reaction to 
carbamazepine 22 years ago. She had developed a hypersensitivity syndrome to 
CBZ six days after treatment initiation and the clinical details are summarised in 
Table 2.1. Previously performed HLA genotyping had shown that the patient 
was a carrier of HLA-A*31:01. 
 
2.2.2 Chemicals 
Carbamazepine (Sigma-Aldrich, UK) was prepared as stock solution (10mg/ml) 
in T-cell medium containing 10% dimethyl sulfoxide (DMSO; Sigma, UK). The 
stock solutions was made up fresh and diluted to the appropriate concentration 
directly before use. Tetanus toxoid was obtained from the Statens Serum 
Institut in Denmark. All other reagents were purchased from Sigma-Aldrich, UK, 
unless stated otherwise. 
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Table 2.1: Clinical data of the CBZ hypersensitive patient. 
Gender Female 
Age (years) 74 
Type of reaction 
Generalized maculopapular rash 
with fever, eosinophilia and 
lymphocytosis 
Time to reaction (days) 6 
Time since reaction 
(years) 
22 
Rechallenge No 
HLA genotype 
A*11:01/31:01 
B*27:05/40:01 
C*01:02/03:04 
DRB1*03:01/04:04 
DQB1*02:01/03:02 
 
 
2.2.3 Cell culture medium 
T-cell culture medium consisted of RPMI 1640 medium supplemented with 
10% pooled human AB serum (Innovative Research, USA), 25mM HEPES buffer, 
2mM L-glutamine, 100μg/ml streptomycin, 100U/ml penicillin and 25μg/ml 
transferrin. To maintain T-cells in long-term culture, the medium was 
supplemented with 200U/ml IL-2 (Preprotech, UK). 
B-cell medium comprised of RPMI 1640 medium supplemented with 10% foetal 
bovine serum (FBS; Invitrogen, UK), 25mM HEPES buffer, 100μg/ml 
streptomycin and 100U/ml penicillin. 
 
2.2.4 Lymphocyte isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood of 
the patient by density gradient centrifugation. The blood was carefully layered 
on an equal volume of Lymphoprep (Axis-Shield, UK) and spun down at 
2000rpm for 25min. The layer of PBMCs was extracted with a Pasteur pipette 
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and washed twice in Hanks balanced salt solution (HBSS) to remove any 
remaining Lymphoprep. Isolated lymphocytes were resuspended in T-cell 
culture medium. 
 
2.2.5 Generation of antigen-presenting cell lines 
Epstein-Barr virus (EBV) transformed B-lymphoblastoid cell lines (B-LCLs) 
were used as antigen-presenting cells. B-LCLs were generated by 
transformation of PBMCs with supernatant (SN) from the EBV-producing B95-8 
cell line (Neitzel 1986). PBMCs (5x 106) were incubated overnight with 5ml of 
filtered (0.45μm syringe filter) EBV-containing B95-8 SN at 37°C. Cyclosporine 
A (CSA) was added at 1μg/ml to inhibit T-cell proliferation. On the next day, 
cells were spun down (1500rpm, 5min), resuspended in B-cell medium 
supplemented with 1μg/ml CSA and plated into a 24-well plate (2.5- 10x 105 
cells; 2ml). Medium was exchanged twice weekly. CSA treatment was stopped 
after 2-3 weeks and cells transferred to tissue culture flasks. 
 
2.2.6 Lymphocyte transformation test 
The lymphocyte transformation test (LTT) represents an in vitro method to 
determine whether drug-specific lymphocytes are present in the blood of 
hypersensitive patients (Pichler and Tilch 2004). 
Isolated PBMCs (1.5x 105; 100ul) were cultured with CBZ (1-100μg/ml; 100ul) 
in a 96-well U bottom plate in triplicate for six days. Tetanus toxoid (TT; 
1μg/ml) was used as positive control. [3H]-thymidine (Moravek, USA) was 
added for the final 16 hours of incubation. Cells were harvested and 
proliferation determined by [3H]-thymidine incorporation using a MicroBeta 
TriLux β-counter (Perkin Elmer, USA). Proliferative responses were expressed 
as stimulation index (SI) using the following formula: SI= cpm of drug-treated 
cultures/ cpm of control. An SI value above 2 was considered a positive 
response (Nyfeler and Pichler 1997). 
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2.2.7 T-cell enrichment culture 
Drug-specific T-cells were enriched by stimulating lymphocytes with CBZ 
repeatedly over four weeks as described previously (Naisbitt et al. 2003a). 
PBMCs (5x 106, 1ml) were cultured with CBZ (25μg/ml) in a 24-well plate for 7 
days. IL-2 containing T-cell medium was added on day 3. On day 7, cells were 
restimulated with autologous irradiated PBMCs (1x 106) and CBZ (25μg/ml). 
Three cycles of restimulation were performed, and wells were split when 
necessary to support proliferation. 
 
2.2.8 51Cr-release cytotoxicity assay 
The cytotoxic activity of T-cell enriched PBMC cultures was assessed in vitro in a 
51Cr-release assay using previously established methods (Brunner et al. 1968; 
Dunkley et al. 1974). 
Autologous B-LCLs (1.5x 106) were incubated with 51Chromium (50μCi; 
PerkinElmer, UK) for 1 hour and then washed three times to remove any free 
51Cr. Radioactive labelled B-LCLs (2.5x 103) were mixed with PBMCs (1- 10x 
104) and incubated for 4 hours at 37°C in the presence and absence of CBZ (10- 
50μg/ml). T-cell mediated killing of B-LCLs was determined by the amount of 
51Cr released into the supernatant and measured by liquid scintillation 
counting. The specific lysis was calculated using the following formula: 
(cpm CBZ treatment – cpm spontaneous release)/(cpm maximum release – cpm 
spontaneous release) x 100. 
 
2.2.9 Generation of drug-specific T-cell clones 
Initially, PBMCs (1x 106, 1ml) were cultured in T-cell medium containing 
25μg/ml CBZ for 14 days in a 48-well plate at 37°C. On day 6 and day 9, IL-2 
supplemented medium was added to the cultures. On day 14, T-cells were 
cloned by serial dilution using established methodology (Naisbitt et al. 2003a). 
Cells were seeded into 96-well U bottom plates at concentrations of 0.5, 1.0 and 
3.0 cells per well. Allogeneic irradiated PBMCs (5x 105), phytohemagglutinin 
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(PHA, 5ug/ml) and IL-2 (200U/ml) were added to stimulate T-cell growth. If 
necessary a further restimulation cycle was performed after two weeks. Well-
growing clones were expanded in new plates and split when necessary. Drug 
specificity of TCCs was assessed by T-cell proliferation assay. 
 
 
Figure 2.1: T-cell cloning procedure. 
PBMCs were cultured for 14 days with drug, then serial diluted at cell densities of 3, 1 and 0.5 
cells per well. T-cell clones were restimulated with allogeneic irradiated APCs after another 14 
days if necessary. Well-growing clones were picked into new plates and expanded. Drug-
specificity was tested by proliferation assay 2 weeks later. 
 
Drug-specific clones were restimulated every 2-3 weeks as described above in 
order to maintain T-cell proliferation. 
In subsequent cloning experiments, T-cell bulks were separated into CD4+ and 
CD8+ T-cells prior to serial dilution using magnetic cell sorting beads (Miltenyi 
Biotech, UK). T-cells were incubated with CD8 Multisort microbeads and 
separated over a magnetic column. The flow through contained the unlabelled 
CD4+ T-cells. After removal of the column from the magnetic field, CD8+ T-cells 
were flushed out using a plunger. 
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2.2.10 T-cell proliferation assay 
The T-cell proliferation assay was used to determine the drug-specificity and 
functionality of the T-cell clones. T-cells (5x 104) were incubated with 
autologous, irradiated B-LCLs (1x 104) and CBZ (10- 50μg/ml) in a 96-well U 
bottom plate. After 48 hours, [3H]-thymidine (0.5μCi) was added and 
proliferation measured by scintillation counting 16 hours later as described in 
2.2.6. TCCs with an SI above 2 were considered to be drug-specific. 
To test for HLA restriction the protocol was modified in two different ways. 
First, autologous B-LCLs were incubated with human anti-HLA blocking 
antibodies (anti-MHC I, anti-MHC II, anti-HLA DR, anti-HLA DQ - all BD 
Bioscience, UK; anti-HLA DP and anti-HLA A30/A31 - Abcam, UK) before being 
added to the proliferation assay. 
Second, T-cell clones were cultured with CBZ in the presence of allogeneic APCs 
expressing HLA alleles of interest. PBMCs of HLA-typed healthy volunteers were 
used to generate allogeneic B-LCLs via the method described in 2.2.5. The 
healthy volunteers were all part of the HLA-typed cell archive established at the 
University (Alfirevic et al. 2012) and their respective HLA genotypes are shown 
in Table 2.2. In another experimental set-up, HLA-DRB1*04:04-transfected T2-
cell lines (kindly donated by the laboratory of Prof. James McCluskey, University 
of Melbourne, Australia) were used as APCs. Wild type T2 cells are a B-
lymphoblast cell line that only expresses HLA-A2 but no HLA class II alleles. 
 
2.2.11 CD phenotyping 
CD phenotype of clones was determined by flow cytometry. TCCs were stained 
with phosphatidylethanolamine (PE) labelled anti-CD4 and fluorescein 
isothiocyanate (FITC) labelled anti-CD8 antibodies for 20min at 4°C. Clones 
were washed and resuspended in HBSS containing 1% FBS and 0.02% sodium 
azide. Fluorescence was measured on a BD FACS Canto II flow cytometer 
recording a minimum of 10,000 events, and data analysed using Cyflogic 
software (CyFlo Ltd., Finland).   
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Table 2.2: HLA genotypes of healthy volunteers selected for this study. 
ID HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 
HV2 02:01/31:01 15:01/44:02 03:03/05:01 01:01/08:01 05:01/06:02 
HV4 03:01/11:01 27:05/47:01 02:02/06:02 03:01/04:04 02:01/03:02 
HV5 02:01/31:01 15:05/40:06 03:03/15:02 04:04/14:04 03:02/05:03 
HV6 02:01/24:02 08:01/15:07 03:03/07:01 03:01/04:04 02:01/03:02 
HV7 24:02/31:01 14:02/40:01 02:02/03:04 01:02/04:04 03:02/05:01 
HV8 02:01/03:01 07:02/44:02 07:04/07:02 03:01/04:04 02:01/03:02 
HV13 24:02/31:01 55:01/56:01 01:02/03:03 04:01/12:01 03:02/03:01 
HV16 01:01/02:01 44:02/57:01 05:01/06:02 01:01/04:04 03:03/05:01 
HV17 02:01/03:01 07:02/57:01 06:02/07:02 15:01/07:01 03:03/06:02 
HV20 29:02/31:01 07:02/15:01 03:03/07:02 13:01/14:01 05:03/06:03 
HV23 02:02/31:01 27:05/51:01 02:02/15:02 16:01/13:01 05:02/06:03 
HV24 11:01/31:01 40:01/51:01 03:04/15:02 04:04/04:08 03:02/03:01 
HV28 02:01/33:01 14:02/52:01 08:02/15:02 01:02/04:04 03:02/05:01 
HV29 02:01/25:01 07:02/18:01 07:02/12:03 15:01/13:01 06:02/06:03 
HV34 01:01/26:01 08:01/35:01 04:01/07:01 01:03/03:01 02:01/05:01 
HV36 01:01/02:01 08:01/44:04 07:01/16:01 03:01/11:01 02:01/03:01 
HV38 01:01/26:01 40:01/57:01 03:04/06:02 01:01/13:01 05:01/06:03 
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2.2.12 Enzyme-linked immunospot assay 
Cytokine secretion was determined by enzyme-linked immunospot (ELISpot) 
assay according to the manufacturer’s protocol. IFN-γ, IL-13, granzyme B and 
perforin kits were purchased from Mabtech, Sweden; and FasL kit was obtained 
from Abcam, UK. 
MultiscreenHTS filter plates (Millipore, UK) were coated with cytokine-specific 
capture antibody and incubated overnight at 4°C. Wells were washed the next 
day with sterile HBSS and blocked with T-cell medium for 30min (for FasL 
assay blocking was performed for 2 hours using 2% skimmed milk). T-cells (5x 
104, 50μl) together with autologous irradiated B-LCLs (1x 104, 50μl) and CBZ 
(25 and 50μg/ml, 100μl) were added to the wells and incubated for 48 hours at 
37°C. The plate was emptied and then washed five times with phosphate 
buffered saline (PBS) (for FasL assay 0.1% Tween-20 was added to PBS). Biotin-
labelled detection antibody was added to the wells and incubated for 2 hours at 
room temperature (RT). After another washing step, streptavidin-alkaline 
phosphatase was added and incubated for one hour at RT. Spots were 
developed by addition of BCIP/NBT substrate until distinct spots were visible. 
An outline of the protocol is depicted in Figure 2.2. Colour development was 
stopped by washing under tap water. When plates had dried completely, spots 
were counted on the AID ELISpot reader. 
 
2.2.13 Statistical analysis 
Statistical analysis was performed using Mann-Whitney U test to compare T-cell 
responses of independent samples and Wilcoxon test for paired samples. 
Kruskal-Wallis H test was used for the assessment of multiple groups. Non-
parametric tests were used due to small sample size which prevented a clear 
assessment whether the data follows the normal distribution. A p-value < 0.05 
was considered significant. 
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Figure 2.2: Schematic illustration of the ELISpot assay. 
 
 
2.3 Results 
 
2.3.1 In vitro response of PBMCs to carbamazepine 
In order to confirm that a sensitisation of T-cells to CBZ had taken place earlier, 
and reactive T-cells were still present in the patient’s circulation, the 
lymphocyte transformation test (LTT) was performed. Isolated PBMCs from the 
patient proliferated strongly in the presence of the drug, with a maximal 
stimulation index of 15.9 recorded at a concentration of 50μg/ml CBZ (Figure 
2.3). 
  Chapter 2 
65 
 
 
Figure 2.3: Lymphocyte transformation test. 
PBMCs were incubated with CBZ (1-100μg/ml) in triplicate for 6 days, and [3H]-thymidine 
added in the final 16 hours of the experiment. Proliferation was determined by scintillation 
counting. A stimulation index above 2 (dashed line) was considered a positive response. (TT= 
tetanus toxoid) 
 
Drug-specific lymphocytes were enriched by weekly stimulation of PBMCs with 
CBZ over four weeks’ time. A subsequently performed IFN-γ ELISpot assay 
showed that CBZ was able to stimulate an increase in IFN-γ secretion in the 
PBMC culture (Figure 2.4), indicating a successful expansion of drug-specific T-
cells. 
 
Figure 2.4: CBZ-specific secretion of IFN-γ after T-cell enrichment culture. 
T-cell enriched PBMCs were 
incubated with CBZ and 
autologous B-LCLs. Cytokine 
secretion of drug-specific T-
cells was visualised in an 
IFN-γ ELISpot assay 
following the 
manufacturer’s protocol. 
(SFC= spot-forming cell)  
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The T-cell enriched PBMCs showed weak cytotoxic activity against autologous 
B-LCLs (Figure 2.5). T-cell mediated killing of 51Cr labelled B-LCL was induced 
at CBZ concentrations above 25μg/ml and at an effector: target cell ratio of 
40:1. 
 
 
Figure 2.5: Cytotoxic activity of T-cell enriched PBMCs after three cycles of 
restimulation. 
T-cell enriched PBMCs were incubated with CBZ (10- 50μg/ml) and 51Cr loaded B-LCLs at the 
indicated effector: target cell ratios for 4 hours. Specific lysis was calculated as (cpm CBZ 
treatment – cpm spontaneous release)/(cpm maximum release – cpm spontaneous release) x 
100. 
 
2.3.2 Characterisation of carbamazepine-specific T-cell clones 
T-cell clones were generated by the serial dilution method as described above. 
In total, three rounds of T-cell cloning were carried out producing 947 clones. 
The third cloning attempt was performed after a magnetic cell separation of the 
CBZ-stimulated T-cell bulks into CD4+ and CD8+ T-cell populations. Only cloning 
of the CD8+ population was performed in order to increase the number of 
available CD8+ TCCs for further characterisation. Reactivity of the clones to CBZ 
was tested by 48-hour proliferation assay. Sixty-seven TCCs displayed robust 
proliferative responses to CBZ (control: 5,525.8 ± 18,928cpm; CBZ 25μg/ml: 
34,418.8 ± 43,632.5cpm) and were therefore classified as drug-specific (Table 
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2.3). Drug-specific clones were phenotyped for CD expression by flow 
cytometry and almost equal numbers of CD4+, CD8+ and CD4+CD8+ TCCs were 
detected (35%, 41% and 24% respectively; Table 2.3). 
 
Table 2.3: Specificity and phenotype of drug-specific T-cell clones. 
 
Clones 
tested 
(n) 
Specific 
clones 
(n) 
Proliferation (cpm) CD phenotype (%) 
control 
CBZ 
(25μg/ml) 
CD4+ CD8+ 
CD4+ 
CD8+ 
to
ta
l 
947 67 
5,525.8 
±18,928.0 
34,418.8 
±43,632.5 
35 41 24 
1 35 10 
8,020.2 
±12,132.7 
50,582.9 
±66,184.1 
100 0 0 
2 600 26 
7,348.5 
±29,381.1 
39,783.7 
±49,183.2 
38 62 0 
3 312 31 
3,175.7 
±1,800.2 
24,721.7 
±23,604.5 
-ǂ 40 60 
Proliferation data presented as mean cpm ± SD. 
ǂ
) only CD8+ T-cell population was cloned. 
 
T-cell clones proliferated to CBZ in a dose-dependent manner irrespective of 
their CD phenotype (Figure 2.6). However, proliferative responses were 
strongest in the CD4+ population reaching a maximum of approximately 
60,000cpm (25ug/ml CBZ; Figure 2.6 A) compared to about 20,000cpm for 
CD8+ and CD4+CD8+ TCCs (Figure 2.6 B+C). This is in line with previous studies 
which have found CD8+ TCCs to proliferate weakly upon CBZ stimulation 
compared to CD4+ clones but instead show strong cytotoxic responses (Wu et 
al. 2007). Eleven well-growing CD4+, five CD8+, and ten CD4+CD8+ clones were 
selected for more detailed analyses. 
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Figure 2.6: CBZ-dependent proliferation of drug-specific CD4+ (A), CD8+ (B), and 
CD4+CD8+ (C) T-cell clones. 
T-cell clones were incubated with autologous irradiated B-LCLs and carbamazepine at indicated 
concentrations for 48 hours. Proliferation was determined by [3H]-thymidine uptake. Data 
represents mean cpm ± SEM of n clones. Statistical analysis was performed using Kruskal-Wallis 
H test for comparison of multiple doses (***p< 0.001). 
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To assess the functionality of the different phenotypic clones, the secretion of 
cytokines and cytolytic molecules was determined by the ELISpot technique 
(Figure 2.7). CD4+ TCCs secreted significant amounts of type 1 and type 2 
cytokines, i.e. IFN-γ (p= 0.02) and IL-13 (p= 0.02) respectively, suggesting a 
mixed Th1/Th2 type effector population (Figure 2.7 A). CD4+ clones displayed 
cytotoxic effector function by secretion of FasL (p= 0.02), and some clones also 
exhibited cytotoxicity through the release of granzyme B and perforin. CD8+ T-
cell responses were associated with strong secretion of IFN-γ (p= 0.02), and 
high levels of cytotoxicity through the release of granzyme B, perforin and FasL 
(p=0.05, 0.01, and 0.004 respectively; Figure 2.6 B). The effector phenotype of 
CD4+CD8+ TCCs resembled the CD8+ population. CD4+CD8+ TCCs secreted high 
levels of IFN-γ (p= 0.004), and only a few clones secreted low amounts of IL-13. 
Cytotoxic activity was demonstrated by high levels of FasL and perforin 
secretion (p= 0.006 and 0.005 respectively; Figure 2.6 C). Granzyme B secretion 
did not increase significantly because of high background levels. 
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Figure 2.7: Secretion of 
cytokines and cytolytic 
molecules from CD4+ (A), CD8+ 
(B), and CD4+CD8+ (C) TCCs 
after CBZ stimulation using 
ELISpot assay. 
Well images show cytokine profile 
of a representative TCC for each 
phenotype. Graphs represent 
mean SFC per well ± SEM of n 
clones. Statistical analysis was 
performed by comparing SFC 
between drug treated and 
untreated wells using Mann-
Whitney U test (*p< 0.05, **p< 
0.01). 
(SFC= spot forming cells; n.p. = 
not performed) 
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2.3.3 HLA restriction of carbamazepine-specific T-cell clones 
For the detailed investigation whether recognition of CBZ by drug-specific TCCs 
was HLA restricted further analysis concentrated on the CD4+ and CD8+ clones. 
In a first step restriction by MHC class I and class II was tested. T-cell clones 
were stimulated with CBZ in the presence of autologous B-LCLs which had been 
pre-treated with human anti-MHC antibodies to inhibit presentation of the drug 
by MHC molecules expressed on the cell surface. CD4+ T-cell responses to CBZ 
were clearly MHC class II restricted, as addition of anti-MHC II antibody, but not 
anti-MHC I, inhibited proliferation (Figure 2.8 A). The response of CD8+ clones 
was restricted by MHC class I (Figure 2.8 B). However, as the CD8+ clones could 
be stimulated by CBZ in the absence of B-LCLs, an effect known as self-
presentation, the results were not as pronounced as for CD4+ clones. When MHC 
blocking antibodies were added to both B-LCLs and TCCs, minor proliferative 
responses could still be detected. 
The fine-specificity of the HLA class II restriction observed in CD4+ clones was 
determined using blocking antibodies against HLA-DR, -DQ and ,-DP 
respectively. CBZ-induced proliferation of CD4+ TCCs could be suppressed by 
antibodies against HLA-DR and –DP (Figure 2.9). With a few exceptions, 
blocking of HLA-DQ had a minor effect on T-cell proliferation of CD4+ clones. 
As there are currently no commercial antibodies available to test for HLA-A, -B, 
and-C restriction, a blocking antibody specific for HLA-A30/A31 was used 
instead to test recognition of CBZ by CD8+ clones. Proliferation of CBZ-specific 
CD8+ clones was suppressed in the presence of anti-HLA-A30/A31 antibody (p= 
0.003, Figure 2.10). These results suggest a HLA-A31 restriction, since the 
patient was a carrier of HLA-A*31:01, but not A*30 (see Table 2.1). However, 
proliferative responses could not be abrogated completely, which was partially 
due to strong self-presentation of CD8+ TCCs (see Appendix F1) and required a 
suboptimal CBZ concentration to be used in the assay. Also, proliferation of 
some CD8+ TCCs was inhibited more strongly by blocking antibodies against 
MHC class I, suggesting that other factors may also be involved in the 
presentation of CBZ. 
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Figure 2.8: MHC 
restriction of CBZ-specific 
CD4+ (A) and CD8+ (B) 
TCCs. 
Autologous irradiated B-LCLs 
were incubated with 
antibodies against MHC class I 
and class II respectively. Pre-
treated B-LCLs were then 
added to TCCs and CBZ in a 
48 hour proliferation assay. 
Results are given as mean 
cpm of duplicate cultures. 
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Figure 2.9: Restriction of CD4+ clones by HLA class II subtypes. 
TCCs were cultured with CBZ and autologous irradiated B-LCLs which had been pre-incubated 
with blocking antibodies against HLA-DR, -DQ, and –DP respectively. Proliferation assay was 
used as read-out. Data represent mean cpm ± SEM of triplicate cultures. Statistical analysis was 
performed comparing cultures without antibody to those treated with HLA blocking antibody 
(*p< 0.05, **p< 0.01, ns=not significant). 
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Figure 2.10: Recognition of CBZ by CD8+ clones in the presence of HLA-A30/A31 
blocking antibody. 
Autologous irradiated B-LCLs were treated with antibodies against either MHC class I or HLA-
A30/A31. TCCs were incubated with B-LCLs and CBZ, which was added at a suboptimal 
concentration of 12μg/ml to avoid self-presentation. Proliferation was determined by [3H]-
thymidine incorporation. Results are presented as mean cpm ± SEM of n clones. Statistical 
analysis was performed using Wilcoxon test for the comparison of paired samples (*p< 0.05). 
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As a next step, allogeneic HLA-matched B-LCLs were used to further assess the 
role of HLA-A*31:01 on the activation of CD8+ TCCs by CBZ. B-LCLs were 
generated from PBMCs of HLA-typed healthy volunteers which are part of an in-
house cell bank specifically set up to investigate HLA-associated ADRs (Alfirevic 
et al. 2012). Healthy volunteers expressing either HLA-A*31:01 or control HLA-
A alleles, which are common in Caucasians and not reported in association with 
CBZ hypersensitivity (HLA-A*01:01, -A*02:01, or -A*03:01), were selected for 
the generation of B-cell lines. The complete HLA genotypes of the different B-
LCLs are shown in Table 2.2. 
CD8+ clones were strongly activated by CBZ in the presence of autologous B-
LCLs and allogeneic HLA-A*31:01+ B-LCLs (Figure 2.11). CBZ-specific responses 
in cultures containing B-LCLs expressing other HLA-A alleles were generally 
weaker, and in some cases below the threshold of self-presentation which were 
therefore considered to be negative.  
Interestingly, when some CD4+ clones were incubated with allogeneic HLA-
A*31:01+ B-LCLs, these clones also started to proliferate upon CBZ stimulation 
(data not shown). Since CD4+ TCCs had previously been shown to be HLA class 
II restricted, the complete HLA haplotype of the antigen-presenting cell lines 
was taken into consideration and analysed for any overlap in HLA class II. The 
HLA-DRB1*04:04 allele was found to be present in all HLA-A*31:01+ B-cell lines 
which induced CD4+ T-cell proliferation. This corresponded with the HLA class 
II restriction data showing preferential HLA-DR restriction. After consulting 
Allele Frequency Net Database (www.allelefrequencies.net, (Gonzalez-Galarza 
et al. 2011)), HLA-DRB1*04:04 was confirmed to be part of a common haplotype 
with HLA-A*31:01 in Caucasians. 
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Figure 2.11: Reactivity of CD8+ TCCs to CBZ presented on allogeneic HLA-matched B-LCLs. 
T-cells were incubated with CBZ (12μg/ml) and partially HLA-matched B-LCLs, and proliferation was determined in a 48-hour proliferation assay. To assess the 
strength of self-presentation, T-cells were also cultured in the absence of B-LCLs (white bars). Proliferation above counts of self-presentation (dashed line) was 
considered a positive response. Results are shown as mean cpm of duplicate cultures. 
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In order to investigate whether CBZ-specific CD4+ T-cell responses were HLA-
DRB1*04:04-restricted, studies using partially HLA-matched B-LCLs were 
performed. CD4+ clones were incubated with CBZ and allogeneic B-LCLs 
expressing either HLA-A*31:01, or HLA-DRB1*04:04, or both alleles. Antigen-
presenting cells negative for both alleles were used as controls. 
CBZ-specific CD4+ clones were stimulated to proliferate in the presence of B-
LCLs expressing HLA-A*31:01 and HLA-DRB1*04:04, but also HLA-
DRB1*04:04+ B-LCLs lacking HLA-A*31:01 (Figure 2.12). No CBZ-induced T-cell 
proliferation was seen in cultures containing B-LCLs expressing only HLA-
A*31:01 or in the HLA-A*31:01 negative and DRB1*04:04 negative controls. 
However, some antigen-presenting cell lines serving as controls were able to 
stimulate a non-specific proliferative response in CD4+ clones, which was 
independent of CBZ as it could also be detected in drug-free cultures. The 
antigenic stimulus causing these responses is currently unknown. 
HLA-DRB1*04:04 restriction of CD4+ clones could be further validated through 
the use of B-cell lines which had been specifically transfected with HLA-
DRB1*04:04 (Figure 2.13). CD4+ clones proliferated vigorously when stimulated 
with CBZ in the presence of HLA-DRB1*04:04-transfected T2-cells. However, T-
cell activation was only seen in cultures containing antigen-presenting cells that 
also expressed HLA-DM (Figure 2.13), indicating that the CLIP peptide prevents 
CBZ from binding to HLA-DR and being presented to T-cells. 
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Figure 2.12: CBZ-specific activation of CD4+ T-cell clones with allogeneic HLA-matched B-LCLs. 
T-cells were incubated with CBZ (25μg/ml) and partially HLA-matched B-LCLs. Proliferation was measured by [3H]-thymidine incorporation. Results are shown as 
mean cpm of duplicate cultures. (A+ = positive for HLA-A*31:01, DRB1+ = positive for HLA-DRB1*04:04) 
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Figure 2.13: CBZ-specific proliferation of CD4+ clones in the presence of HLA-
DRB1*04:04 transfected B-cells. 
T-cells were incubated with CBZ and HLA-DRB1*04:04 transfected T2 cell lines. Proliferation 
was determined by [3H]-thymidine uptake. Data represent mean cpm ± SEM of n clones. 
Statistical analysis was performed using Mann-Whitney U test (**p< 0.01, ns= not significant). 
 
 
2.4 Discussion 
 
In this chapter, carbamazepine-specific T-cells were isolated from a CBZ 
hypersensitive patient expressing HLA-A*31:01 and subsequently used to 
explore whether drug-specific T-cells displayed HLA restriction and if HLA-
A*31:01 was functionally involved in T-cell activation. 
A positive lymphocyte transformation test with a maximal SI of 15.9 confirmed 
a hypersensitivity reaction to carbamazepine in vitro and that drug-specific T-
cells were still present in the patient’s blood even many years after resolution of 
clinical symptoms. Isolated T-lymphocytes displayed effector functions when 
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stimulated with CBZ, which was demonstrated by drug-induced IFN-γ secretion 
and killing of autologous B-LCLs. 
Drug-specific T-cell clones were generated using established in vitro cloning 
methods. However, it has previously been shown that this leads to the preferred 
expansion of CD4+ clones, i.e. approximately 90% of TCCs express the CD4 co-
receptor (Naisbitt et al. 2003a; Wu et al. 2007). The reasons are not entirely 
clear, but might be explained in part by the reduced proliferation capacity of 
CD8+ T-cells resulting in decreased T-cell expansion rate (Wu et al. 2007). A 
revised cloning protocol, including magnetic cell separation of the different T-
cell phenotypes prior to serial dilution, was therefore used in order to increase 
the number of CD8+ clones available for functional studies. As a result, almost 
equal numbers of CBZ-specific CD4+ and CD8+ clones (35% and 41% 
respectively) were obtained. The clones displayed a concentration-dependent 
proliferation profile and cytotoxic effector functions. Similar to previous studies 
(Wu et al. 2007), CD4+ T-cells proliferated vigorously when stimulated with CBZ 
but showed limited cytotoxicity, whereas CD8+ T-cell activation was 
characterised by high levels of cytotoxic molecules and low proliferation rates. 
Stimulation of CBZ-specific CD4+ and CD8+ T-cells was restricted by MHC class II 
and MHC class I respectively. However, the results for CD8+ clones were 
partially obscured by self-presentation. Drug presentation between T-cells 
without the need for APCs has been reported previously (von Greyerz et al. 
2001), but the origin and function of self-presenting T-cells has not yet been 
resolved. Attempts to overcome self-presentation by blocking MHC on both T-
cells and B-LCLs were only marginally successful (data not shown), which might 
be due to up-regulation of MHC following T-cell activation (Van Den Elsen et al. 
2004). 
HLA restriction experiments using an antibody directed against HLA-A30/A31 
demonstrated for the first time that drug-specific CD8+ T-cells isolated from an 
HLA-A*31:01 positive individual respond to CBZ in a HLA-A31 restricted 
manner in vitro. For some clones blocking of MHC class I seemed to inhibit 
proliferation more effectively. This might be due to a higher binding affinity of 
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the antibody or alternatively indicate that additional factors might facilitate 
presentation of CBZ to CD8+ T-cells. 
Studies with HLA-matched B-LCLs support a functional role of HLA-A*31:01 in 
activating CBZ-specific CD8+ clones. CBZ-induced proliferation of CD8+ clones 
was strongest when HLA-A*3101+ B-LCLs were present. However, to a lesser 
extend T-cell activation was also seen with B-LCLs expressing other HLA-A 
alleles, which again suggests CBZ might not be exclusively recognized in the 
context of HLA-A*31:01. 
Responses of CD4+ clones were restricted mainly by HLA-DR and –DP. Blocking 
of HLA-DQ affected CD4+ T-cell proliferation to a minor extent and was only 
observed in a few clones. Previous studies had shown that the majority of drug-
specific CD4+ TCCs respond to CBZ in a HLA-DR restricted manner, despite a 
few clones which had been restricted by HLA-DQ (Naisbitt et al. 2003a). 
However, no restriction by HLA-DP had been observed. The function of HLA-DP 
in autoimmune disorders has been far less studied than that of other HLA class 
II subtypes and HLA-DP is mostly omitted from HLA genotyping. This could 
explain why hardly any HLA-DP associations, beryllium hypersensitivity 
representing a rare exception (Dai et al. 2013), have been detected to date. Due 
to this knowledge gap, further experiments concentrated on investigating the 
role of HLA-DR in CD4+ T-cell activation. However, it cannot be excluded that 
HLA-DP might be involved in CBZ presentation to CD4+ T-cells. 
Knowing that the patient is a carrier of HLA-DRB1*04:04 and that this allele 
forms a common haplotype with HLA-A*31:01 in Caucasians, HLA mismatch 
studies were performed with APCs expressing HLA-DRB1*04:04 and/or HLA-
A*31:01 or control DRB1 alleles. 
CD4+ clones recognized CBZ presented by HLA-A*31:01+ DRB1*04:04+ B-LCLs, 
but also with B-LCLs expressing only HLA-DRB1*04:04 suggesting a functional 
role for HLA-DRB1*04:04. It is important to note that some B-LCLs induced 
non-specific proliferation of CD4+ clones, which was observed in the absence of 
drug stimulation. This might be due to cross-reactivity of the drug-specific TCCs. 
As the generation of B-LCLs involves transformation with Epstein-Barr virus, 
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viral peptides may be produced by B-LCLs and presented in the context of MHC. 
If the TCR expressed on drug-specific T-cells is able to cross-recognise the viral 
peptides, this may lead to T-cell activation. This has been observed previously 
in some DRESS patients with reactions to drugs including carbamazepine, 
sulfamethoxazole and allopurinol (Picard et al. 2010). Another explanation 
might be that some clones display HLA alloreactivity, i.e. clones recognise 
allogeneic HLA molecules as antigenic structures and become activated. This 
has been reported in cases of Graft-versus-host disease where virus-specific 
lymphocytes could be isolated from patients showing cross reactivity against 
allogeneic HLA molecules (Amir et al. 2010). Virus specificity and HLA 
alloreactivity were mediated by the same TCR. 
HLA-DRB1*04:04 restricted recognition of CBZ by CD4+ clones was further 
substantiated when HLA-transfected T2 cell lines were used as APCs. T2 
wildtype cells lack HLA class II expression and only display HLA-A2 on their cell 
surface. In the presence of HLA-DRB1*04:04 transfected T2 cells, CD4+ clones 
proliferated strongly when stimulated with CBZ. This finding strengthens the 
assumption that HLA-DRB1*04:04 may be functionally relevant in CBZ-specific 
CD4+ T-cell responses. Interestingly, T-cell proliferation was only observed if 
HLA-DM was expressed at the same time. As HLA-DM is responsible for the 
removal of the class II invariant chain peptide (CLIP) prior to antigen loading of 
HLA class II molecules, binding of CBZ to HLA-DRB1*04:04 seems to be 
hindered in the presence of CLIP. This might be due to insufficient binding 
affinity between CBZ and CLIP preventing the formation of a stable drug-
peptide-MHC complex. Alternatively, CBZ may only bind to an empty HLA 
binding groove, thereby inducing a change to the peptide repertoire, which in 
turn causes T-cell activation. Further studies are needed in order to fully 
understand the implication of this observation. 
In conclusion, CBZ-specific CD4+ and CD8+ T-cell clones could be generated from 
isolated PBMCs of a HLA-A*31:01 positive hypersensitive patient. A HLA-
A*31:01-dependent activation of CD8+ clones could be demonstrated for the 
first time, implying a functional relevance of the genetic association. 
Additionally, a HLA class II allele, i.e. HLA-DRB1*04:04, was shown to be 
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functionally involved in CD4+ T-cell activation. Genetic data from genome-wide 
association studies and next-generation sequencing studies have shown that 
HLA-DRB1*04:04 was more prevalent in hypersensitive patients than in 
controls, but this does not reach statistical significance (unpublished data). The 
strong linkage disequilibrium between HLA-A*31:01 and DRB1*04:04 suggests a 
common haplotype may contribute to the multi-clonal response seen in 
Caucasian carbamazepine hypersensitive patients. The significance of the 
results presented in this chapter is strongly limited by the fact that the data is 
based on only one patient. Therefore further studies involving a larger patient 
cohort are needed in order to confirm the observations described here. 
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Chapter III 
Stimulation of a primary immune response 
to carbamazepine in healthy volunteers 
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3.1 Introduction 
 
An array of in vitro assays have been developed to assist in the diagnosis of 
drug-induced hypersensitivity reactions (HSRs), alongside in vivo provocation 
and skin patch tests. In vitro tests are a safe alternative for patients by avoiding 
resensitisation or exacerbation of the reaction (Porebski et al. 2011). 
Additionally, in vitro assays allow testing of several drugs in parallel, which may 
help identify the causative drug and assess potential cross-reactivity to 
alternative medication. Furthermore, the assays can be used to gain further 
insight into the pathomechanisms implicated in the development of HSRs 
(Porebski et al. 2011). 
The lymphocyte transformation test (LTT) represents the most common in vitro 
test in the diagnosis of HSRs (Nyfeler and Pichler 1997). It measures the 
proliferative response of T-cells isolated from peripheral blood of patients upon 
stimulation with a specific drug in vitro. The LTT shows high specificity (85-
100%) in detecting the causative drug, but its sensitivity varies depending on 
the drug and clinical phenotype (Nyfeler and Pichler 1997). In severe forms of 
HSRs, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, the 
LTT often fails to show a positive response (Kano et al. 2007; Tang et al. 2012). 
A more sensitive method to detect drug-specific T-cells in vitro involves the 
measurement of drug-induced cytokine release using enzyme-linked 
immunoassays, such as ELISA or ELISpot (Porebski et al. 2011). In a study by 
Rozieres and colleagues, increased secretion of IFN-γ could be detected in T-
cells isolated from amoxicillin-hypersensitive patients, but not in control 
patients (Rozieres et al. 2009). The analysis of IL-5 levels in combination with 
IFN-γ, IL-13 or IL-2, following stimulation of T-cells with drug in vitro, has been 
proposed a valuable diagnostic tool in HSRs diagnosis, as the release of these 
cytokines seems to be independent of the class of drug and clinical phenotype 
(Lochmatter et al. 2009). Furthermore, up-regulation of cell surface markers, 
e.g. CD69, has been demonstrated to be a suitable method for the detection of 
drug-specific T-cells in vitro (Beeler et al. 2008). 
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However, all of the above described methods assess the reactivity of drug-
specific memory T-cells which have been originally primed in vivo. In order to 
study immune responses to drugs using naive T-cells from healthy volunteers, a 
different approach is required. Naïve T-cells have to be primed in vitro with the 
aim of generating a memory T-cell population expressing a similar phenotype to 
T-cells primed in vivo. 
Two different strategies have been used in order to induce a primary immune 
response in cells from healthy volunteers. Engler and co-workers were able to 
induce a primary T-cell response to sulfamethoxazole (SMX) and its reactive 
nitroso metabolite SMX-NO by stimulating peripheral blood mononuclear cells 
(PBMCs) repeatedly over five weeks with the drug in the presence of autologous 
antigen-presenting cells (APCs) (Engler et al. 2004). This approach has been 
successfully translated to prime PBMCs from HLA-B*57:01+ and HLA-B*15:02+ 
drug-naïve volunteers to abacavir (ABC) and carbamazepine (CBZ) respectively 
(Chessman et al. 2008; Ko et al. 2011). The second in vitro priming method 
involves culturing of purified naïve T-cells with dendritic cells as professional 
APCs and the drug antigen of interest. This system has been well established for 
priming naïve T-cells against chemicals contact sensitizers (Dietz et al. 2010). 
Recently, a similar assay has been developed to induce drug-specific responses 
in naïve T-cells from healthy volunteers (Faulkner et al. 2012). The method was 
shown to be successful in generating a primary immune response against the 
model allergen SMX-NO, and its application for other drugs associated with 
HSRs is currently under investigation (Faulkner et al. 2012; Monshi et al. 2013). 
Given that HSRs generally occur at low frequency and are unpredictable in 
nature, prospective studies in humans are not feasible. At the same time, valid 
animal models are lacking, as drug-induced HSRs are also idiosyncratic in 
animals and mechanisms seem to differ for different drugs as well as between 
species (Uetrecht 2007). Moreover, the discovery that some reactions only 
develop in individuals expressing specific HLA alleles, e.g. ABC causing 
hypersensitivity exclusively in HLA-B*57:01+ patients, has highlighted the need 
to refine existing models to study HSRs in vitro. This has resulted in a growing 
interest to use genetically characterised immune cells from drug-naïve healthy 
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donors for functional studies attempting to characterise the mechanisms 
involved in HSRs, and predict the potential of a drug to cause an immune 
response (Alfirevic et al. 2012). 
In this chapter, the above described in vitro priming methods were used to 
explore the possibility of inducing a primary immune response to 
carbamazepine in HLA-A*31:01+ healthy volunteers. HLA-A*31:01 is the first 
allele which has been shown to be strongly associated with CBZ-induced HSRs 
in Caucasian populations (McCormack et al. 2011). Generally, the frequency of 
HLA-A*31:01 in Europeans is relatively low, ranging between 2-6% (derived 
from www.allelefrequencies.net). However, the presence of HLA-A*31:01 in 
patients treated with CBZ increases the risk to develop CBZ-induced HSRs from 
5% to 26 %, indicating it could be a clinically relevant marker for the prediction 
of CBZ-induced HSRs in Europeans (McCormack et al. 2011). The local cell bank 
of HLA-typed lymphocytes from 400 healthy volunteers (Alfirevic et al. 2012) 
was used as resource to test the propensity of CBZ to induce drug-specific T-cell 
activation in non-sensitised HLA-A*31:01+ individuals. 
 
 
3.2 Methods 
 
3.2.1 Volunteer characteristics 
PBMCs from eight HLA-A*31:01+ healthy volunteers, five HLA-A*31:01- donors, 
and three HLA-B*15:02+ donors were used in this study. The samples were part 
of our HLA-typed cell archive from 385 healthy individuals, comprising 23 HLA-
A*31:01+ and 7 HLA-B*15:02+ donors in all (Alfirevic et al. 2012). 
The healthy volunteers had been recruited from the North West of England 
between August 2009 and April 2010, and each volunteer initially donated 
100ml blood. DNA was isolated from 10ml blood to determine the HLA 
genotype of each individual, whereas the remaining 90ml of blood was used to 
isolate PBMCs for functional in vitro studies. The isolated PBMCs (96x 106 cells 
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± 40x 106 per donor) were stored at -150°C until needed. Individual donors 
were approached for a second blood donation by the responsible study nurse, if 
more cells were required. The healthy volunteers could withdraw their consent 
from participating in the study at any time. 
The complete HLA-genotypes of the 16 samples included in this study are 
shown in Table 3.1. 
 
Table 3.1: HLA-genotypes of healthy volunteer samples included in this study. 
ID HLA-A HLA-B HLA-C HLA-DRB HLA-DQB 
HV3 03:01/31:01 07:02/07:02 07:02/07:02 15:01/08:01 04:02/06:02 
HV5 02:01/31:01 15:05/40:06 03:03/15:02 04:04/14:04 03:02/05:03 
HV9 01:01/31:01 08:01/39:01 07:01/12:03 16:01/03:01 02:01/05:02 
HV11 31:01/66:01 27:05/40:01 02:02/03:04 01:01/04:01 03:02/05:01 
HV13 24:02/31:01 55:01/56:01 01:02/03:03 04:01/12:01 03:02/03:01 
HV14 24:02/33:03 15:02/44:03 07:01/08:01 07:01/12:02 02:01/03:01 
HV15 31:01/33:03 40:01/50:01 03:04/06:02 03:01/04:04 02:01/03:02 
HV19 02:01/02:01 40:01/50:01 03:04/06:02 15:01/07:01 02:01/06:02 
HV20 29:02/31:01 07:02/15:01 03:03/07:02 13:01/14:01 05:03/06:03 
HV21 01:01/31:01 07:02/37:01 06:02/07:02 15:01/15:01 06:02/06:02 
HV22 01:06/29:02 27:05/44:03 02:02/16:01 04:01/07:01 02:01/03:02 
HV25 11:01/11:01 15:02/15:25 04:03/08:01 11:06/12:02 03:01/03:01 
HV26 01:01/25:01 07:02/40:01 03:04/07:02 01:01/15:01 05:01/06:02 
HV31 02:01/24:02 40:01/40:02 03:03/07:02 15:01/14:05 05:03/06:02 
HV35 11:01/24:02 15:02/15:02 08:01/08:01 15:01/12:02 03:01/06:01 
HV39 01:01/24:02 08:01/44:02 05:01/07:01 11:01/04:04 03:02/03:01 
 
 
3.2.2 Chemicals 
Carbamazepine (Sigma-Aldrich, UK) was prepared as stock solution (10μg/ml) 
in T-cell medium comprising 10% DMSO (Sigma-Aldrich, UK). The stock 
solution was made up fresh before each experiment and diluted to the 
appropriate concentration immediately before use. Unless stated otherwise, all 
other reagents were purchased from Sigma-Aldrich. 
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Chemical analogues of carbamazepine, namely 2-monohalo and 2,8-dihalo 
derivatives (Figure 3.1), were synthesized by the Department of Chemistry 
(Elliott et al. 2012). 
 
 
Figure 3.1: Structures of halogenated derivatives of carbamazepine 
 
3.2.3 Cell culture media 
T-cell and B-cell lines were cultured in their respective cell culture medium as 
described previously in chapter 2.2.3. T-cell medium was used to culture 
monocyte-derived dendritic cells. 
For the work performed in the Department of Microbiology & Immunology, 
University of Melbourne, RF10 medium was used to culture both the T- and B-
cell lines. RF10 medium consisted of RPMI 1640 medium (Gibco, USA) 
supplemented with 10% FBS (Bovogen Biologicals, Australia), 7.5mM HEPES 
(MP Biomedicals, Australia), 2mM L-glutamine (MP Biomedicals, Australia), 
150μg/ml streptomycin, 150U/ml benzylpenicillin (CSL, Australia), 150μM non-
essential amino acids (Gibco, USA), and 76μM β-mercaptoethanol. 
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3.2.4 Lymphocyte transformation test 
The lymphocyte transformation test was performed as described earlier in 
chapter 2.2.6 in order to confirm that the healthy donors had not been 
previously sensitised to CBZ. 
 
3.2.5 4-week induction culture 
Lymphocytes were repeatedly stimulated with CBZ in vitro over four weeks to 
induce a primary immune response to the drug using previously described 
methodology (Engler et al. 2004). 
Freshly thawed PBMCs (5x 106, 2ml) from each volunteer were cultured in T-
cell medium containing 25μg/ml CBZ in a 24-well plate. On day 3, fresh medium 
supplemented with IL-2 (200U/ml; Preprotech, UK) was added to the cultures. 
On day 7, lymphocytes were restimulated with CBZ (25μg/ml) in the presence 
of autologous, irradiated PBMCs (1x 106) as feeder cells. Restimulation was 
repeated every week, and wells were split when necessary to sustain 
proliferation of T-cell lines. 
 
3.2.6 In vitro T-cell priming assay 
An alternative in vitro method to stimulate primary responses to drugs in naïve 
T-cells from healthy individuals was recently developed within the Department 
(Faulkner et al. 2012); and the procedure outlined below was carried out by Dr. 
Lee Faulkner. 
 
Isolation of PBMCs and magnetic cell separation 
PBMCs were isolated from 100ml fresh whole blood of the selected healthy 
donors using the density gradient centrifugation method as described 
previously in chapter 2.2.4. Monocytes were isolated by magnetic cell 
separation using CD14 microbeads (Miltenyi Biotec, UK). T-cells were isolated 
from non-CD14 cells by negative selection using the Pan T isolation kit II 
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(Miltenyi Biotec, UK). Next, regulatory T-cells were removed using CD25 
microbeads (Miltenyi Biotec, UK). The remaining T-cells were further separated 
into naïve and memory populations using CD45RO microbeads (Miltenyi Biotec, 
UK). Magnetic cell separation was carried out according to the manufacturer’s 
instructions. The phenotype and purity of the isolated cells was assessed by 
flow cytometry using CD14-FITC, CD3-APC, CD25-PE, CD45RA-FITC, CD45RO-
Cy5, CD4-FITC, CD8-PE antibodies (all BD Bioscience, UK; except CD25-PE, 
Miltenyi Biotec, UK). The purity of the separated cell populations exceeded 
95%. All cells were frozen down and stored at -150°C until needed. 
Generation of monocyte-derived dendritic cells 
CD14+ monocytes (6 x106, 6ml) were differentiated into dendritic cells (DCs) for 
7-8 days in 6-well plates using T-cell medium containing granulocyte-
macrophage colony-stimulating factor (GM-CSF; 800U/ml; Preprotech, UK) and 
IL-4 (800U/ml; Preprotech, UK). Fresh medium (3ml) supplemented with GM-
CSF and IL-4 was added every 2 days. 
T-cell and monocyte-derived DC co-culture 
Freshly thawed naïve T-cells (2 x106, 1ml) were cultured with immature 
monocyte-derived DCs (8 x105, 500μl) and CBZ (100μg/ml, 500μl) in a 24-well 
plate for 7-8 days. 
 
3.2.7 Generation of antigen-presenting cell lines 
EBV-transformed B-lymphoblastoid cell lines (B-LCL) were used as antigen-
presenting cells (APCs) for read-outs following 4-week induction cultures. B-
LCLs were generated for each of the healthy volunteers used in this study as 
described previously in chapter 2.2.5. 
PHA blasts were used as APCs in the intracellular cytokine staining (ICS) assay, 
which was performed at the Department of Microbiology & Immunology, 
University of Melbourne. PHA blasts were generated by culturing PBMCs (2 
x106) from the selected volunteers with phytohemagglutinin (PHA; 20μg/ml) in 
a 24-well plate for 7 days. On day 3, fresh IL-2 supplemented medium was 
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added to the cultures. On day 7, PHA blasts were washed and expanded into 
tissue culture flasks. Proliferation was maintained by adding fresh IL-2 
containing medium every 2-3 days. 
 
3.2.8 T-cell proliferation assay 
CBZ-specific proliferation of T-lymphocytes was assessed by [3H]-thymidine 
incorporation, which has been described in detail in chapter 2.2.10. 
 
3.2.9 Enzyme-linked immunospot assay 
CBZ-induced secretion of cytokines was determined by enzyme-linked 
immunospot (ELISpot) assay using the same protocol as described in chapter 
2.2.12. 
 
3.2.10 Intracellular cytokine staining (ICS) assay 
T-cells (2 x105) were incubated with PHA blasts (1 x105) and CBZ (25μg/ml) in 
a 96-well U-bottom plate (final volume 200μl). Anti-CD3/anti-CD28 monoclonal 
antibodies and phorbol 12-myristate 13-acetate (PMA)/ ionomycin were used 
as positive controls. After 2 hours, Brefeldin A (10μl/ml) was added to the 
cultures to prevent cytokine secretion, and incubation was continued overnight. 
The next day, cells were spun down and the supernatant removed. The cells 
were surface stained (30min on ice) with fluorescent-conjugated antibodies 
CD3-PerCP (BD Pharmingen, USA), CD4-APC-Cy7 (Biolegend, USA), and CD8-
FITC (BD Pharmingen, USA) in the dark for 30min on ice. This was followed by a 
brief washing step with PBS (120μl). Next, cells were fixed for 30min using 1% 
para-formaldehyde (ProSciTech, Australia), and then washed with PBS. In the 
last step, cells were permeabilised using 0.3% saponin and intracellular 
cytokines were stained using fluorescent-labelled antibodies, including TNFα-
PE-Cy7 (BD Pharmingen, USA), IFNγ-Pacific Blue (Biolegend, USA), granzyme B-
Alexa Fluor 700 (BD Pharmingen, USA), and IL4-APC (eBioscience, USA) (see 
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Appendix T1 for more details). Samples were run on a BD FACS LSRII flow 
cytometer and data analysed using FlowJo software (Tree Star Inc., USA). 
 
3.2.11 T-cell cloning 
T-cell lines derived from the 4-week induction cultures or T-cell priming assays 
were used to generate drug-specific T-cell clones. The protocol for T-cell cloning 
has been described in detail in chapter 2.2.9. 
 
3.2.12 Statistical analysis 
One-way ANOVA was performed on the proliferation data. ELISpot data were 
analysed by Student’s t-test, applying Bonferroni correction for multiple testing 
if necessary. ICS were therefore analysed using the non-parametric Mann-
Whitney U test, as low sample numbers prevented an assessment for normal 
distribution. 
 
 
3.3 Results 
 
3.3.1 In vitro stimulation of PBMCs 
PBMCs from HLA-A*31:01 positive and A*31:01 negative healthy volunteers 
were tested in a lymphocyte transformation test to exclude the possibility of 
prior sensitisation to CBZ. Proliferative responses to CBZ were negative in all 
healthy volunteers tested (Figure 3.2). In contrast, lymphocytes from HLA-
A*31:01+ volunteers proliferated markedly when stimulated with tetanus 
toxoid (TT), with SI values ranging between 4 and 22. However, responses to TT 
were negative in all HLA-A*31:01- volunteers. 
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Figure 3.2: Lymphocyte transformation test of PBMCs from HLA-A*31:01+ (A-C) and 
A*31:01- (D-F) healthy donors. 
PBMCs were cultured for 6 days in presence of CBZ (25μg/ml), and [3H]-thymidine was added 
for the final 16h of the assay. Proliferation was determined by scintillation counting. A 
stimulation index of >2 (dashed line) was considered a positive response. 
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Additionally, an IFN-γ ELISpot assay was carried out to confirm the results from 
the LTT, which is considered a less sensitive assay and might fail to detect weak 
responses. CBZ did not induce IFN-γ secretion in lymphocytes from any 
volunteer, whereas PHA lead to a robust release of IFN-γ in all donors tested 
(Figure 3.3). The consistent response to PHA indicated that the cells isolated 
from the volunteers were still functional, and suggested that the missing 
response to TT in the LTT of some volunteers might be due to incomplete 
vaccination. 
Figure 3.3: IFN-γ secretion of PBMCs from 
healthy volunteers stimulated with CBZ or PHA 
(positive control). Representative assay from 
HLA-A*31:01+ (A) and HLA-A*31:01- (B) 
volunteer cells are shown. 
PBMCs (1x 106) were incubated with CBZ (25μg/ml) 
for 2 days, and spots developed according to the 
manufacturer’s protocol. 
 
 
 
3.3.2 4-week induction cultures 
Following the protocol by Engler and colleagues (Engler et al. 2004), PBMCs 
from three non-sensitised individuals expressing HLA-A*31:01 (HV9, HV11, and 
HV15) were repeatedly stimulated with CBZ over four weeks with the aim of 
eliciting a primary immune response to the drug. In parallel, T-cell cultures 
from three HLA-A*31:01- (HV19, HV22, and HV31) and two HLA-B*15:02+ 
(HV25 and HV35) healthy donors were set up to be used as negative and 
positive controls respectively. 
After 5 weeks, reactivity of T-lymphocytes to CBZ was tested by proliferation 
assay (Figure 3.4) and IFN-γ ELISpot (Figure 3.5) in order to assess whether 
sensitisation to CBZ had been induced. 
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A weak but significant increase in proliferation to different concentrations of 
CBZ was only observed in T-cells from volunteer HV15 (Figure 3.4 C). The 
statistically significant decrease in proliferation of T-cells from volunteer HV9, 
seen at the highest concentration of CBZ used in this assay, was attributed to 
the cytotoxic effect the drug is known to cause at doses of 100μg/ml CBZ and 
above (Figure 3.4 B). In contrast, there was no CBZ-induced proliferation in T-
cells from any HLA-A*31:01- volunteer, but stimulation with PHA activated T-
cells significantly (Figure 3.4 D). Furthermore, CBZ was unable to induce a 
proliferative response in T-cells from HLA-B*15:02+ volunteers (Figure 3.4 E). 
However, the majority of CBZ-reactive T-lymphocytes in HLA-B*15:02+ 
individuals have previously been shown to be CD8+ T-cells (Ko et al. 2011), 
which might not be detected in the proliferation assay due to their low 
proliferation rate. 
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Figure 3.4: CBZ-specific proliferation of T-cells isolated from healthy volunteers 
following 4-week induction culture. (A-C) T-cell responses from HLA-A*31:01+ 
volunteer cultures; (D+E) results of representative T-cell cultures from a HLA-A*31:01- 
and HLA-B*15:02+ volunteer respectively. 
T-cells were incubated with CBZ (10- 100μg/ml) in the presence of autologous irradiated B-
LCLs for 48h, and proliferation was determined by [3H]-thymidine incorporation. Data 
represent mean cpm ± SEM of triplicate cultures. Statistical analysis was performed using one-
way ANOVA (indicated as line above graph) with Tukey post-hoc test (noted in brackets) (*p< 
0.05, **p< 0.01, ***p< 0.001). 
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The release of IFN-γ, measured by ELISpot assay, was used as a second read-out 
to detect CBZ-specific T-cell activation (Figure 3.5). HLA-A*31:01+ T-cell 
cultures secreted high levels of IFN-γ at baseline, thus, no drug-induced increase 
in cytokine secretion could be observed (Figure 3.5 A). In contrast, no IFN-γ 
release was seen in T-cells isolated from HLA-A*31:01- donors, neither before 
nor after stimulation with CBZ (Figure 3.5 B). However, stimulation of T-cells 
from HLA-B*15:02+ volunteers with CBZ led to a two-fold increase in IFN-γ 
secretion (Figure 3.5 C). 
 
 
Figure 3.5: CBZ-induced IFN-γ secretion of T-cells from HLA-A*31:01+ (A),  HLA-
A*31:01- (B) and HLA-B*15:02+ (C) donors after 4-week induction culture. 
T-cells (5x 105) were incubated with CBZ (25μg/ml) and autologous irradiated B-LCLs (1x 105) 
for 2 days, and spots visualised following the manufacturer’s instructions. Number of spot-
forming cells is presented in the lower right corner of each image. 
 
Successful priming of drug-naïve T-cells from healthy donors against ABC had 
been reported previously. After a 14-day priming period of PBMCs from healthy 
donors with ABC, Chessman and co-workers were able to detect a drug-induced 
increase in IFN-γ and TNF-α levels in CD8+ T-cells by ICS (Chessman et al. 
2008). Thus, in a second attempt to sensitise drug-naïve T-cells isolated from 
HLA-A*31:01+ volunteers, the ICS assay was used as alternative detection 
method to identify CBZ-reactive T-cells following the 4-week induction culture. 
Similar to the studies by Chessman et al., CBZ-primed T-cells from three healthy 
donors (HV3, HV5, and HV20) were stained for IFN-γ and TNF-α after a four 
week restimulation period. No increase in IFN-γ producing T-cells was 
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observed for any of the HLA-A*31:01+ healthy volunteers tested. One volunteer, 
i.e. HV3, showed a marked increase in TNF-α producing CD4+ T-cells (from 12 % 
to 19% of total CD4+ T-cells) when stimulated with CBZ (Figure 3.6 A); 
however, this was not statistically significant. 
As mentioned previously, IL-5 and cytotoxic molecules, such as granzyme B, had 
been reported to be robust markers for the in vitro detection of drug-specific T-
cells from hypersensitive patients. Thus, in vitro primed volunteer T-cell 
cultures were subjected to a second ICS assay which covered additional 
cytokines, including granzyme B, IL-4 and IL-5. No expansion of T-cells 
expressing IL-4 or IL-5 could be detected in any of the volunteers tested. 
However, a strong increase in granzyme B producing CD8+ T-cells (from 28% to 
75% of total CD8+ T-cells) was observed for one of the healthy volunteer, i.e. 
HV5, following CBZ stimulation (Figure 3.6 B). Due to the high standard 
deviation, the increase was not statistically significant. Increased expression of 
granzyme B was also seen in the CD4+ T-cell population of this volunteer, 
although to a lesser extent.  
 
3.3.3 DC-T-cell co-cultures 
An alternative strategy to prime drug-naïve T-cells in vitro has been developed 
recently using monocyte-derived DCs (Faulkner et al. 2012). As attempts to 
generate CBZ-specific T-cells from healthy volunteers using the 4-week 
induction protocol were largely unsuccessful, we decided to apply this novel 
experimental system instead. 
Naïve T-cells from two HLA-A*31:01+ healthy donors (HV3 and HV13) were 
cultured with autologous monocyte-derived DCs and CBZ for 8 days, and 
subsequently proliferation and cytokine secretion was assessed by [3H]-
thymidine uptake and ELISpot method respectively. Likewise, priming of naïve 
T-cells isolated from a HLA-B*15:02+ healthy volunteer (HV14) was performed. 
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Figure 3.6: Cytokine expression of T-cells from two HLA-A*31:01+ volunteers (A+B) 
upon CBZ stimulation (after 4-week induction culture). 
T-cells were stimulated with CBZ (25μg/ml) and autologous, irradiated B-LCLs overnight: 
brefeldin A was added after 2h to inhibit cytokine release. Cells were permeabilised the next 
day and stained for intracellular cytokines as well as surface markers CD4 and CD8. Graphs 
represent mean ± SEM of duplicate cultures. Statistical analysis was performed using Mann-
Whitney U-test. 
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Figure 3.7: CBZ-specific proliferation and cytokine secretion of T-cells from HLA-
A*31:01+ volunteers (A+B) and a HLA-B*15:02+ volunteer (C) after DC T-cell co-
culture. 
Purified, naïve T-cells were cultured with CBZ and autologous monocyte-derived DCs for 8 days. 
T-cells (1x 105) were restimulated with CBZ (6- 100μg/ml) in the presence of autologous 
monocyte-derived DCs (4x 103). Proliferation was determined by [3H]-thymidine uptake, with 
graphs showing mean cpm ± SEM of triplicate cultures. Cytokine release was measured by 
ELISpot assay, and data are given as mean SFC ± SEM of duplicate cultures. For proliferation 
data, statistical analysis was performed using one-way ANOVA (with Tukey post-hoc test; **p< 
0.01, ***p< 0.001). Student’s t-test was used to analyse ELISpot results (*p< 0.03). (SFC= spot-
forming cells) 
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A weak but significant proliferative response to CBZ could be detected in one of 
the HLA-A*31:01+ donors (Figure 3.7 A), whereas T-cells from the second HLA-
A*31:01+ donor did not show a significant increase in proliferation when 
stimulated with CBZ (Figure 3.7 B). Conversely, CBZ stimulated a strong and 
highly significant response of T-cells isolated from the HLA-B*15:02+ volunteer 
(Figure 3.7 C). Moreover, proliferation levels of T-cells in the absence of CBZ 
differed greatly between HLA-A*31:01+ and HLA-B*15:02+ donors, showing a 
two- to four-fold increase in background proliferation rates of T-cells from HLA-
A*31:01+ volunteers compared to the HLA-B*15:02+ donor. 
Release of cytokines, including INF-γ, IL-13 and granzyme B, was the second 
endpoint examined. CBZ was able to stimulate a weak significant increase in 
IFN-γ secretion of T-cells from all three volunteers (Figure 3.7 A-C). However, 
baseline levels of INF-γ released by T-cells expressing HLA-A*31:01 was 
increased two-to three-fold compared to T-cells expressing HLA-B*15:02. No 
significant increase in IL-13 or granzyme B secretion was observed for any of 
the volunteers. 
 
3.3.4 T-cell cloning 
T-cells from two HLA-A*31:01+ volunteers (HV5 and HV15) and two HLA-
B*15:02+ donors (HV14 and HV35), all of which had shown a CBZ-specific 
response in one of the above described read-outs following in vitro priming, 
were cloned by serial dilution in order to confirm a primary immune response 
to CBZ had been induced. Furthermore, T-cell cloning would allow a more 
detailed analysis of the phenotypic and functional characteristics of in vitro 
sensitised T-cells. Two individuals lacking the CBZ-associated HLA risk alleles 
(HV31 and HV39), and one HLA-A*31:01+ donor (HV20) with a negative 
response in the ICS after T-cell priming, served as controls. The cloning results 
for all seven volunteers are summarised in Table 3.2. 
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Table 3.2: Specificity and phenotype of CBZ-specific T-cell clones generated 
from healthy volunteers. 
Volunteer 
ID 
Clones 
tested (n) 
Specific 
clones (n) 
[mean SI] 
Dose-response 
(cpm) 
CBZ 0        25μg/ml 
CD phenotype 
(%) 
CD4       CD8 
HLA-A*31:01+ 
HV5 91 
7 
[2.7] 
8,170 
±6,161 
20,415 
±13,539 
n.d. n.d. 
HV15 64 
3 
[2.2] 
333 
±262 
760 
±508 
n.d. n.d. 
HV20 360 
16 
[8.4] 
5,135 
±6,359 
22,788 
±17,479 
50 30 
HLA-B*15:02+ 
HV14 312 
4 
[2.2] 
747 
±287 
1,696 
±722 
n.d. n.d. 
HV35 240 
44 
[9.2] 
4,488 
±5,077 
18,695 
±14,280 
14 67 
Controls (A*31:01- B*15:02-) 
HV31 96 
5 
[4.4] 
n.s. n.s. n.d. n.d. 
HV39 336 
4 
[2.5] 
n.s. n.s. n.d. n.d. 
n.d. = not determined; n.s. = not specific 
 
Only a few CBZ-specific clones, with very low SI values, could be generated from 
HLA-A*31:01+ volunteers HV5 and HV15 (Table 3.2). For donor HV15, the low 
proliferation counts (< 1000cpm) in presence and absence of CBZ indicated that 
identified drug-specific clones represented false positive results. The seven 
clones generated from volunteer HV5 lost their specificity within about one 
month, precluding any detailed analysis. In contrast, sixteen CBZ-reactive clones 
could be generated from volunteer HV20, of which 50% were CD4+ clones and 
30% expressed CD8 (Table 3.2). The remaining 20% of T-cell clones comprised 
CD4+ as well as CD8+ T-cells, and therefore resembled T-cell lines rather than 
clones. Upon CBZ stimulation, the clones displayed a drug concentration-
dependent proliferation profile and secreted significant amounts of IFN-γ 
(Figure 3.8 A). These results were rather surprising, given that earlier attempts 
to prime T-cells from this volunteer in vitro had been unsuccessful. 
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Disparate numbers of drug-specific clones were also detected among the HLA-
B*15:02+ volunteers. Forty-four CBZ-responsive clones could be generated from 
donor HV35 (Table 3.2). Phenotyping for CD expression revealed two-thirds of 
the clones were CD8+ and one-third CD4+. T-cell clones (TCC) proliferated to 
CBZ in a dose-dependent manner, and high levels of IFN-γ secretion were 
detected in presence of the drug (Figure 3.8 B). From the second HLA-B*15:02+ 
volunteer, i.e. HV31, only four TCC could be generated, all of which displayed 
very weak proliferation counts and SI values (Table 3.2). Within a few weeks 
these clones no longer responded to CBZ stimulation. 
 
 
Figure 3.8: CBZ-specific proliferation and IFN-γ secretion of TCC from a HLA-A*31:01+ 
(A) and a HLA-B*15:02+ volunteer (B). 
TCC were incubated with CBZ (7- 70μg/ml) and autologous irradiated B-LCLs for 48 hours. 
Proliferation was determined by [3H]-thymidine incorporation; and data are shown as mean 
cpm ± SEM of n clones. IFN-γ secretion was measured by ELISpot assay, and graphs represent 
mean SFC ± SEM of n clones. Statistical analysis was performed using one-way ANOVA with 
Tukey post-hoc test (proliferation) and Student’s t-test (ELISpot) (*p< 0.05, **p< 0.01, ***p< 
0.001). 
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From the volunteers selected as controls, nine clones were initially considered 
to be drug-specific from the calculated SI values (Table 3.2). However, when the 
proliferation assay was repeated two weeks later all nine clones failed to show 
a drug-specific response. 
Although it would have been interesting to examine the HLA restriction profile 
of the CBZ-specific clones generated from the HLA-B*15:02+ volunteer (HV35), 
in a similar way as reported in the study by Wei and colleagues (Wei, C. Y. et al. 
2012a), this was not possible due to the underrepresentation of cells expressing 
relevant HLA-B alleles in our HLA-typed cell archive, which would have been 
needed to generate HLA-matched APCs. Instead, structural aspects of CBZ 
presentation to the T-cell clones was explored using a series of halogenated CBZ 
derivatives recently synthesized by the Department of Chemistry. It had been 
shown that halogenation at the aromatic ring inhibited or reduced (2-fluoro 
CBZ) hydroxylation, and thus formation of reactive arene oxide intermediates in 
vitro (Elliott et al. 2012), indicating that the halogenated CBZ analogues are 
metabolically inert while largely retaining the same chemical properties as CBZ. 
Increasing evidence suggests that the parent drug CBZ can function as antigen 
causing T-cell activation, requiring neither metabolism nor formation of 
haptenated peptides (Wu et al. 2006; Yang et al. 2007; Wei, C. Y. et al. 2012a). 
The use of halogenated analogues therefore served as an alternative strategy to 
explore whether CBZ-reactive T-cells can be activated by the drug without the 
need for metabolism. 
When the clones from the HLA-B*15:02+ volunteer were stimulated with the 
halogenated derivatives, different patterns of cross-reactivity could be 
observed. Although the maximal response was lower with the derivatives, 
significant proliferative responses could be detected for almost all CBZ 
analogues (Fig. 3.9). All six clones were activated by at least 3 of the analogues. 
However, only two clones could be stimulated with 2,8-dibromo CBZ, which is 
likely due to steric effects preventing adequate binding of the drug to the HLA-
peptide complex. 
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Figure 3.9: Activation of CBZ-primed T-cell clones from a HLA-B*15:02+ drug-naive 
individual with halogenated derivatives of CBZ. 
TCC were incubated with CBZ or CBZ analogues (300μM) and autologous B-LCLs for 48 hours. 
Proliferation was measured by addition for [3H]-thymidine and subsequent scintillation 
counting. Data are presented as mean cpm ± SEM of n clones. One-way ANOVA with Tukey post-
hoc test was used to compare responses in the presence and absence of drug (ns= not 
significant, *p< 0.05, ***p< 0.001). (2-Br CBZ was not available for this study) 
 
 
3.4 Discussion 
 
In vitro priming of T-cells from healthy volunteers represents a promising new 
tool to study the pathomechanisms implicated in drug-induced HSRs and 
predict the risk of a drug to cause hypersensitivity. Several methods to 
stimulate a primary T-cell immune response from non-sensitised individuals 
have been developed recently using the well-characterised drug antigens SMX 
and SMX-NO. Furthermore, successful priming of T-cells from drug-naïve 
individuals expressing HLA-B*57:01 and B*15:02 has been accomplished with 
ABC and CBZ respectively (Chessman et al. 2008; Ko et al. 2011). 
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In this study, we attempted to elicit a primary immune response to CBZ in 
healthy individuals expressing HLA-A*31:01 using the same methods. In 
addition, priming of T-cells from HLA-B*15:02+ healthy donors was performed 
in order to compare T-cell responses to those observed in HLA-A*31:01+ 
volunteers. 
The first attempt to prime T-cells from HLA-A*31:01+ volunteers involved 
repeated stimulation of lymphocytes with CBZ over four weeks. Three different 
endpoints- T-cell proliferation, IFN-γ secretion, and production of intracellular 
cytokines- were investigated in order to detect drug-specific responses. In 
contrast to the findings for ABC (Chessman et al. 2008), in vitro stimulation of 
drug-naïve T-cells with CBZ did not result in a primary immune response in all 
volunteers expressing HLA-A*31:01. 
In the proliferation assay, only one out of three volunteers showed a weak to 
moderate response to CBZ. However, measuring proliferative responses may 
not be sensitive enough if priming occurred predominantly in CD8+ T-cells, 
which would be expected in context of HLA class I alleles and has been shown to 
be the case for in vitro primed T-cells from HLA-B*15:02+ donors (Ko et al. 
2011). Furthermore, the strength of the detectable T-cell response is limited by 
the low frequency of antigen-specific precursor T-cells within the PBMC 
cultures (Esser et al. 2014). When the more sensitive ELISpot assay was utilised 
as a read-out, no CBZ-induced increase in IFN-γ secretion could be detected for 
any of the HLA-A*31:01+ volunteers. This may be partially due to the high 
background levels of IFN-γ released in the absence of drug, indicating the 
presence of pre-activated T-cells. Similar observations have been reported 
previously (Engler et al. 2004), and it has been suggested that the addition of 
high amounts of IL-2 during the 4-week induction cultures may be responsible 
for the strong, but non-specific T-cell stimulation. Conversely, no increased 
baseline levels of IFN-γ were observed in T-cells from HLA-B*15:02+ donors, 
and stimulation with CBZ led to a clear increase in IFN-γ release. This suggests 
that other, currently unknown factors, must be involved in causing non-specific 
T-cell activation in HLA-A*31:01+ volunteers. Finally, analysis of intracellular 
cytokine production did not reveal a CBZ-specific increase of cytokines in T-
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cells from all three HLA-A*31:01+ volunteers. Instead, two HLA-A*31:01+ 
individuals showed increased TNF-α and granzyme B expression in CBZ-
stimulated T-cells respectively. Whether the weak T-cell responses seen in 
some of the HLA-A*31:01+ individuals represent true positive results cannot be 
determined at this stage. A repetition of the assays would be required to 
confirm that a primary T-cell stimulation to CBZ can be induced in these 
volunteers. 
In a second approach to sensitise naïve T-cells to CBZ, the in vitro T-cell priming 
assay recently developed by Faulkner and colleagues was applied (Faulkner et 
al. 2012). Highly purified naïve T-cells from HLA-A*31:01+ volunteers were 
cultured with CBZ in the presence of autologous DCs for one week. It was 
anticipated that the removal of regulatory T-cells (Treg) and the use of 
monocyte-derived DCs as highly specialised antigen-presenting cells would 
improve in vitro priming conditions, leading to the induction of more robust 
CBZ-specific T-cell responses. For one of the HLA-A*31:01+ volunteers, a weak 
but significant CBZ-specific T-cell response could be detected in both the 
proliferation assay as well as the IFN-γ ELISpot. However, T-cells from the 
second HLA-A*31:01+ volunteer only responded in the IFN- γ ELISpot. At the 
same time, baseline levels of proliferation and IFN-γ secretion were found to be 
strongly increased in both samples, indicating the presence of pre-activated T-
cells. As observed previously, this was not the case for T-cells from the HLA-
B*15:02+ donor. Here, stimulation with CBZ led to an increased release of IFN-γ 
and a strong proliferative response, which was highly significant. From the 
preliminary data presented here, it appears that the DC-T-cell priming method 
may be more efficient in inducing a primary T-cell stimulation. However, a 
larger number of volunteers should be tested before a firm conclusion is drawn. 
Because the two preceding in vitro priming methods produced conflicting 
results depending on the detection method used to determine primary T-cell 
stimulation, generation of CBZ-specific T-cell clones was attempted. T-cell 
cloning was performed from three HLA-A*31:01+ volunteers in total, of which 
two had earlier displayed a positive response. Varying numbers of clones were 
isolated from the three HLA-A*31:01+ donors, and most clones were not found 
  Chapter 3 
110 
 
to be CBZ-specific. Moreover, CBZ-reactive clones from the formerly negative 
HLA-A*31:01+ volunteer showed the strongest responses, whereas CBZ-
responsive clones from the formerly positive volunteers quickly lost specificity. 
A similar situation was observed when T-cell cloning from two HLA-B*15:02+ 
volunteers was performed. Although both samples had previously responded in 
the priming assay, only minimal numbers of CBZ-specific clones could be 
isolated from one of the volunteers, and after a short culture period, they 
became unresponsive to CBZ treatment. T-cell clones from the second HLA-
B*15:02+ volunteer, in contrast, displayed strong and stable proliferative 
responses. These clones were used in a substudy examining the influence of 
CBZ metabolism on T-cell activation. Halogenated derivatives of CBZ, which 
have been shown to be resistant to metabolism in vitro, could clearly stimulate 
CBZ-responsive clones to proliferate, suggesting T-cell activation was mediated 
by the parent drug in a metabolism-independent process. However, whether 
the primary stimulation of drug-naïve T-cells from the HLA-B*15:02+ healthy 
volunteer to CBZ was induced by the parent drug, a reactive metabolite, or a 
drug protein adduct, remains to be demonstrated. 
Overall, T-cell responses to CBZ varied greatly among the HLA-A*31:01+ 
individuals tested in this study, clearly indicating that factors additional to HLA-
A*31:01 are needed in order to induce a primary immune response to CBZ. This 
is not surprising given that the positive predictive value of HLA-A*31:01 in 
Caucasians was determined to be 43% (Yip, V. L. et al. 2012), i.e. 57% of 
individuals carrying the allele do not develop hypersensitivity when treated 
with CBZ. 
In context of HLA-B*15:02, Ko et al. reported that primary stimulation of T-cells 
from HLA-B*15:02+ healthy donors to CBZ could only be achieved if T-cells 
expressing a specific TCR were present. In absence of the specific T-cell 
clonotypes no CBZ-specific response could be detected (Ko et al. 2011). 
Whether specific TCR clonotypes may be required for eliciting CBZ-specific 
responses in HLA-A*31:01+ individuals has not been investigated yet. 
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Other factors that have been reported to affect in vitro priming efficiency 
include inadequate antigen presentation, lack of co-stimulatory cytokines, and 
the presence of Treg suppressing an immune response (Jedema et al. 2011). The 
removal of Treg prior to the DC-based priming assay may explain why primary 
T-cell stimulation might have been slightly more successful in this part of the 
study. With regards to the cytokine milieu, addition of IL-7 has been proposed 
to specifically stimulate the growth of naïve T-cells without inducing 
background proliferation, and may substitute IL-2 treatment (Fry and Mackall 
2005). However, one of the most critical factors for the successful stimulation of 
primary T-cell responses to drugs relates to the presentation of drug antigen. 
For many drugs causing hypersensitivity, including CBZ, the exact antigenic 
structure has not yet been identified. Thus, we cannot be sure that sufficient 
amounts of drug antigen are present during the in vitro priming process. 
Further studies examining the mechanisms of drug antigen formation are 
therefore needed in order to advance our understanding of how drug-specific 
immune responses develop. 
Taken together, there are many variables which may affect the process to 
stimulate primary T-cell responses to drugs in vitro. Identifying these variables 
and subsequent adaptation of current priming protocols to control for them 
should lead to enhanced in vitro T-cell stimulation and give more robust 
responses. 
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4.1 Introduction 
 
Carbamazepine (CBZ) is known to cause a variety of hypersensitivity reactions 
(HSRs), most commonly affecting the skin, ranging from mild maculopapular 
rashes to severe reactions, such as Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN) (Zaccara et al. 2007). Two distinct HLA class I 
alleles, i.e. HLA-B*15:02 and HLA-A*31:01, have recently been found to be 
associated with an increased risk for the development of CBZ hypersensitivity. 
However, the two alleles have been linked to different clinical phenotypes of 
CBZ hypersensitivity and also act as predisposing factors for different ethnic 
groups (Yip, V. L. et al. 2012). HLA-B*15:02 is strongly associated with CBZ-
induced SJS and TEN in Southeast Asian populations (Chung et al. 2004; 
Locharernkul et al. 2008; Mehta et al. 2009; Chang et al. 2011), whereas HLA-
A*31:01 occurs at increased frequency in Japanese, Korean and Caucasian 
patients across all phenotypes of CBZ hypersensitivity (Kim et al. 2011; 
McCormack et al. 2011; Ozeki et al. 2011). 
Drug-specific T-cells isolated from hypersensitive patients have been shown to 
respond to CBZ in vitro, and presentation of CBZ to drug-specific T-cells was 
demonstrated to be MHC-dependent, but did not require intracellular 
metabolism or antigen processing (Wu et al. 2007). These observations support 
the p-i concept, proposing that a direct non-covalent binding of the drug to HLA 
or T-cell receptor (TCR) can cause T-cell activation and ultimately result in 
development of HSRs. However, the molecular mechanism through which CBZ 
activates T-cells and more specifically how the drug interacts with HLA alleles 
to stimulate T-cells remains largely unknown. 
A fundamental step in the activation of antigen-specific T-cells is the recognition 
of a peptide-MHC complex (pMHC) by the corresponding TCR. This interaction 
can be described as one of the crucial events in adaptive immune responses, 
taking place in two highly selective steps (Lundegaard et al. 2010). First, the 
antigenic structure has to bind to the HLA molecule. Second, pMHC has to be 
recognised by the TCR of T-cells. 
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Individual HLA molecules can only bind a restricted range of epitopes, which is 
mainly defined by the physicochemical properties of the amino acids forming 
the HLA binding groove. The amino acid sequence of peptides which are able to 
bind to a specific HLA allele create the so-called peptide binding motif of the 
HLA allele (Gowthaman and Agrewala 2009). 
Traditionally, MHC peptide elution studies were used to define the binding 
motif of individual HLA alleles (Gowthaman and Agrewala 2009). In order to 
store and analyse the vast amount of data generated during these experiments, 
several bioinformatic tools have been developed over the past years. Advances 
in bioinformatics and increased availability of computational models have 
enabled the study of immunological processes in silico. This gave rise to the field 
of computational immunology or immunoinformatics (Petrovsky and Brusic 
2002; Tomar and De 2010); and it is now possible to predict HLA binding 
specificities and identify new epitopes using computational methods. 
Immunoinformatic resources comprise immunological databases, sequence 
alignment tools, epitope prediction algorithms, structural modelling and 3D 
simulations, as well as various mathematical models (Yan 2010). The methods 
are aimed at reducing time-consuming and expensive experimental procedures, 
thereby assisting in testing research hypotheses and guiding experimental 
research processes (Yan 2010). Immunoinformatic analyses are usually 
conducted in a systematic way starting at the DNA level comparing genetic 
sequence information, followed by correlating the genetic structure to the 
functional core, and finally using three-dimensional modelling to depict any 
structure-function relationship (Yan 2010). Experimental assays can then be 
used to test the structure-function associations and prove in silico findings. 
In this chapter the individual binding characteristics of HLA-A*31:01 and HLA–
B*15:02 were explored using publicly accessible bioinformatic tools. A 
systematic in silico analysis was conducted to investigate whether any 
similarities exist between HLA-A*31:01 and –B*15:02 with regards to their 
structure and/ or epitope binding specificity, which might provide a basis for 
their respective association with CBZ-induced HSRs. 
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Moreover, it has recently been proposed that CBZ might be able to stimulate T-
cell responses in a similar way to abacavir, binding directly to the susceptible 
HLA allele and thereby altering the peptide repertoire (Illing et al. 2012). 
For HLA-B*15:02, initial experimental evidence seems to support this 
mechanistic hypothesis (Illing et al. 2012). However, studies investigating the 
influence of CBZ on the peptide repertoire of HLA-A*31:01 have not yet been 
performed. Therefore, a conventional MHC peptide elution study using a HLA-
A*31:01-transfected C1R cell line was carried out, aiming to establish whether 
the standard peptide binding motif of HLA-A*31:01 can be modified by CBZ 
treatment. 
 
 
4.2 Methods 
 
HLA in silico analysis was conducted in collaboration with Dr. Andrew Jones and 
Dr. Faviel Gonzalez Galarza from the Institute of Integrative Biology, University 
of Liverpool. 
 
4.2.1 HLA sequence alignment 
Amino acid sequence alignment was performed using CLUSTAL W2 (available 
at http://www.ebi.ac.uk/Tools/msa/clustalw2/) to determine differences and 
similarities between selected alleles. Sequences were extracted in FASTA file 
format from dbMHC database (see Table 4.1) and entered into CLUSTAL W2 for 
analysis. 
 
4.2.2 Peptide binding motifs 
Peptide binding motifs published for HLA-A*31:01 and -B*15:02 were obtained 
from MHC Motif Viewer and SYFPEITHI databases (Table 4.1). 
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Motifs were compared manually by eye to determine the preferred amino acids 
at each position of nonamer peptide ligands. 
 
4.2.3 3D modelling 
The three-dimensional model structures of HLA-A*31:01 and HLA-B*15:02 
were generated using MODELLER 9.9 software (Sali and Blundell 1993), and 
structures of HLA-A*11:01 (PDB ID 1Q94) and HLA-B*15:01 (PBD ID 1XR8) 
published on the RCSB Protein Data Bank (PDB) were used as templates 
respectively. The selected HLA template structures both represented the closest 
matching alleles for which a crystal structure was available on the Protein Data 
Bank. After screening Immune Epitope Database (IEDB) and SYFPEITHI 
database (Table 4.1), a common epitope reported to bind to both HLA-A*31:01 
and HLA-B*15:02 was modelled into the HLA binding groove. 
Theoretical 3D structures of HLA-A*31:01 and HLA-B*15:02 were sent to 
RAMPAGE (http://mordred.bioc.cam.ac.uk/~rapper/rampage.php) for 
validation of the three-dimensional spacing of amino acids by Ramachandran 
plot. Valid 3D structures were visualised in PyMol (DeLano 2002). 
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Table 4.1: Bioinformatic resources and databases used in this study 
Name Description URL Reference 
IMGT/HLA Database on HLA 
sequences and 
analysis tools 
http://www.ebi.ac.uk/ipd
/imgt/hla/ 
(Robinson et al. 
2013) 
dbMHC Database 
comprising DNA 
and clinical data 
related to MHC 
http://www.ncbi.nlm.nih.
gov/projects/gv/mhc/ 
(Wheeler et al. 
2004) 
CLUSTAL 
W 2.0 
Program for 
multiple sequence 
alignments of 
nucleotide or amino 
acid sequences 
http://www.ebi.ac.uk/To
ols/msa/clustalw2/ 
(Larkin et al. 
2007) 
IEDB Database on B- and 
T-cell epitopes, 
including search 
interface 
http://www.iedb.org/ (Peters et al. 
2005) 
SYFPEITHI Database of MHC 
ligands and peptide 
binding motifs 
http://www.syfpeithi.de/ (Rammensee, H. 
et al. 1999) 
MHC Motif 
Viewer 
Repository of MHC 
binding motifs 
http://www.cbs.dtu.dk/bi
otools/MHCMotifViewer/
Home.html 
(Rapin et al. 
2008) 
RSCB 
Protein 
Data Bank 
Archive of crystal 
structures of 
biological 
macromolecules 
http://www.rcsb.org/pdb
/home/home.do 
(Berman et al. 
2000) 
RAMPAGE Program assessing 
Ramachandran 
plots of protein 
structures 
http://mordred.bioc.cam.
ac.uk/~rapper/rampage.p
hp 
(Lovell et al. 
2003) 
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The methods outlined below have been described previously (Illing et al. 2012) 
and the work was carried out in the laboratories of Prof. James McCluskey, 
Department of Microbiology& Immunology, University of Melbourne, Australia 
and Prof. Anthony Purcell, Department of Biochemistry, Monash University, 
Melbourne, Australia. 
 
4.2.4 Transfection of C1R cell lines 
This part of the work was performed by Patricia Illing, Department of 
Microbiology& Immunology, University of Melbourne, Australia. 
C1R cells were transfected with either HLA-A*31:01 or one of two control 
alleles, HLA-A*03:01 or HLA-A*31:04 (cDNA clones for each were purchased 
from GenScript, USA), using a murine stem cell virus-based retroviral 
expression system (Szymczak et al. 2004; Holst et al. 2006). The B-lymphoblast 
cell line C1R is considered a HLA-A,B negative mutant cell line which only 
expresses HLA-C*04 and low amounts of HLA-B*35 on its surface (Zemmour et 
al. 1992). 
 Briefly, cDNA constructs were ligated into the MSCV-IRES-GFP retroviral 
expression vector (pMIG; Clonotech laboratories, USA) and transformed into 
E.coli. Vectors containing the correct insert were introduced into 293T HEK 
cells by retroviral transduction for replication. C1R cell lines were subsequently 
transfected with viral vectors produced by 293T cells. Successfully transfected 
C1R cell lines were screened for surface HLA expression by flow cytometry 
followed by single cell sorting of highly HLA expressing cells. 
 
4.2.5 C1R cultures 
HLA-transfected C1R cell lines were cultured in 100ml RF10 medium (see 
chapter 3.2.3) in T175 flasks at 37°C. C1R cell lines were grown in duplicate 
cultures, one left untreated and one treated with 25μg/ml CBZ, until a cell 
density of approximately 1x108 cells/culture was reached. The culture medium 
was changed every 2-3 days to maintain proliferation. C1R cells were harvested 
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by centrifugation (2400rpm, 15min, 4°C), washed twice in cold PBS, then 
pelleted in 50ml falcon tubes at 5-10x107 cells and frozen immediately on dry 
ice. Cell pellets were stored at -80°C until needed. 
In a second experimental set-up, HLA-A*31:01 transfected C1R cells were 
grown to high density in T175 flasks in presence and absence of CBZ. Cultures 
were then transferred into 2L roller bottles and cultured at 37°C under constant 
rolling. 300ml RF10 medium (+/- 25μg/ml CBZ) was added every 2-3 days until 
1-1.2L of dense cell cultures were obtained. Cells were harvested as described 
above and frozen at 5-10x108 cells. 
During the culture period, HLA surface expression was monitored regularly 
using flow cytometry. 
 
4.2.6 Preparation of w6/32 cross-linked Protein A resin 
W6/32 hybridoma cells (Barnstable et al. 1978) were cultured in 800ml RF3 
(RF10 with only 3% FBS) medium in roller bottles at 37°C under constant 
rolling. When cell density was considered high enough, a 500ml cell suspension 
was spun down (2400rpm, 20min, 4°C) and supernatant was filtered through 
Nalgene® Rapid Flow 0.2μm aPES vacuum filter (Thermo Scientific, USA). 
The subsequent steps were carried out by Rochelle Ayala. 
W6/32 anti-MHC I antibody was purified by Affinity Chromatography Profina 
Purification System (Bio-Rad, Australia). The antibody was eluted into PBS 
according to the manufacturer’s protocol. 
2ml Protein A Sepharose Fast Flow (PAS; Amersham, GE Healthcare, UK) was 
applied to a Poly-Prep Chromatography column (Bio-Rad, Australia), washed 
with PBS and resuspended in PBS supplemented with 20mg purified w6/32 
antibody. PAS mix was incubated at 4°C for 30min slowly rotating end over end. 
The mixture was poured into a Poly-Prep Chromatography column and the 
flow-through passed over the column a second time. W6/32 bound resin was 
washed with filtered 50mM H3BO3, 50mM KCl (Ajax Finechem, Australia), 4mM 
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NaOH pH 8.0 (ChemSupply, Australia). Resin was equilibrated in 0.2M 
Triethanolamine pH 8.2 (Ajax Finechem, Australia). W6/32 was cross-linked to 
PAS by incubation in 40mM Dimethylpimelimidate (DMP; Sigma-Aldrich, USA) 
in 0.2M Triethanolamine pH 8.2. Cross-linking reaction was terminated using 
ice-cold 0.2M Tris pH 8.0, and any un-cross-linked w6/32 was removed with 
0.1M citric acid (Ajax Finechem, Australia). Resin was equilibrated into PBS and 
stored at 4°C for max. 1 week until used. Directly before use the w6/32 affinity 
column was run into wash buffer 1 (see Table 4.2). 
 
4.2.7 Elution and Purification of MHC bound peptides 
Frozen C1R pellets were ground in a Retsch Mixer Mill MM 400 (Retsch, 
Germany) under cryogenic conditions and resuspended in 20ml lysis buffer 
containing 0.5% IGEPAL (Sigma-Aldrich, USA), 50mM Tris pH 8.0, 150mM NaCl 
(Merck-Millipore, Germany) and protease inhibitors (Complete Protease 
Inhibitor Cocktail Tablet; Roche Molecular Biochemicals, Switzerland). Cell 
lysates were incubated for 45min at 4°C rotating slowly end over end. Lysates 
of 1x108 cells were spun down at 13,000rpm for 20min. For 1x109 cell pellets, 
lysates were cleared by ultracentrifugation at 45,000rpm. Any remaining 
particles were removed by passing the lysates through a Pre-Prep 
Chromatography column containing only PAS, which was pre-washed with 
wash buffer 4 and equilibrated into wash buffer 1 prior to use. Lysates were 
then passed through 1ml of w6/32 resin in a Pre-Prep Chromatography column 
(prepared as described above) to capture MHC class I bound peptides. Any 
unspecific bound material was removed by washing with 20ml of wash buffers 
1-4 sequentially (see Table 4.2). Peptide-MHC complexes were eluted off the 
column using 4ml of 10% acetic acid. Peptides were separated from the protein 
components (MHC class I heavy chain and β2m) using a 4.6mm internal 
diameter x 50mm long monolithic reversed-phase (RP) C18 High Performance 
Liquid Chromatography (HPLC) column (Chromolith Speed Rod, Merck-
Millipore, Germany) on an ÄKTAmicro™ HPLC system (GE Healthcare, UK) 
operated by UNICORNTM software (GE Healthcare, UK). The mobile phase 
consisted of 0.1% trifluoroacetic acid (TFA, Thermo Scientific, USA) [buffer A] 
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and 80% acetonitrile (Fisher Scientific, USA)/ 0.1% TFA [buffer B]. The column 
was pre-equilibrated into 2% buffer B (98 % buffer A) at a flow rate of 
1ml/min, and then loaded with the eluted peptide/protein mix via a 5ml 
injection loop. The separation of peptides from the protein components was 
facilitated by an increasing gradient of buffer B. Explicitly, after re-equilibration 
of the column into 2% buffer B, the concentration of buffer B increased linearly 
to 40% over 4ml, to 45% over the subsequent 4ml (to resolve peptides), then to 
100% over the next 2ml. The flow rate was maintained at 1ml/min throughout 
and UV absorbance of eluted material was monitored at 215nm. Fractions of 
500μl volume expected to contain peptides were collected in 1.7ml Protein 
LoBind Eppendorf tubes. 
 
Table 4.2: Composition of wash buffers for peptide elutions. 
Wash buffer components 
1 
0.005% IGEPAL, 50mM Tris pH 8.0, 150mM NaCl, 5mM EDTA, 
100uM PMSF, 1μg/ml Pepstatin A 
in MilliQ H2O 
2 50mM Tris pH 8.0, 150mM NaCl in MilliQ H2O 
3 50mM Tris pH 8.0, 450mM NaCl in MilliQ H2O 
4 50mM Tris pH 8.0 in MilliQ H2O 
 
 
4.2.8 Peptide identification by mass spectrometry 
This part of the work was undertaken by Patricia Illing at the Department of 
Biochemistry, Monash University, Australia. 
Peptide containing fractions were concentrated using a speed vacuum 
concentration system (LABCONCO, USA) and loaded onto a microfluidic trap 
column packed with ChromXP C18-CL 3μm particles (300Å nominal pore size; 
AB SCIEX, USA), pre-equilibrated in 0.1% formic acid (AnalaR, Australia), 5% 
acetonitrile at 5μl/min using an Eksigent NanoUltra cHiPLC system (AB SCIEX, 
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USA). An analytical (15 cm x 75 μm ChromXP C18-CL 3) microfluidic column 
(AB SCIEX, USA) was switched in line and peptides separated using a linear 
gradient of 0-64% acetonitrile over 55min at a flow rate of 300nl/min. 
Separated peptides were analysed using an AB SCIEX 5600 TripleTOF mass 
spectrometer equipped with a Nanospray III ion source and accumulating up to 
20 MS/MS spectra per second. Acquired data was analysed with Protein PilotTM 
software version 4.5 (AB SCIEX, USA) searching against the human proteome, 
and identified peptides subjected to strict bioinformatic criteria assigning 
confidence values to each peptide. A false discovery rate was calculated by use 
of a decoy database. 
 
4.2.9 Generation of peptide binding motifs 
The peptide binding motif of HLA-A*31:01 was generated through analysis of 
the mass spectrometry data using excel analysis files designed by Patricia Illing 
and Nathan Croft at the Department of Biochemistry, Monash University, 
Australia.  
The distribution of peptides of specific length was calculated, as well as the 
frequency with which amino acids appeared at a specific position within the 
peptides. 
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4.3 Results 
 
4.3.1 In silico modelling 
 
HLA sequence alignment 
Initially, amino acid (AA) signatures of HLA-A*31:01 and HLA-B*15:02 were 
compared to members of the respective serotype and supertype family. The 
alignment was performed for the AA sequence of the α1 and α2 domain (exon 
two and three) forming the binding cleft of HLA class I molecules. AA changes 
highlighted by the programme CLUSTAL W2 were extracted and residues 
located in the binding pockets A- F of HLA class I molecules, previously 
described by Saper and colleagues (Saper et al. 1991), were analysed further. 
When HLA-A*31:01 was compared to members of the HLA A31 serotype, as 
defined by the WHO and listed on the IMGT/HLA database, no AA residue was 
found to occur exclusively in HLA-A*31:01 (Table 4.3). Unique AA residues 
could be observed in isolated alleles of the A31 serotype but not in HLA-
A*31:01. In total, only 12 out of 182 residues differed between A31 serotype 
members, eight of which were located in binding pockets (Table 4.3). 
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2
4
 
Table 4.3: Summary of HLA A31 serotype sequence alignment. 
Residue 
(Pocket) 
Physicochem 
66 
(A/B) 
s 
73 
(C) 
n 
77 
(F) 
s 
80 
(F) 
n 
81 
(F) 
n 
97 
(C/E) 
n 
114 
(D/E) 
s 
167 
(A) 
n 
A*31:02 K I D T L M Q W 
A*31:12 N I D T L K Q W 
A*31:01 N I D T L M Q W 
A*31:04 N I D T L I R W 
A*31:05 N I D T L M Q G 
A*31:10 N T N I A M Q W 
Physicochemical properties of amino acid residues: s= strong similarity; n= not conserved 
 
Table 4.4: Summary of HLA A03 supertype sequence alignment. 
Residue 
(Pocket) 
Physicochem 
9 
(B/C) 
n 
63 
(A/B) 
s 
70 
(B/C) 
s 
73 
(C) 
n 
97 
(C/E) 
n 
114 
(D/E) 
s 
152 
(E) 
n 
156 
(D/E) 
n 
163 
(A) 
n 
171 
(A) 
s 
A*33:01 T N H I M Q V L T H 
A*33:03 T N H I M Q V L T Y 
A*31:01 T E H I M Q V L T Y 
A*74:01 F E H T M Q V L T Y 
A*66:01 Y N Q T R Q E W R Y 
A*68:01 Y N Q T M R V W T Y 
A*03:01 F E Q T I R E L T Y 
A*11:01 Y E Q T I R A Q R Y 
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A second sequence alignment was performed on the HLA A03 supertype family 
as defined in the paper by Sidney et al. (2008). HLA supertypes represent 
groups of HLA molecules which show an overlap in peptide specificity and 
therefore display similar peptide binding motifs (Sidney et al. 2008). As 
expected the variation in AA sequences was broader for the HLA A03 supertype 
than the A31 serotype. Sequences varied in 22 of the 182 residues forming the 
binding cleft, with ten AAs located in HLA class I binding pockets. AA changes 
were detected in all binding pockets apart from the F-pocket, which was found 
to be fully conserved across the A03 supertype. But no AA residue was specific 
to HLA-A*31:01 (Table 4.4). 
In parallel, HLA-B*15:02 was analysed in comparison to HLA alleles of the HLA 
B75 serotype and B62 supertype respectively (Table 4.5 and 4.6). Six residues 
were found to vary among the alleles of the HLA B75 serotype, and five of the 
residues were positioned in binding pockets. No alterations were observed in 
the A and C pockets. The only variable residue of the F pocket, residue 95, 
fluctuated between leucine and isoleucine (Table 4.5). Most altered residues 
were defined by two different amino acids, with the exception of residue 67 
which was characterised by a different amino acid for nearly every allele. 
However, none of the AA residues were solely expressed by HLA-B*15:02 (Table 
4.5). For the HLA B62 supertype, AA sequences differed in 25 residues in total. 
Sixteen residues were determined to be part of the binding pockets A to F 
(Table 4.6). Most variations affected only a single HLA allele but not HLA-
B*15:02. Limited sequence variations which affected HLA-B*15:02 alongside 
HLA-B*15:13 were observed for residues 63 (Glu63Asn) and 113 (His113Tyr). 
However, the different amino acids in both positions were determined to be of 
strong similarity regarding their physicochemical properties. 
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Table 4.5: Summary of HLA B75 serotype sequence alignment. 
Residue 
(Pocket) 
Physicochem 
67 
(B) 
n 
95 
(F) 
s 
113 
(D) 
s 
152 
(E) 
n 
156 
(D/E) 
n 
B*15:02 S I Y E L 
B*15:21 C I Y E L 
B*15:31 S L Y V L 
B*15:08 F L H E W 
B*15:11 Y L H E W 
 
 
Table 4.6: Summary of HLA B62 supertype sequence alignment. 
Residue 
(Pocket) 
Physicochem 
63 
(A/B) 
s 
66 
(A/B) 
n 
67 
(B) 
n 
70 
(B/C) 
n 
74 
(C) 
n 
77 
(F) 
w 
80 
(F) 
n 
81 
(F) 
n 
95 
(F) 
n 
97 
(C/E) 
n 
113 
(D) 
s 
114 
(D/E) 
s 
116 
(F) 
n 
156 
(D/E) 
n 
167 
(A) 
n 
171 
(A) 
s 
B*15:01 E I S T Y S N L L R H D S W W Y 
B*46:01 E K Y R D S N L L R H D S W W Y 
B*15:12 E I S T Y S N L L R H D S W G Y 
B*15:02 N I S T Y S N L I R Y D S L W Y 
B*15:13 N I S T Y N I A I R Y D S L W Y 
B*52:01 E I S T Y N I A W T H N Y L W H 
Physicochemical properties of amino acid residues: s= strong similarity; w= weak similarity; n= not conserved 
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Next, an alignment of HLA-A*31:01 and B*15:02 was performed, including 
A*03:01 and B*46:01 as control alleles (Table 4.7). HLA-A*03:01 and HLA-
B*46:01 were selected as control alleles due to their high frequency in 
Caucasian and Asian populations respectively, and therefore assumed not to be 
a risk factor for CBZ hypersensitivity. Additionally, both control alleles are part 
of the respective HLA supertype. Especially modifications in the B- and F-pocket 
were considered to be of interest, as these pockets are known to interact with 
anchor residues P2 and PΩ of binding peptide epitopes (Sidney et al. 2008). 
Furthermore, the F-pocket of the HLA-B*57:01 allele had previously been shown 
to be the major binding site for abacavir, an antiretroviral drug known to cause 
hypersensitivity syndrome in patients carrying HLA-B*57:01 (Chessman et al. 
2008; Illing et al. 2012). 
The AA sequences of the four alleles varied in 37 residues, of which 13 were 
located in binding pockets (Table 4.7). Although the alignment shows the 
highest variety between AA sequences in comparison to afore described 
alignments, almost 80% of the AA residues of the α1 and α2 domains were fully 
conserved. Three residues of the F pocket (77, 80, 116) were found to be 
modified, clearly separating the HLA-A alleles from HLA-B (Table 4.7). In the B 
pocket, alterations in five residues (9, 63, 66, 67, 70) were observed; and the 
physicochemical properties of two of these residues (63, 70) were 
characterised as strongly similar across the four alleles. However, none of the 
13 altered amino acids were the same for HLA-A*31:01 and B*15:02. 
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Table 4.7: Differences in amino acid sequence between HLA-A*31:01 and HLA-B*15:02 and two control alleles. 
Residue 
(Pocket) 
Physicochem 
9 
(B) 
n 
63 
(B/A) 
s 
66 
(B) 
n 
67 
(B) 
n 
70 
(B) 
s 
73 
(C) 
n 
74 
(C) 
n 
77 
(F) 
w 
80 
(F) 
w 
97 
(C/E) 
n 
114 
(D/E) 
n 
116 
(F) 
w 
152 
(E) 
n 
A*03:01 F E N V Q T D D T I R D E 
A*31:01 T E N V H I D D T M Q D V 
B*15:02 Y N I S N T Y S N R D S E 
B*46:01 Y E K Y R T D S N R D S E 
Physicochemical properties of amino acid residues: s= strong similarity; w= weak similarity; n= not conserved 
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Peptide binding motifs 
Following the analysis of the AA sequence characteristics of HLA-A*31:01 and 
B*15:02, the nature of binding peptide epitopes was examined. 
First, published binding motifs of the two HLA alleles were obtained from the 
MHC Motif viewer website (Figure 4.1). The most outstanding feature for both 
HLA-A*31:01 and B*15:02 is the very dominant P9 anchor residue indicating 
that the binding specificity of both alleles is strongly determined by the C-
terminal residue of nonamer peptides. The binding contribution of this AA 
residue is far more prominent in HLA-A*31:01 and B*15:02 than in common, 
classical HLA class I alleles, e.g. HLA-A*02:01 and HLA-B*08:01 (Figure 4.1). 
Furthermore, the C-terminal binding site of HLA-A*31:01 shows a strong 
preference for peptides with a basic arginine residue, whereas HLA-B*15:02 
prefers neutral to hydrophobic amino acids at the P9 position. Generally, the 
main anchor residues of HLA class I binding peptides are the positions P2 and 
P9, but this is not the case for HLA-A*31:01 or B*15:02. When comparing the 
binding motifs of the two alleles to motifs of classic HLA class I alleles, such as 
HLA-A*02:01, the P2 residue does not seem to act as an anchor residue for 
either HLA-A*31:01 or B*15:02 (Figure 4.1). Nor does any other peptide residue 
appear to function as a substitute for the missing anchor residue. 
These observations are largely consistent with the data available from the 
SYFPEITHI database (Table 4.8). However, the peptide binding motif of HLA-
B*15:02 published on SYFPEITHI displays position P2 as anchor residue. For 
HLA-A*31:01, peptide positions P2, P3 and P6 are classified as auxiliary anchor 
residues. When the preferred amino acids in positions P1 to P9 were compared 
between HLA-A*31:01 and B*15:02, a considerable overlap could be detected in 
position P2, P3 and P4 (Table 4.8). Nonetheless, HLA-A*31:01 seemed to 
accommodate a wider range of amino acids in its’ binding pockets which 
suggests that HLA-A*31:01 exhibits weaker binding specificity in preferred 
amino acids with the exception of anchor position P9. 
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Figure 4.1: Peptide 
binding motifs of HLA-
A*31:01, HLA-B*15:02 and 
two control HLA alleles. 
Logo-plots were extracted 
from the MHC Motif 
Viewer (Rapin et al. 
2008). 
Binding motifs are plotted 
for nonamer peptides. 
Amino acids with a positive 
binding effect are mapped 
on the positive y-axis; 
negative amino acids with a 
negative binding effect are 
shown on the negative y-
axis. The height of each 
amino acid represents the 
relative contribution to the 
binding specificity. 
The pie chart represents the 
reliability index (upper 
number) for the binding 
motif, which is determined 
by Pearson correlation 
calculating the pseudo 
sequence distance (lower 
number) to the nearest 
neighbouring allele with a 
well-characterised binding 
specificity. 
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Table 4.8: Comparison of HLA-A*31:01 and HLA-B*15:02 peptide binding 
motifs derived from SYFPEITHI database (Rammensee, H. et al. 1999). 
P= position of amino acid in nonamer; A= HLA-A*31:01; B= HLA-B*15:02 
 
3D structural modelling 
As no crystal structures for either HLA-A*31:01 nor HLA-B*15:02 were available 
on the RSCB Protein Data Bank, three-dimensional model structures were 
generated in silico using MODELLER 9.9 software. The structures of HLA-
A*11:01 (Li, Lenong and Bouvier 2004) and HLA-B*15:01 (Roder et al. 2006) 
were determined to be the closest neighbouring alleles for which a crystal 
structure had been deposited on PBD, and thus were used as template 
structures. HLA-A*31:01 differs in 18 AA residues from HLA-A*11:01, with eight 
amino acids (9, 70, 73, 97, 114, 152, 156, 163) located in binding pockets. Five 
amino acid residues vary between HLA-B*15:02 and HLA-B*15:01, of which four 
amino acids (63, 95, 113, 156) form parts of binding pockets. 
The 3D models of HLA-A*31:01 and HLA-B*15:02 comprised each of the HLA 
alleles in complex with the Escherichia coli peptide KLAEIFQPF, as HLA 
molecules without embedded peptide are considered to be unstable and might 
show a different three-dimensional architecture. KLAEIFQPF had been 
identified as a common binder of both HLA-A*31:01 and B*15:02, after 
comparing published peptide epitopes for each of the HLA alleles on IEDB and 
SYFPEITHI database. Peptide epitopes were cross-matched for common peptide 
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binders between HLA-A*31:01 and B*15:02 which were not present in the 
previously selected control alleles, i.e. HLA-A*03:01 and HLA-B*46:01. 
Spatial arrangement of amino acids in the generated 3D structures was 
validated by Ramachandran plot via RAMPAGE (see Appendix F2). Both models 
satisfied the evaluation criteria of the Ramachandran analysis (Table 4.9). In 
each model only 1 amino acid was considered as an outlier, however, in both 
cases the amino acid in question did not fall in the HLA binding region and was 
therefore considered to be unimportant. 
 
Table 4.9: RAMPAGE results for 3D models of HLA-A*31:01 and HLA–B*15:02. 
Ramachandran plot 
Evaluation 
HLA-A*31:01 HLA-B*15:02 
Residues in favoured 
region (98% expected) 
730 (97.9%) 371 (98.1%) 
Residues in allowed 
region (2% expected) 
7 (1.9%) 6 (1.6%) 
Residues in outlier 
region 
1 (0.3%) 1 (0.3) 
 
To assess the structural characteristics of the peptide binding cleft of HLA-
A*31:01 and B*15:02, the 3D models were visualised in PyMol and the binding 
cleft of each allele was selected for display. Further analysis concentrated on the 
spatial conformation of altered amino acids between template and model 
structures which were located in HLA class I binding pockets. 
The binding cleft of HLA-A*31:01 displayed modifications in eight amino acids 
in comparison to HLA-A*11:01 (Figure 4.2). When the AA sequence of HLA-
A*03:01 was taken into consideration as additional control allele, only four AA 
residues remained specific to HLA-A*31:01. The modified residues Gln70His, 
Thr73Ile, Ile97Met and Arg114Gln displayed an altered spatial conformation 
which could affect peptide binding, and thus might demarcate the binding 
specificity of HLA-A*31:01 (Figure 4.2). The altered residues were located 
across binding pockets B to E (70-B/C, 73-C, 97-C/E, 114-D/E). 
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The three-dimensional model of HLA-B*15:02 showed changes in only four 
binding pocket residues when compared to HLA-B*15:01 (Figure 4.3). The 
altered amino acids Glu63Asn, Leu95Ile, His113Tyr and Trp156Leu were 
located in binding pockets A/B, F, D and D/E respectively. Importantly, the 
sequences of HLA-B*15:01 and B*46:01 are identical in these four positions. In 
conjunction with a change in physiochemical properties, the structural 
conformation of AA residues 63 and 113 might mark the binding specificity of 
HLA-B*15:02 (Figure 4.3). 
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Figure 4.2: Binding cleft of HLA-
A*31:01 in comparison to HLA-
A*11:01. 
The graphics represent the three-
dimensional ribbon structure of the 
HLA binding cleft (grey). Altered 
amino acid residues which are 
located in binding pockets are 
highlighted as stick structures. 
The red sticks depict amino acids 
which are characteristic to HLA-
A*31:01 when residues were 
compared to sequences of HLA-
A*11:01 and A*03:01. The blue 
sticks illustrate amino acids which 
vary across all three HLA-A alleles. 
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Figure 4.3: HLA-B*15:02 
binding cleft in relation to 
HLA-B*15:01. 
The HLA binding cleft (grey) is 
depicted in ribbon configuration 
and modified amino acids 
located in binding pockets are 
highlighted as stick structures. 
Red amino acids are unique to 
HLA-B*15:02 in comparison to 
amino acid sequences of HLA-
B*15:01 and B*46:01. 
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4.3.2 Peptide elution studies 
In order to characterise the peptide binding motif of HLA-A*31:01 in vitro and to 
test whether CBZ is able to modify the HLA-A*31:01 peptide repertoire, the B-
lymphoblastoid cell line C1R was transfected with HLA-A*31:01 or a control 
HLA-A allele, i.e. HLA-A*03:01 or HLA-A*31:04. C1R cells are considered to lack 
HLA class I expression, except for HLA-C*04 and minor amounts of HLA-B*35, 
and are a widely used tool for functional studies of individual HLA class I alleles 
(Zemmour et al. 1992). HLA-A*03:01 and HLA-A*31:04 were selected as control 
alleles, on the grounds that HLA-A*03:01 was absent in CBZ hypersensitive 
patients in our GWAS (McCormack et al. 2011) and HLA-A*31:04 shows a high 
similarity to HLA-A*31:01 with only two changes in AA sequence. 
HLA-transfected C1R cells were cultured in the presence and absence of CBZ, 
and HLA-bound peptides isolated by affinity chromatography using the anti-
HLA class I specific antibody w6/32. The purified peptide-HLA complexes were 
eluted with acetic acid, which also facilitates dissociation of peptide and HLA, 
and separated by RP-HPLC. When the chromatograms of CBZ-treated cultures 
were compared to untreated cultures, no peak signifying the accumulation of 
CBZ could be detected in the UV trace (Figure 4.4). The peptide-containing 
fractions were subsequently analysed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). 
Unmodified CBZ could be clearly detected in all drug-treated samples (Figure 
4.5). However, CBZ levels were no higher for HLA-A*31:01 than for the control 
alleles, suggesting binding of CBZ to HLA-A alleles was non-specific (data not 
shown). No CBZ metabolites could be observed in the MS spectra of the peptide 
fractions. 
Next, the peptide repertoire presented by HLA-A*31:01 in the presence and 
absence of CBZ was assessed in more detail. 
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Figure 4.4: Chromatograms of RP-HPLC separation of material eluted from HLA-A*31:01-transfected C1R cells in the absence (A) and presence (B) 
of CBZ. 
Eluted peptides from HLA-A*31:01 were separated from β2m and HLA heavy chain by RP-HPLC. The blue line shows the UV traces of the eluted material, and the 
green line represents the buffer gradient. The red box indicates the retention time interval containing CBZ.  
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Figure 4.5: Detection of CBZ by LC-MS/MS. 
CBZ-containing fractions were analysed by LC-MS/MS and CBZ was detected in all drug-treated 
cultures, as exemplified by this spectrum (predicted mass MH+= 237.1022 Da). 
 
 
 
Figure 4.6: Length distribution of peptides eluted from HLA-A*31:01-transfected C1R 
cells in absence and presence of CBZ. 
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A total of 3329 and 2667 peptides were identified from the untreated and CBZ-
treated HLA-A*31:01-transfected C1R cultures respectively. After removal of 
peptides specific for HLA-C*04 and HLA-B*35 using an in-house built decoy 
database, only 693 and 605 peptides remained that were determined to be 
presented by HLA-A*31:01 in the absence and presence of CBZ respectively. 
In a first step, the distribution of peptide lengths was evaluated, as depicted in 
Figure 4.6. Most peptides were eight to eleven amino acids long, with nonamers 
being most abundant. Overall, there was no change in peptide length 
distribution between drug-treated and untreated cell lines (Figure 4.6). 
Next, the binding motif of nonamer peptides was generated by calculating the 
relative frequency of each amino acid at each residue of the peptide. The 
resulting HLA-A*31:01 binding motif displayed a dominant arginine residue at 
position P9, which was the only obvious anchor residue (Table 4.10 A). This is 
characteristic for HLA-A*31:01 and concordant with previously published 
motifs (see Figure 4.1). Furthermore, treatment of HLA-A*31:01 transfectants 
with CBZ did not seem to induce any substantial changes in preferred AA 
residues within the HLA-A*31:01 peptide binding motif (Table 4.10 B). 
This was examined in more detail by extracting the nonamer peptides unique to 
the untreated or CBZ-treated C1R cultures (99 and 91 peptides respectively), 
and comparing the AA frequencies at positions P1 to P9 (Table 4.11). AA 
frequencies were classified as increased or decreased if a difference of more 
than five percentage points was observed. In general, only minor differences 
were detected. In the presence of CBZ, hydrophobicity decreased marginally at 
positions P2, P3, P5 and P9, whereas it increased slightly at P6. Furthermore, a 
small shift in preferred amino acids at P7 and P8 towards charged residues 
could be observed (Table 4.11). 
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Table 4.10: Peptide binding motif of HLA-A*31:01 in absence (A) and presence 
(B) of CBZ. 
 
A) HLA-A*31:01 - untreated 
9mers 
(n=220) 
P1 P2 P3 P4 P5 P6 P7 P8 P9 
Dominant 
(≥40%) 
                R 
Strong 
(≥20%) 
  F 
  
D           L 
Moderate 
(≥10%) 
R 
F 
Y 
P 
L 
  
E 
D 
I 
  
L 
  
V L 
  
F 
  
Increased 
(≥5%) 
V 
I 
K 
A 
S 
L 
T 
L 
V 
T 
F 
I 
G 
L 
S 
V 
P 
V 
L 
R 
T 
F 
K 
A 
F 
E 
V 
D 
S 
A 
I 
P 
I 
T 
A 
R 
F 
E 
S 
S 
F 
E 
Y 
N 
K 
P 
G 
 
 
B) HLA-A*31:01 - CBZ treated 
9mers 
(n=212) 
P1 P2 P3 P4 P5 P6 P7 P8 P9 
Dominant 
(≥40%) 
                R 
Strong 
(≥20%) 
  F 
  
D           L 
Moderate 
(≥10%) 
R 
F 
Y 
  
L 
  
E 
D 
  
  
L 
V 
V 
T 
L 
  
F 
  
Increased 
(≥5%) 
K 
I 
L 
V 
M 
S 
T 
P 
V 
L 
T 
N L 
P 
S 
G 
V 
T 
I 
F 
V 
S 
A 
L 
R 
T 
K 
P 
F 
E 
I 
R 
P 
D 
G 
R 
E 
F 
I 
H 
S 
E 
F 
S 
Y 
T 
K 
N 
P 
M 
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Table 4.11: CBZ-induced shift in preferred amino acid residues of nonamer 
peptides specific for HLA-A*31:01. 
AA 
Frequency 
P1 P2 P3 P4 P5 P6 P7 P8 P9 
Increased ↑ 
(>5PPT, 
<10PPT) 
M 
L 
Y   S V E 
R 
E  
Decreased ↓ 
(>5PPT, 
<10PPT) 
V F 
P 
F  I S V 
A 
G 
S 
L 
PPT= percentage points 
 
At the same time, however, it became apparent the binding motifs still 
contained considerable amounts of HLA-C*04 specific peptides. This was most 
evident in the anchor residues P2 and P9 which showed a strong preference for 
amino acids Phe and Leu/Phe respectively; and was further supported by the 
strong Asp residue in position P3 (Table 4.10). These amino acid residues are 
typical for peptides presented by HLA-C*04 in wild-type C1R cells 
(Schittenhelm et al. 2014). 
As a consequence, the peptide sets were screened again manually and all 
peptides exhibiting a classic HLA-C*04 motif were removed. This resulted in a 
decrease of HLA-A*31:01 specific nonamer peptides to 140 and 133 peptides 
for untreated and CBZ-treated C1R cells respectively, of which 55 and 58 
peptides were unique to each of the data sets. These peptide numbers were 
determined to be too low to generate a reliable binding motif and prevented 
any further analysis at this point. 
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4.4 Discussion 
 
In the first part of this chapter, in silico analyses were performed in order to 
explore whether the two distinct HLA class I alleles associated with CBZ 
hypersensitivity, i.e. HLA-A*31:01 and HLA-B*15:02, bear any similarities in 
their structure or binding specificity which might explain their individual 
correlation with CBZ-induced hypersensitivity. 
When comparing the sequences of HLA-B75 serotype alleles, which comprises 
HLA-B*15:02, no relevant changes in amino acids forming the A-, C- and F-
pockets could be observed. Alignment of the alleles forming the HLA-B62 
supertype indicated that alterations in amino acid residues 63, 113 and 156, 
which are located in the B- and D-pocket, distinguish HLA-B*15:02 to some 
extent from the other HLA-B alleles. Analysis of the 3D structure of HLA-
B*15:02 implied that residues 63N and 113Y could delineate the binding 
specificity of HLA-B*15:02 from other HLA-B alleles, and therefore CBZ may be 
interacting primarily with these residues. 
A recent study by Wei and colleagues confirmed most of the in silico findings 
described above (Wei, C. Y. et al. 2012a). They demonstrated that CBZ was able 
to bind directly to HLA-B*15:02 interacting with amino acid residues 63N, 95I 
and 156L within the HLA binding groove (Wei, C. Y. et al. 2012a). Computational 
docking of CBZ to HLA-B*15:02 showed that the energetically most favoured 
binding positions of CBZ were all predicted to be located in the B-pocket near 
residue 62R (Wei, C. Y. et al. 2012a). 
Amino acid sequence alignment of HLA-A*31:01 to other HLA-A31 serotype 
alleles did not reveal any AA residue or binding pocket which might permit 
specific binding of CBZ to HLA-A*31:01. When the sequence of HLA-A*31:01 was 
compared to members of the HLA-A03 supertype, no differences were observed 
in amino acids of the F-pocket, making it unlikely to be a preferred binding site 
for CBZ. The 3D model structure revealed that the binding specificity of HLA-
A*31:01 might be characterised by AA residues 70Q, 73T, 97I and 114R. If the 
findings on HLA-B*15:02 are taken into consideration, these observations 
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suggest that binding of CBZ to HLA-A*31:01 might occur in close proximity to 
these residues. However, in contrast to HLA-B*15:02, no in vitro studies 
investigating the binding mode of CBZ to HLA-A*31:01 have been published yet. 
Further studies are therefore needed in order to verify the hypothesis 
presented here. This would involve the application of computational docking 
programmes, as well as in vitro assays using antigen-presenting cells expressing 
HLA-A*31:01 and closely related HLA-A alleles to define the exact binding site 
of CBZ. 
Direct comparison of the HLA-A*31:01 sequence to HLA-B*15:02 showed no 
overlap in AA residues in addition to those which also exist in the control alleles 
HLA-A*03:01 and B*46:01. Comparable observations have been reported 
recently in a study by Niihara et al., leading them to the conclusion that the two 
HLA alleles show no similarities in presentation of antigens (Niihara et al. 
2012). However, the data presented in this chapter show that the 
physicochemical properties of AA residues 63 and 70, both located in the B-
pocket, can be considered to be strongly alike, suggesting some indirect 
structural similarities between the two alleles may exist. As a result, CBZ may 
bind at slightly different locations within the HLA binding groove based on the 
unique amino acid microenvironment of the individual HLA alleles. 
 
Previous in vitro studies established that CBZ binding to HLA occurred directly 
in the absence of metabolism and antigen processing, suggesting CBZ-specific T-
cells are activated through a p-i like mechanism (Wu et al. 2007; Wei, C. Y. et al. 
2012a). This was further supported by a peptide elution study of HLA-B*15:02-
transfected cell lines which failed to detect any CBZ-modified peptides (Yang et 
al. 2007). The altered peptide repertoire model, recently published in the 
context of abacavir hypersensitivity (Illing et al. 2012; Norcross et al. 2012; 
Ostrov et al. 2012), could provide an alternative mechanism explaining the 
HLA-restricted activation of T-cells by CBZ. The second part of this chapter 
therefore focused on the peptide repertoire presented by HLA-A*31:01. A 
classic peptide elution study was carried out in order to determine whether CBZ 
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treatment leads to changes in peptides presented by HLA-A*31:01 and 
subsequently might induce T-cell activation. 
Free CBZ was detected by mass spectrometry in peptide fractions originating 
from drug-treated HLA-A*31:01-transfected C1R cells, suggesting CBZ bound 
non-covalently to pMHC, and dissociated after treatment with acetic acid prior 
to HPLC purification. However, CBZ was not found to be enriched in HLA-
A*31:01 transfectants compared to C1R cells transfected with control HLA-A 
alleles, i.e. HLA-A*03:01 and A*31:04, indicating that CBZ does not bind 
preferentially to HLA-A*31:01. This is in stark contrast to the findings published 
for abacavir and HLA-B*57:01, and CBZ and HLA-B*15:02 (Illing et al. 2012). 
Furthermore, no additional peaks or ions with mass shift indicating metabolites 
of CBZ could be detected in the mass spectra. However, the in vitro system used 
in this study may not mirror the in vivo situation, as lymphocytes only show 
limited metabolic activity (Raucy et al. 1999). 
As expected, the length of peptides recovered from HLA-A*31:01 transfectants 
were typical of peptides presented by HLA class I alleles (Rammensee, Hans-
Georg 1995; Burrows et al. 2006). As for abacavir and HLA-B*57:01, the 
distribution of peptide lengths was not affected by CBZ treatment (Illing et al. 
2012). Sequencing of eluted peptides from HLA-A*31:01 in the presence and 
absence of CBZ using mass spectrometry allowed the generation of HLA-
A*31:01 specific binding motifs. The binding motif of untreated HLA-A*31:01 
generally agreed with previously published motifs on MHC motif viewer (Rapin 
et al. 2008) and SYFPEITHI database (Rammensee, H. et al. 1999), showing only 
one anchor residue at position P9 with a dominant preference for arginine. Only 
minor shifts in AA preferences across nonamer peptides could be observed 
after CBZ treatment. However, it needs to be noted that both peptide motifs 
were clouded by remnant HLA-C*04 specific peptides. This was deduced from 
the occurrence of amino acids Phe, Pro and Leu/Phe as strong residues at 
positions P2, P3 and P9 respectively, which is typical for HLA-C*04 peptides in 
C1R cells (Schittenhelm et al. 2014). Contamination of the binding motif of HLA-
A*31:01 by HLA-C*04 peptides could be explained in parts by loss of HLA-
A*31:01 expression on C1R cells. Regular monitoring of HLA surface expression 
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of HLA-transfected C1R cell lines showed a clear decrease in HLA-A*31:01 
expression over time (data not shown). Overall, this effect results in a relative 
reduction of HLA-A*31:01 specific peptides and a corresponding increase in 
HLA-C*04 specific peptides with regards to total peptide numbers presented on 
C1R cells. As a consequence, in order to ascertain whether CBZ is able to induce 
a change in peptides presented by HLA-A*31:01, this study would need to be 
repeated using a new HLA-transfected cell line, showing a higher, more stable 
expression of HLA-A*31:01. 
In conclusion, the structural binding specificity of HLA-B*15:02 and HLA-
A*31:01 was analysed in silico, and potential binding sites for CBZ derived 
through consolidated AA sequence comparison and three-dimensional 
structure modelling. The research findings published by Wei et al. have 
provided evidence supporting the in silico data presented for HLA-B*15:02 in 
this study, and at the same time substantiate the in silico observations 
presented for HLA-A*31:01. However, defined in vitro studies are warranted to 
confirm the binding position of CBZ within the HLA-A*31:01 binding groove. 
The peptide elution study performed on HLA-A*31:01-transfected cell lines 
provided some very preliminary evidence that CBZ may be able to alter the 
peptide repertoire presented by HLA-A*31:01. MS analysis revealed the 
presence of unmodified CBZ, which adds to the existing evidence that CBZ may 
induce drug-specific T-cell responses through a non-covalent binding 
mechanism to HLA. At this stage, however, it cannot be excluded that in vivo a 
hapten mechanism might be important in the development of CBZ-induced 
HSRs. 
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5.1 Introduction 
 
It has been well-established that T-lymphocytes play a central role in delayed-
type drug-induced hypersensitivity reactions (HSRs). The pathomechanisms 
involved in HSRs are thought to include the presentation of a drug antigen in 
context of HLA to T-cells and their respective T-cell receptor (TCR). The drug 
may either bind covalently to a peptide presented on a HLA molecule, as defined 
by the hapten hypothesis (Landsteiner and Jacobs 1935), or directly interact 
with either the HLA or TCR molecule through a non-covalent interaction, as 
proposed by the p-i concept (Pichler 2002). Ultimately, recognition of a drug 
antigen by a specific TCR, particularly its complementarity-determining region 
3 (CDR3), results in T-cell activation and clonal expansion of effector T-cells. In 
recent years, specific HLA alleles have been found to be associated with certain 
drug-induced HSRs (see chapter 1.6.4), and in some cases their function in drug 
antigen presentation is beginning to be uncovered (Chessman et al. 2008; Illing 
et al. 2012; Norcross et al. 2012; Ostrov et al. 2012; Wei, C. Y. et al. 2012a; 
Monshi et al. 2013). However, the impact of the TCR in the pathogenesis of HSRs 
remains largely unknown. 
In several autoimmune and infectious disease settings, such as multiple 
sclerosis, psoriasis, influenza A or HIV (Pantaleo et al. 1994; Lehner et al. 1995; 
Musette et al. 1996; Hwang et al. 2003), analysis of the TCR repertoire has 
shown that specific TCR subtypes are responsible for antigen recognition and 
initiation of an immune response. This suggests that the presence or absence of 
specific TCRs may influence the magnitude of an immune response to a specific 
antigen. 
With regards to drug hypersensitivity, only a few studies have investigated 
whether drug-specific T-cells show predominant expression of specific TCRs. 
Generally, heterogeneous TCR Vβ profiles have been observed among individual 
patients hypersensitive to a specific drug, and only a few commonly used TCR 
Vβ subtypes could be detected (Cederbrant et al. 2000; Hashizume et al. 2002). 
Most recently, Ko and colleagues investigated the TCR usage in Han Chinese 
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patients carrying the risk allele HLA-B*15:02 and suffering from 
carbamazepine-induced Stevens-Johnson syndrome (SJS) (Ko et al. 2011). They 
were able to show that only patients expressing a specific TCR Vβ in 
combination with the risk allele HLA-B*15:02 developed CBZ-induced SJS, 
providing initial evidence that specific TCRs may function as an additional risk 
factor in drug-induced HSRs (Ko et al. 2011). This finding may also explain why 
some patients carrying the HLA risk allele do not develop hypersensitivity. 
Whether specific TCR Vβs may play a pathogenic role in other populations and 
other phenotypes of CBZ hypersensitivity remains to be established. 
Several methods have been developed over the last few years to measure the 
TCR diversity of T-cell populations. A panel of fluorescent-labelled monoclonal 
antibodies targeting the variable (V) region of the TCR β-chain can be used to 
examine TCR protein expression levels. This method follows a standard flow 
cytometry staining protocol, can be easily implemented, and delivers rapid 
results. A more refined technique is the CDR3 spectratyping method, also 
known as the immunoscope approach, first described by Pannetier et al. (1995). 
This method determines the lengths of the CDR3 region of the different TCRs 
used by antigen-specific T-cells by polymerase chain reaction (PCR) and 
subsequently separates the PCR products by electrophoresis (Pannetier et al. 
1995). With this approach, T-cell responses to a specific antigen can be 
classified into polyclonal, oligoclonal, or monoclonal, depending on the CDR3 
length profile. More detailed profiles of the T-cell repertoire implicated in an 
antigen-specific immune response can be acquired by sequencing of the CDR3 
region; and this can be performed on polyclonal T-cell populations as well as on 
a single-cell level (Turner et al. 2006). Analysis of the TCR repertoire is often 
limited to testing TCR Vβ expression for two main reasons. First, the majority of 
T-cells (≥90%) are known to express α:β TCRs (Davis and Bjorkman 1988). 
Second, a single α:β T-cell can display up to two TCRs which consist of either 
one of two α-chains but the same β-chain (Padovan et al. 1993). 
Until now, the T-cell receptor repertoire and its potential influence on the 
susceptibility of an individual to develop a drug-specific immune response have 
largely been ignored. With the findings by Ko et al (2011), however, it has 
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become evident that further research into TCR diversity in context of drug-
induced HSRs is needed in order to fully understand the mechanisms leading to 
drug-specific T-cell activation. This may also assist in determining more 
accurately who may be at risk of developing a reaction when administered a 
drug. In the case of flucloxacillin, for example, it has been demonstrated that 
drug-protein conjugates are present in the plasma of all patients treated with 
the antibiotic (Jenkins et al. 2009), but only a small subset of patients develop 
hypersensitivity. One reason for this could be that particular TCR subtypes 
which are able to recognize the drug antigen need to be present in an individual 
in order to develop flucloxacillin hypersensitivity. 
The main aim of this chapter was to establish a protocol for CDR3 spectratyping 
allowing us to characterise the TCR Vβ repertoire of different drug-specific T-
cell populations. For the work presented in this study, naïve T-cells from 
healthy donors were primed to nitroso sulfamethoxazole (SMX-NO), a 
commonly used model drug antigen. The TCR Vβ usage of SMX-NO specific T-
cells was then analysed and compared to the TCR diversity of naïve T-cells. 
Protein and mRNA expression levels of 24 TCR Vβ subtypes were assessed 
using flow cytometry and CDR3 spectratyping respectively. 
 
 
5.2 Methods 
 
5.2.1 Healthy volunteers 
100ml blood was taken from six randomly selected healthy volunteers after 
informed consent was obtained. The study protocol was approved by the 
University of Liverpool research ethics committee. Peripheral blood 
mononuclear cells (PBMCs) were isolated by density gradient centrifugation as 
described in chapter 2.2.4. 
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5.2.2 Chemicals 
Nitroso sulfamethoxazole (SMX-NO; Dalton Pharma Services, Canada) was 
prepared as stock solution (50mM) in DMSO (Sigma-Aldrich, UK), and diluted in 
T-cell medium to a concentration of 200μM before use. All other reagents were 
purchased from Sigma-Aldrich, if not stated otherwise. 
 
5.2.3 Cell culture media 
T-cells and monocyte-derived dendritic cells (DCs) were cultured in T-cell 
medium as specified in chapter 2.2.3. For the culture of naïve T-cells, the culture 
medium was prepared without penicillin and streptomycin. 
 
5.2.4 In vitro T-cell priming assay 
The individual steps of the in vitro T-cell priming assay, including magnetic cell 
separation, generation of monocyte-derived DCs and DC-T-cell co-cultures, 
were carried out by Dr. Lee Faulkner according to the protocol described in 
detail in chapter 3.2.6. For this study, SMX-NO (50μM) was used as the drug 
antigen. 
2x 106 freshly isolated naïve T-cells from each volunteer were frozen down in 
RNAlater (stored at -80°C) to be used for TCR Vβ CDR3 spectratyping analysis. 
After the in vitro T-cell priming culture, T-cells were restimulated with fresh 
monocyte-derived DCs (DC:T-cell ratio 1:25) and SMX-NO (50μM) in a 24-well 
plate for three days. Memory T-cells were then isolated by magnetic cell 
separation using CD45RO microbeads (Miltenyi Biotech, UK), and 2x 106 
CD45RO+ T-cells were immediately frozen down in RNAlater for CDR3 
spectratyping analysis. The remaining memory T-cells were used for TCR Vβ 
FACS analysis. 
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5.2.5 Detection of SMX-NO specific T-cell responses 
After the week-long DC-T-cell co-culture, SMX-NO specificity of primed T-cells 
was assessed by a proliferation assay. 
T-cells (1x 105) were incubated with monocyte-derived DCs (4x 103) and SMX-
NO (1.5- 25μM) in triplicate for three days in a 96-well U bottom plate. 
Phytohemagglutinin (PHA; 20μg/ml) was used as a positive control. [3H]-
thymidine (0.5μCI/well) was added for the final 16h of the culture period. Cells 
were harvested and proliferation was determined by scintillation counting 
using a MicroBeta TriLux β-counter (Perkin-Elmer, USA). 
 
5.2.6 T-cell receptor Vβ analysis by flow cytometry 
This part of the study was performed by Dr. Lee Faulkner. 
TCR Vβ protein expression was determined using the IOTest Beta Mark TCR Vβ 
repertoire kit (Immunotech, Beckman Coulter, UK). Aliquots of T-cells (50μl) 
were stained with 24 different fluorescence-conjugated TCR Vβ antibodies (as 
mixtures of 8 x 3 antibodies, 4μl each) for 20min in the dark at RT. At the same 
time, cells were stained with an APC-conjugated anti-CD3 monoclonal antibody 
(BD Bioscience, UK) to enable gating on T-cells during FACS analysis. T-cells 
were washed with PBS (500μl), spun down (1500rpm, 5min), and resuspended 
in HBSS containing 10% FBS (300μl). The samples were run on a BD FACS 
Canto II flow cytometer recording a minimum of 50,000 events, and data was 
analysed using Cyflogic software (CyFlo Ltd., Finland). 
 
5.2.7 RNA Extraction and Reverse Transcription 
Total RNA was extracted from naïve and SMX-NO primed memory T-cells 
(2x106) using the RNeasy mini kit (Qiagen, UK), following the manufacturer’s 
protocol. After the RNA was eluted from the spin column using RNase-free 
water (30μl), the eluate was passed over the column a second time in order to 
increase the RNA concentration. Total RNA was quantified using the NanoDrop 
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N-8000 spectrophotometer (Thermo Scientific, UK), and RNA integrity assessed 
using the Agilent Bioanalyser (Agilent, UK). 
Total RNA (0.4μg) was reverse transcribed to cDNA using the iScript cDNA 
synthesis kit (Bio-Rad, UK), as recommended by the manufacturer. 
 
5.2.8 T-cell receptor Vβ CDR3 spectratyping 
As described previously by Pannetier and colleagues, analysis of the CDR3 sizes 
within the 24 TCR Vβ chains was performed in a two-step polymerase chain 
reaction (PCR) (Pannetier et al. 1998). The primers are listed in Appendix T2. 
CDR3 spectratyping was performed in the laboratory of Prof. Stefan Martin, 
Department of Dermatology, University Medical Centre Freiburg, Germany. 
PCR amplification of cDNA 
For each sample, aliquots of cDNA (20ng) were amplified with 1 of 24 Vβ 
forward primers (10μM; metabion, Germany) and a Cβ reverse primer (10μM; 
metabion, Germany) on the thermal cycler Bio-Rad iCycler (Bio-Rad, Germany) 
using the HotStartTaq Master Mix kit (Qiagen, Germany). The final reaction mix 
contained 12.5μl master mix, 1.3μl Vβ forward primer, 1.3μl reverse primer, 1μl 
cDNA and 8.9μl RNase-free water. The thermal cycling conditions were as 
follows: heat activation of Taq polymerase at 95°C for 5min, followed by 40 
cycles of denaturation at 95°C for 45s, annealing at 60°C for 45s, extension at 
72°C for 1min, and a final extension step at 72°C for 10min. 
Run-off PCR 
PCR products from the first PCR were submitted to three cycles of an elongation 
run-off reaction with a FAM-labelled Cβ primer (10μM; metabion, Germany). 
The final reaction mix contained 0.1μl run-off primer, 0.1μl Pfu polymerase 
(Promega, Germany), 1μl dNTPs (30μM; Promega, Germany), 1μl 10x Pfu buffer 
(Promega, Germany), 1μl PCR product, and 6.8μl RNase-free water. The PCR 
was performed on the thermal cycler Bio-Rad iCycler (Bio-Rad, Germany) under 
the following conditions: 94°C for 2min, 5 cycles of 94°C for 25s, 60°C for 45s, 
and 72°C for 45s, followed by a final elongation step of 72°C for 10min. 
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CDR3 spectratyping by GeneScan 
Run-off PCR product (2μl) was added to a mix of Hi-Di formamide (10μl; 
Applied Biosystems, Germany) and 500 LIZ size standard (1μl; Applied 
Biosystems, Germany) in a Thermo-Fast 96 PCR Detection plate (Applied 
Biosystems, Germany). The plate was sealed with a 96-well Plate Septa (Applied 
Biosystems, Germany) and the samples denaturated at 94°C for 2min. CDR3 size 
was determined on the ABI PRISM 3300 Genetic Analyzer, and data analysed 
using GeneMapper 4.0 software (Applied Biosystems, USA). 
 
5.2.9 Statistical analysis 
Proliferative responses of SMX-NO primed T-cell lines were analysed by 
Student’s test using Bonferroni correction for multiple testing. A P-value of < 
0.02 was considered significant. 
 
 
5.3 Results 
 
5.3.1 SMX-NO specific T-cell responses 
Purified naïve T-cells from six healthy donors were cultured with 50 μM SMX-
NO in the presence of autologous monocyte-derived DCs for eight days. 
Following the priming period, T-cells were restimulated with monocyte-derived 
DCs and SMX-NO for 3 days, and proliferative responses to SMX-NO were 
assessed by [3H]-thymidine uptake. 
In five out of six healthy volunteers, SMX-NO was able to induce significant 
proliferation of T-cells (Figure 5.1). Maximal responses were observed at a 
concentration of 25μM SMX-NO, apart from donor S5 (max. at 12μM; Figure 
5.1). These results demonstrated that SMX-NO reactive T-cells had been 
generated during the priming cultures. However, the maximum proliferative 
response of T-cells from donor S1 only showed a stimulation index of 1.5 (at 
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25μM SMX-NO), which was not statistically significant (Figure 5.1). This 
suggested that priming to SMX-NO had not been successful in this volunteer. 
 
 
Figure 5.1: Proliferative response of T-cells from healthy donors to SMX-NO after in 
vitro T-cell priming assay. 
Naïve T-cells were cultured in the presence of autologous monocyte-derived DCs and SMX-NO 
for 8 days. T-cells (1x 105) were then restimulated with SMX-NO (12+ 25 μM) and autologous 
monocyte-derived DCs (4x 103) for 72 hours, and [3H]-thymidine was added for the final 16 
hours. Proliferation was determined by scintillation counting. Data represent mean cpm ± SEM 
of triplicate cultures. (*p< 0.02, **p< 0.003; Student’s t test).   
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5.3.2 TCR Vβ usage of SMX-NO responsive T-cells 
Using flow cytometry, we next analysed the TCR Vβ repertoire expressed by 
SMX-NO primed memory T-cells, and then compared the TCR Vβ usage of SMX-
NO responsive T-cells from each donor to the corresponding naïve T-cell 
population. 
An expansion of the TCR Vβ repertoire covered by the monoclonal antibodies 
was observed in T-cells from five donors following in vitro priming to SMX-NO, 
indicating clonal expansion of drug-specific T-cells had occurred (Table 5.1). 
Only a minor increase in TCR Vβ coverage was detected for T-cells from donor 
S1, supporting the assumption that in vitro priming had been unsuccessful. The 
sample was consequently excluded from further analysis. In naïve T-cells all 24 
TCR Vβs could be detected, with mean expression levels ranging from 0.18% for 
Vβ 9 up to 6.98% for Vβ 2 (see Appendix T3). After in vitro priming, an increase 
in expression levels of up to 16/24 TCR Vβs was seen in SMX-NO specific T-cells 
from the five positive donors (Figure 5.2). Skewing of individual TCR Vβ 
subtypes was examined as described by Hashizume et al. (2002) defining 
skewed TCR Vβ usage as the percentage of a particular TCR Vβ which is above 
the mean percentage + 3 SD of the same TCR Vβ in normal cells (in this study: 
naïve T-cells) (Hashizume et al. 2002). Skewed usage of TCR Vβ 4 and 9 was 
detected in SMX-NO reactive T-cells from all five individuals (Figure 5.2 & Table 
5.2). Usage of TCR Vβ 11, 13.6, 14 and 18 was found to be skewed in four 
donors respectively. Further, preferential expression of TCR Vβ 5.2 and 5.3 was 
observed in three of the five donors (Figure 5.2 & Table 5.2). In contrast, 
expression of TCR Vβ 1, 2 and 5.1 was substantially decreased (< mean %- 3SD 
of TCR Vβ in naïve cells) in three of the five donors (Appendix T3). 
 
Table 5.1: Coverage of the TCR Vβ repertoire of T-cells before (naïve) and 
after priming to SMX-NO (memory) using flow cytometry. 
TCR Vβ coverage (%) S1 S2 S3 S4 S5 S6 
Naïve 61 56 52 57 53 50 
Memory 65 83 78 71 76 65 
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Figure 5.2: Clonogram of naïve and SMX-NO primed memory T-cells from five healthy 
donors. 
TCR Vβ repertoire in naïve (white bars) and SMX-NO primed memory (black bars) CD3+ T-cells 
was measured by flow cytometry using fluorescence conjugated monoclonal antibodies against 
24 TCR Vβ. Data represent mean percentages of T-cells expressing the individual TCR Vβ 
subtypes. (◊ = skewed TCR Vβ usage, defined as percentage above mean value +3SD of TCR Vβ 
in naïve T-cells) 
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Figure 5.2 (continued): Clonogram of naïve and SMX-NO primed memory T-cells from 
five healthy donors. 
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Table 5.2: Summary of common skewed TCR Vβ usage (= mean % of TCR 
Vβ in naïve T-cells +3SD) of SMX-NO responsive T-cells from five healthy 
donors as detected by FACS analysis. 
TCR Vβ 4 5.2 5.3 9 11 13.6 14 18 
S2 ●   ● ●  ●  
S3 ● ● ● ● ● ● ● ● 
S4 ● ● ● ● ● ● ● ● 
S5 ● ● ● ● ● ● ● ● 
S6 ●   ●  ●  ● 
 
 
5.3.3 CDR3 spectratyping analysis of TCR Vβ diversity 
The TCR Vβ repertoire of naïve T-cells and memory T-cells reactive to SMX-NO 
was analysed in more detail by CDR3 spectratyping. 
Total RNA from naïve and memory T-cells was reverse transcribed to cDNA, 
and TCR Vβ chain transcripts amplified with 24 Vβ gene-specific primers and a 
Cβ primer. PCR products were subsequently amplified in a run-off reaction 
using a fluorescently labelled Cβ primer, and products analysed on an 
automated sequencer regarding the CDR3 size pattern of each TCR Vβ subtype. 
In the absence of antigenic stimulation CDR3 size profiles of individual TCR Vβs 
show a Gaussian-like distribution. A distortion of the CDR3 profiles 
characterised by the emergence of single or multiple dominant peaks within the 
TCR Vβ spectratyping profiles signifies antigen specific T-cell stimulation 
leading to clonal expansion. 
Nineteen of the 24 TCR Vβ subtypes could be detected in naïve T-cells from all 
five healthy volunteers. As expected, the majority of the TCR Vβ spectratyping 
profiles of naïve T-cells (52% and above) displayed a polyclonal distribution of 
CDR3 lengths (defined as quasi-Gaussian profile with ≥ 5 peaks) in all donors 
(see Appendix T3). Transcripts of TCR Vβ 2, 4, 11, 20 and 21 were present in 
some of the donors, but absent in others. For volunteers S3 and S5, no 
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spectratyping profile could be established for TCR Vβ 6 and TCR Vβ 8, 11, 17, 
and 23 respectively, as the genetic analyser failed to detect the size standard 
(no sizing data available). 
In SMX-NO primed memory T-cells, 19/24 TCR Vβ chains were present in all 
five donors responsive to SMX-NO (Appendix T4). TCR Vβ 2, 3, 4, 20 and 21 
could only be detected in some of the donors (Table 5.3). Due to missing sizing 
data, spectratyping failed for TCR Vβ 5, 6 and 24, and TCR Vβ 3, 17 and 23 in 
donors S2 and S4 respectively (Table 5.3). After SMX-NO priming, up to 80% of 
TCR Vβ subtypes showed an oligoclonal distribution of CDR3 lengths (skewed 
Gaussian profile with at least one dominant peak). Skewing of CDR3 profiles 
from poly- to oligoclonal distribution could be observed for between six and 
fifteen TCR Vβs (Table 5.3), indicating the expansion of a clonal T-cell 
population reactive to SMX-NO. Representative CDR3 spectratyping profiles of 
skewed TCR Vβs are shown in Figure 5.3. 
The TCR Vβs presenting skewed CDR3 profiles were compared among the five 
SMX-NO responsive donors to determine whether SMX-NO stimulation induced 
common skewing of specific TCR Vβ subtypes. SMX-NO specific memory T-cells 
from all five volunteers showed oligoclonal expression of TCR Vβ 18 (Table 5.3). 
Skewed usage of TCR Vβ 13B was observed in four donors, and TCR Vβ 1, 5, 9, 
13A, and 14 displayed a skewed CDR3 pattern in three individuals respectively 
(Table 5.3). These results suggest that T-cell responses to SMX-NO derived 
antigens may be in part controlled by public TCRs, which are present in all 
individuals responsive to SMX-NO treatment, alongside private TCR repertoires 
specific to each individual. 
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Table 5.3: TCR Vβ subtypes with oligoclonal distribution of CDR3 sizes following SMX-NO priming. 
 
● = oligoclonal expansion; x = not detected; s = no sizing data 
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Figure 5.3: Representative TCR Vβ spectratyping profiles of T-cells from healthy 
donors S2 (A) and S4 (B) showing skewed CDR3 lengths distribution after in vitro 
priming of naïve T-cells to SMX-NO. 
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5.3.4 Comparison of flow cytometric TCR Vβ analysis and CDR3 
spectratyping 
When skewed TCR Vβ subtypes of SMX-NO responsive memory T-cells 
identified by flow cytometry were compared to those observed in CDR3 
spectratyping, the results overlapped in large parts (Table 5.4). However, 
skewing of some TCR Vβs was only detected in the CDR3 spectratyping analysis 
(e.g. Vβ 1 in S2 and S5; Table 5.4). To some extent this was anticipated, as CDR3 
spectratyping is a more sensitive detection method with which even subtle 
changes in frequencies of clonal T-cell populations can be distinguished. On the 
other hand, preferential usage of some TCR Vβ subtypes was only observed in 
the FACS analysis (e.g. Vβ 4 and 11; Table 5.4). One reason for this could be that 
the specific TCR Vβ transcript could not be amplified due to inadequate binding 
specificity of the corresponding Vβ primer, which might have been the case for 
TCR Vβ 4. Alternatively, non-specific binding of monoclonal antibodies from the 
TCR repertoire kit might have caused false positive results, which could explain 
the events seen for TCR Vβ 11. Previous studies using both flow cytometry and 
CDR3 spectratyping to determine TCR Vβ usage have generally reported good 
correlation between the results obtained by flow cytometry and CDR3 
spectratyping (Pantaleo et al. 1994; Ortonne et al. 2006; Okajima et al. 2009). 
However, a comparison between the respective studies is difficult, as different 
antibodies and primers were used in each study, and strategies for data 
analysis, including criteria for determining clonal expansion, varied greatly. 
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Table 5.4: Skewed TCR Vβ usage of SMX-NO responsive T-cells as detected by flow cytometry (a) and CDR3 spectratyping (b). 
TCR Vβ 1 4 5 
(=5.1-3) 
9 11 13A 
(=13.6) 
13B 14 18 23 
 a b a b a b a b a b a b aⱡ b a b a b a b 
S2 
 
● ● x 
  
● ● ● 
   
ⱡ 
 
● 
  
● 
  
S3 
  
● x ● s ● 
 
● 
 
● 
 
ⱡ ● ● ● ● ● ● 
 
S4 
  
● x ● ● ● ● ● 
 
● ● ⱡ ● ● ● ● ● 
  
S5 
 
● ● s ● ● ● 
 
● s ● ● ⱡ ● ● 
 
● ● ● s 
S6 ● ● ● x 
 
● ● ● 
  
● ● ⱡ ● 
 
● ● ● 
 
● 
a= flow cytometric analysis; b= CDR3 spectratyping analysis; ●= skewing; x= not detected; s= no sizing data; ǂ= no antibody available. Nomenclature of TCR Vβ 
monoclonal antibodies largely corresponds to the nomenclature of the TCR Vβ primer, with a few exceptions as indicated in brackets (for more details see 
Appendix T5). 
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5.4 Discussion 
 
There is a large body of evidence demonstrating that drug-specific T-cells are 
the essential effector cells in delayed-type drug hypersensitivity reactions. It 
has been shown that the recognition of drug antigens by T-cells requires the 
interaction of the drug with HLA and TCR. Most studies investigating the 
molecular mechanisms involved in drug-induced HSRs have focused on the 
interaction of drug antigens with HLA expressed on the surface of APCs, 
whereas the role of the T-cell receptor in mediating drug hypersensitivity has 
been left largely unexplored. However, the recent study by Ko et al. (2011) has 
illustrated that specific T-cell receptors, similar to HLA alleles, may function as 
susceptibility factors for certain forms of drug-induced HSRs. Thus, the aim of 
this study was to establish a robust protocol which would allow a 
comprehensive characterisation of the TCR repertoire of T-cells from drug 
hypersensitive patients and healthy controls. 
Although various methods exist to determine the TCR repertoire diversity in 
individuals, we decided to concentrate on flow cytometric analysis and 
molecular CDR3 spectratyping, as both techniques have been widely used 
across different disease settings (Ortonne et al. 2006; Okajima et al. 2009; Hsieh 
et al. 2013; Tzifi et al. 2013). Naïve T-cells from healthy volunteers primed 
against SMX-NO were utilised to set up the different methods for TCR Vβ typing 
for several reasons. First, large amounts of T-lymphocytes were needed to 
optimize each of the assays, which excluded the use of patient samples. Also, the 
naïve T-cell population could be used as a baseline for TCR diversity in an 
individual. Third, in vitro priming of T-cells against SMX-NO has repeatedly 
been shown to be successful, producing stable drug-specific T-cell responses 
(Engler et al. 2004; Faulkner et al. 2012). 
In contrast to a previous study by Faulkner et al. (2012), priming of naïve T-
cells against SMX-NO was only successful in five of the six healthy volunteers. As 
the in vitro priming assay used in both studies is rather novel, and only a small 
number of samples have been processed, it seems more than likely that priming 
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will not be effective in 100% of samples. Although using a different in vitro 
priming protocol, a study by Engler et al. (2004) demonstrated that SMX-NO 
specific responses could be induced in nine out of ten drug-naïve donors. 
However, proliferative responses to SMX-NO were only detected in six donors, 
whereas nine individuals showed drug-specific cytotoxicity in a standard 
chromium release assay (Engler et al. 2004). Thus, it may be useful to include a 
more sensitive method, e.g. ELISpot assay, to test for drug specificity of in vitro 
primed T-cells. 
The flow cytometric analysis of TCR Vβ expression on drug-naïve T-cells 
showed that all 24 TCR Vβs were present in the five proliferation positive 
donors, with mean expression levels ranging from 0.18% for Vβ 4 to 6.98% for 
Vβ 2, and an average TCR Vβ coverage of 53.47%. Following SMX-NO in vitro 
priming, TCR Vβ coverage increased to a mean value of 74.58%, suggesting 
drug-specific clonal expansion had occurred. This is in line with previous 
studies which generally describe coverage of ≥ 70% of the total TCR repertoire 
(van den Beemd et al. 2000; McLean-Tooke et al. 2008; Tzifi et al. 2013), and it 
also matches the reference value of the TCR Vβ antibody kit reported to cover 
about 70% of the normal TCR Vβ repertoire. However, only a minor increase in 
TCR coverage (from 60% to 65%) was detected for T-cells from donor S1, 
confirming that in vitro priming against SMX-NO had been ineffective in this 
case. SMX-NO primed memory T-cells from the five drug-responsive volunteers 
displayed broad TCR Vβ usage, with increased expression levels in up to 16 TCR 
Vβs. TCR skewing was observed for 9 different Vβ subtypes across the five 
donors. Together these results suggest that multiple TCRs may be involved in 
drug antigen recognition. Similar observations have been made in T-cells 
responsive to abacavir, in which case the extensive TCR usage is thought to be 
responsible for the recognition of diverse novel self peptides presented on HLA-
B*57:01 in the presence of abacavir (Illing et al. 2012). Given that a range of 
SMX-NO protein adducts known to stimulate T-cells from hypersensitive 
patients have been reported in the literature (Schnyder et al. 2000; Farrell et al. 
2003; Callan et al. 2009; Castrejon et al. 2010), this result was somewhat 
anticipated. Further, common skewing of particular TCR Vβ subtypes (Vβ 4 and 
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Vβ 9) in all five drug-responsive individuals indicates that a public TCR 
repertoire may be involved in recognition of SMX-NO derived antigens. 
In order to gain a more complete picture of the clonal expansion occurring as a 
result of in vitro priming of T-cells against SMX-NO, CDR3 spectratyping 
analysis was performed. Eleven TCR Vβ subtypes were present in naïve as well 
as SMX-NO specific T-cells from all five volunteers, whereas six TCR Vβs (2, 3, 4, 
11, 20, and 21) were only detected in some of the donors. Spectratyping of 8 
TCR Vβs (3, 5, 6, 8, 11, 17, 23, and 24) failed in some cases due to missing sizing 
data. In most cases this technical issue can be solved by repeating the 
amplification and GeneScan run for the specific TCR Vβ in question. However, 
due to shortage of reagents and time constraints, we were unable to re-run the 
samples in this study. In naive T-cells most TCRs displayed polyclonal CDR3 
patterns, whereas CDR3 profiles of SMX-NO specific T-cells showed oligoclonal 
expansions across several TCR Vβ subtypes. For the individual volunteers, 
skewing of TCR Vβ profiles from polyclonal to oligoclonal distribution of CDR3 
sizes was detected in up to 16 different Vβ subtypes. Again, this may be 
explained by the various antigenic structures formed by SMX-NO, which are 
then recognised by different TCR Vβ subtypes. Further, common skewing of 
particular TCR Vβs was observed among the five donors, including TCR Vβ 18 in 
5/5 donors, TCR Vβ 13B in 4/5 donors, and TCR Vβ 1, 5, 9, 13A, and 14 in 3/5 
volunteers respectively. These findings strengthen the concept that a public 
TCR repertoire may be implicated in SMX-NO specific T-cell responses. 
Skewed TCR Vβ usage of SMX-NO responsive memory T-cells identified by 
CDR3 spectratyping only partially match the results obtained by flow 
cytometry. This was somewhat anticipated, as the definition and assessment of 
TCR Vβ skewing differs greatly between the two methods. The assessment of 
clonality of T-cells and definition of cut-off values is critical to obtain accurate 
results. For this reason, the use of a mathematical scoring system, e.g. as 
described by Okajima et al. (2008), might improve the evaluation of the TCR Vβ 
repertoire usage of different T-cell populations. 
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Another factor that might have affected our analysis is the fact that TCR Vβ 
usage of naïve T-cells, representing the control population, was analysed 
directly without undergoing an in vitro culture period. In contrast, analysis of 
SMX-NO specific memory T-cells was performed after 11 days of in vitro culture. 
Thus, any skewing of TCR Vβ usage due to in vitro culture conditions was not 
taken into account, and this could explain some of the discrepancies observed 
between the results from TCR Vβ spectratyping and flow cytometric analysis. 
Overall, we have been successful in testing the TCR Vβ usage of drug-specific T-
cells using both the CDR3 spectratyping method as well as TCR Vβ flow 
cytometric analysis. Further optimisation of the experimental set-up and data 
analysis strategy is however needed in order to achieve consistent and robust 
results, characterising the full scope of TCR Vβ expression patterns of drug-
reactive T-cells. 
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Drug-induced hypersensitivity reactions (HSRs) represent a diverse group of 
adverse reactions which occur only in a minority of patients and cannot be 
predicted from the pharmacological mechanism of the drug. Extensive research 
in the field has shown that specific components of the immune system are 
involved in most, if not all, of these reactions. However, the detailed 
pathomechanisms leading to drug hypersensitivity have not yet been fully 
uncovered. 
Drug-specific T-cells have been identified as the key components in delayed-
type HSRs, and T-cells isolated from hypersensitive patients have been 
characterised extensively in vitro regarding their cellular phenotype and 
effector functions (Mauri-Hellweg et al. 1995; Zanni et al. 1999; Schnyder et al. 
2000; Naisbitt et al. 2003a; Naisbitt et al. 2003b; Nassif et al. 2004). This has 
helped considerably to define the different phenotypes of delayed-type HSRs 
and also explain the variety of clinical manifestations. 
The discovery that certain forms of drug hypersensitivity are strongly 
associated with specific HLA alleles has provided a new indication to the 
molecular mechanisms underlying these reactions. Furthermore, this has 
opened up the possibility of predicting patients at risk of developing drug 
hypersensitivity. A prime example is HLA-B*57:01 associated abacavir (ABC) 
hypersensitivity (see chapter 1.6.5). 
Similar achievements have been made in regards to carbamazepine-induced 
Stevens-Johnson syndrome (SJS) associated with HLA-B*15:02. Carbamazepine 
(CBZ) was found to specifically interact with HLA-B*15:02 resulting in CD8+ T-
cell stimulation (Wei, C. Y. et al. 2012a). However, as HLA-B*15:02 is expressed 
almost exclusively in South-east Asian populations, pharmacogenetic testing 
has been restricted to patients of Asian ancestry (Ferrell and McLeod 2008). 
In Caucasian patients, genetic studies have recently revealed a strong 
association between CBZ-induced HSRs and HLA-A*31:01, suggesting HLA-
A*31:01 may be a molecular target for CBZ, and the allele may therefore 
represent a possible genetic marker for CBZ hypersensitivity in Europeans 
(McCormack et al. 2011). 
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Thus, following the examples of CBZ and HLA-B*15:02 as well as ABC and HLA-
B*57:01, the relationship between HLA-A*31:01 expression and CBZ-induced T-
cell activation was explored in vitro using isolated PBMCs from a HLA-A*31:01+ 
CBZ hypersensitive patient (chapter 2). 
CD8+ T-cell clones from the patient were shown to be HLA-A31 restricted, and 
strong proliferative responses to CBZ were observed in the presence of 
allogeneic HLA-A*31:01+ APCs. The data present the first tentative proof that 
HLA-A*31:01 is functionally involved in mediating CBZ-specific T-cell responses. 
However, some CD8+ clones could be activated if APCs expressing other HLA-A 
were present, suggesting that recognition of CBZ may not be defined solely by 
HLA-A*31:01. A comprehensive study using APCs expressing HLA-A allotypes 
closely related to HLA-A*31:01 should facilitate the characterisation of the 
binding capacity of CBZ to HLA-A and determine the amino acid residues 
involved in CBZ presentation, as has been accomplished for CBZ in association 
with HLA-B*15:02 and for ABC (Chessman et al. 2008; Wei, C. Y. et al. 2012a). 
Ideally, this would involve the use of HLA transfected cell lines expressing a 
single HLA allele rather than EBV-transfected B-cells from healthy donors 
expressing the full range of HLA class I and class II alleles in order to avoid any 
HLA cross-reactivity. 
In chapter 2, I also investigated the HLA restriction profile of CD4+ T-cells 
isolated from the CBZ hypersensitive patient. In contrast to the predominant 
CD8+ T-cell response in CBZ-induced SJS patients, drug-specific CD4+ T-cells are 
commonly found in patients with CBZ-induced hypersensitivity syndrome or 
maculopapular rash. It was therefore of interest to see whether CD4+ T-cells 
from the patient also displayed specific HLA restriction. Activation of CD4+ 
clones was restricted by HLA-DP and DR simultaneously. In other autoimmune 
diseases, such as narcolepsy and type I diabetes, it has previously been reported 
that HLA class II alleles may co-operatively confer immune recognition (Temajo 
and Howard 2009; Han et al. 2012). Although it would have been interesting to 
explore further how each of the two HLA class II loci affects the stimulation of 
CD4+ T-cells by CBZ, the lack of information on HLA-DP prevented further 
analysis. Instead, I focused on HLA-DR, and in particular HLA-DRB1*04:04. This 
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allele has been shown to be part of a common haplotype with HLA-A*31:01 in 
Caucasians, and the patient expressed both HLA alleles. In accordance with this, 
it was demonstrated that CD4+ clones from the patient responded to CBZ in a 
HLA-DRB1*04:04 restricted manner. This suggests that CBZ is able to interact 
with several HLA molecules, which may lead to the phenotypically diverse T-
cell responses seen in Caucasian patients. Nevertheless, whether the HLA 
restriction profile observed in the patient is universally applicable needs to be 
confirmed in a larger cohort of patients. 
 
Due to the low incidence of drug-induced HSRs, the recruitment of drug 
hypersensitive patients to clinical studies has always been a large obstacle. 
Furthermore, in vitro studies investigating the immunological mechanisms have 
so far relied on the use of patient derived drug-specific memory T-cells, which 
does not allow the prediction of the allergic potential of a drug. As a result, 
several research groups have recently attempted to generate primary T-cell 
responses to drugs using cells from drug-naïve healthy volunteers (Engler et al. 
2004; Chessman et al. 2008; Ko et al. 2011; Faulkner et al. 2012; Monshi et al. 
2013; Wuillemin et al. 2013). 
Using the in vitro priming methods reported in the literature, I tried to generate 
a primary immune response to CBZ in drug-naïve T-cells isolated from HLA-
A*31:01+ healthy volunteers (chapter 3). A weak CBZ specific T-cell response 
could be induced in five out of eight HLA-A*31:01+ donors. However, activation 
of T-cells was not observed consistently across all read-out methods applied, 
but instead was limited to individual assays. Ideally, the drug specificity of the 
individual T-cell cultures would have been evaluated using the complete panel 
of read-outs available, however, the amount of T-cells that could be recovered 
after in vitro priming were in most cases insufficient to test all end-points. For 
this reason, it was difficult to determine in which of the samples a genuine T-
cell response to CBZ had been elicited and which, if any, might have represented 
an artefact. At the same time, the persistently elevated background levels of 
IFN-γ in T-cells from HLA-A*31:01+ volunteers suggested that these T-cells may 
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be more prone to bystander T-cell activation compared to those from HLA-
B*15:02+ donors, which in turn may obscure a response caused by CBZ. Further 
investigations are needed in order to understand the differences in bystander 
stimulation of T-cells from HLA-B*15:02+ compared to HLA-A*31:01+ donors. 
However, the data in chapter 3 clearly indicate that the expression of HLA-
A*31:01 on its own is not sufficient to stimulate a primary T-cell response to 
CBZ. The analysis of the extended HLA haplotype did not reveal any common 
pattern between the samples tested, making it unlikely that HLA-DRB1*04:04 
might play a role, as reported earlier for the HLA-A*31:01+ hypersensitive 
patient. 
 
Multiple factors, both environmental and genetic, are thought to contribute to 
the risk of an individual to develop a hypersensitivity reaction. Most recently, 
after specific T-cell clonotypes had been identified to play a role in mediating T-
cell responses to CBZ in HLA-B*15:02+ patients (Ko et al. 2011), the T-cell 
receptor has been brought forward as a possible susceptibility factor in drug-
induced hypersensitivity. 
In order to examine whether a specific TCR may be involved in CBZ-induced 
HSRs in HLA-A*31:01+ patients, a protocol for the comprehensive analysis of the 
TCR Vβ repertoire was established (chapter 5). 
Methods for the examination of TCR Vβ expression by flow cytometry as well as 
molecular CDR3 spectratyping were set up individually. The protocols were 
tested using naïve T-cells from healthy donors that were primed against the 
model drug antigen SMX-NO, as patient samples were considered too valuable. 
The TCR Vβ usage of the different T-cell subsets, i.e. naïve and SMX-NO specific 
memory T-cells, could be determined successfully on both protein and mRNA 
level. However, the data analysis process requires further optimisation in order 
to improve the coherence between the two read-outs, and thus allow a detailed 
characterisation of the TCR repertoire expressed by drug-specific T-cells. 
In an earlier attempt to characterise the TCR Vβ usage of a few selected T-cell 
clones from the HLA-A*31:01+ hypersensitive patient, flow cytometric analysis 
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had produced inconsistent results (data not shown). Expression of a single TCR 
Vβ could only be detected on two clones, whereas for the majority of CBZ-
specific clones no definite TCR Vβ usage could be determined. It may be that the 
TCR expressed by these particular clones was not covered by the antibody kit. 
In some cases, however, it seemed that non-specific binding of the monoclonal 
antibodies had occurred which masked the true TCR expression levels of the 
clones. For this reason, it was considered necessary to set up the more sensitive 
CDR3 spectratyping method, which encompasses a slightly broader range of 
TCR Vβs, and has already been used successfully in the study by Ko et al. (2011). 
Using the optimised spectratyping protocol, it should be possible to screen 
drug-specific T-cells from HLA-A*31:01+ CBZ hypersensitive patients for TCR Vβ 
expression, and determine whether particular TCR Vβs predominantly occur in 
patients compared to tolerant controls. If this were the case, this may explain 
why some carriers of the HLA risk allele remain tolerant to CBZ. Likewise, this 
could also explain why in some cases in vitro priming of drug-naïve T-cells from 
HLA-A*31:01+ volunteers had failed. 
Besides, if the corresponding TCR Vα chain could be identified, this would 
provide an opportunity to generate TCR transfected cell lines that could be used 
as an alternative to T-cell clones derived from patients, thereby avoiding the 
laborious process of T-cell cloning and the problems associated with it (e.g. loss 
of drug specificity). In previous studies it has been demonstrated that TCR 
transfected hybridoma cells show the same specificity and drug recognition 
pattern as the T-cell clones they were derived from originally, and therefore 
provide a valuable tool for the investigation of drug-TCR interactions (Schmid et 
al. 2006). 
In addition, CDR3 spectratyping would allow to assess whether T-cell response 
to CBZ in HLA-A*31:01+ patients are poly-, oligo- or monoclonal in nature, and 
hence give an indication of the scope of CBZ-derived antigens that may be 
involved in T-cell activation. 
Until now, the drug antigen(s) causing CBZ hypersensitivity remains elusive. 
Most evidence gained from in vitro studies so far points towards CBZ, the parent 
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drug, inducing the activation of T-cells. First, fixation of APCs with aldehyde, 
which inhibits the processing of proteins, did not suppress T-cell stimulation by 
CBZ, suggesting that the formation of a haptenated protein is not required (Wu 
et al. 2006; Wu et al. 2007; Wei, C. Y. et al. 2012a). Also, mass spectrometry 
analysis was unable to detect any CBZ-modified peptides bound by HLA-
B*15:02 (Yang et al. 2007; Illing et al. 2012). Second, addition of glutathione and 
other neutralising agents, which capture reactive metabolites, did not inhibit T-
cell responses to CBZ, signifying a metabolism-independent process (Wu et al. 
2006). Third, CBZ-pulsed APCs did not induce the activation of T-cells, 
suggesting a non-covalent binding mechanism (Wu et al. 2006; Wei, C. Y. et al. 
2012a). 
According to current hypotheses, presentation of CBZ as drug antigen could 
take place in either one of two ways: CBZ may bind non-covalently to a peptide-
HLA complex or directly to the TCR (p-i mechanism), or CBZ may be loaded into 
an empty HLA binding groove leading to a change of the peptide repertoire 
presented by the HLA allele (altered peptide model). The strong associations 
with HLA-B*15:02 and A*31:01 suggest that CBZ binding occurs at the HLA 
rather than the TCR interface. 
The data presented in chapter 3 and chapter 4 adds to the existing evidence that 
CBZ binds directly to the HLA molecule and subsequently induces T-cell 
activation. 
In a novel approach to assess the effect of metabolic activation of CBZ on T-cell 
stimulation, it was shown that halogenated derivatives of CBZ, which are stable 
against metabolic transformation, stimulated a proliferative response in T-cell 
clones from a HLA-B*15:02+ volunteer (chapter 3). Similarly, CBZ-specific 
clones isolated from a HLA-A*31:01+ patient could also be activated by the 
halogenated derivatives (Farrell et al. 2013). These findings further strengthen 
the concept that the metabolic activation of CBZ is not needed in order to form 
an antigenic structure that is presented to T-cells. 
Mass spectrometry analysis of peptides eluted from a HLA-A*31:01 expressing 
cell line treated with CBZ in vitro did not exhibit any CBZ-modified peptides 
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(chapter 4). Instead, unbound CBZ could be detected in the peptide fractions. 
These results support a non-covalent binding mechanism of CBZ to HLA-
A*31:01. However, whether the interaction between CBZ and HLA molecule 
occurred within in the HLA binding groove and affected the peptide binding 
specificity of the HLA allele could not be determined conclusively, as too low 
numbers of HLA-A*31:01 specific peptides were identified to perform a detailed 
comparison of peptide binding in absence and presence of drug. 
In chapter 4, I performed in silico analysis of the binding specificity of HLA-
A*31:01 in comparison to B*15:02; this suggested that CBZ may bind in close 
proximity to the B-pocket of the HLA-A*31:01 molecule, but in a slightly shifted 
location compared to HLA-B*15:02. Earlier computational modelling studies 
have indicated that CBZ is most likely to bind to HLA-B*15:02 within the B-
pocket of the peptide binding cleft, underneath the peptide residues P4/P6 
(Illing et al. 2012; Wei, C. Y. et al. 2012a). In vitro studies involving the refolding 
of the individual HLA molecules in complex with a self-peptide and CBZ, and 
subsequent crystallisation of the drug-peptide-HLA complexes may provide 
proof of the in silico observations described in the literature and in this thesis. 
Taken together, the preliminary results from the in silico modelling and peptide 
elution study indicate that the altered peptide model may apply to interactions 
occurring between CBZ and HLA risk alleles and consequently cause T-cell 
activation. However, these findings need to be confirmed in further studies 
before a firm conclusion is drawn. 
Another question that remains to be answered in this context is: where do the 
T-cells responding to drug antigens or altered peptides originate from? 
In relation to this, it has been hypothesised that a subpopulation of memory T-
cells, which have been primed to a different antigen earlier, may be able to 
cross-react with the drug and/or altered peptide (Adam et al. 2011). Given that 
memory T-cells have a lower activation threshold than naïve T-cells, this could 
explain why the HLA-TCR interaction may be sufficient to cause T-cell 
activation. It has further been proposed that these pre-activated memory T-cells 
may be derived through heterologous immune responses induced by viral 
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infections, which have been associated with an increased risk of developing 
hypersensitivity (Adam et al. 2011; Ostrov et al. 2012). 
In case of CBZ, however, it seems that pre-activated memory T-cells are not a 
prerequisite to stimulate a primary T-cell response, as highly purified naïve T-
cells from HLA-B*15:02+ healthy volunteers could be successfully primed 
against CBZ (chapter 3). Thus, primary T-cell responses against CBZ and other 
drugs may be induced through different processes of drug antigen presentation, 
which may also occur concurrently (Pichler 2013). 
As a matter of fact, we have recently shown that a reactive metabolite of CBZ is 
able to form stable adducts with human serum albumin (HSA) in vitro, and the 
equivalent metabolite-conjugated HSA peptides could be identified in patients 
on regular CBZ treatment (data unpublished). However, at this stage, it is 
unclear whether these haptenated peptides may have antigenic potential and 
may induce T-cell responses in CBZ susceptible individuals. Following the in 
vitro studies performed with the contact sensitizer 2,4-dinitrobenzene sulfonic 
acid (Dietz et al. 2010), it may be possible to prepare synthetic HSA peptides 
haptenated with the CBZ metabolite and test these initially in T-cells from 
hypersensitive patients to assess their T-cell activation potential. Subsequently, 
priming of naïve T-cells from HLA-B*15:02+ donors against the synthetic CBZ-
modified HSA peptides could be attempted to evaluate the role of CBZ-modified 
peptides in generating primary T-cell responses. 
 
Overall, it is difficult to link T-cell responses observed in vitro to the conditions 
occurring in vivo. The majority of mechanistic studies has relied on the use of T-
cells derived from hypersensitive patients, and can therefore only describe the 
processes involved in the secondary stimulation of T-cells in vitro. The steps 
leading to the initial sensitisation of T-cells against a drug in vivo however 
remain unclear. Although it has been possible to induce a primary T-cell 
response in vitro against a few drugs (including SMX-NO, ABC and CBZ), the 
formation of the respective antigenic complex and its structure has not yet been 
elucidated. It can therefore not be excluded that the stimulation of a primary 
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immune response against a drug, both in vivo and in vitro, requires the 
formation of drug-modified protein adducts, which may have the ability to 
activate the innate as well as the adaptive immune system. 
 
In conclusion, a number of questions remain to be answered in order to fully 
understand the individual molecular processes involved in drug-induced HSRs. 
These relate especially to the mechanism of initial sensitisation to a drug, the 
formation of the drug antigen complex, as well as the function of the TCR in 
drug antigen recognition. Future research efforts aiming to resolve these 
ambiguities may permit to predict the risk of a drug to cause hypersensitivity, 
and ultimately assist in the development of safer drugs in future. 
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Figures 
F1 Self-presenting CD4+ (A) and CD8+ (B) T-cell clones reactive to CBZ. 
F2 Ramachandran plots of 3D-model structures of HLA-A*31:01 (A) and 
HLA-B*15:02 (B) generated by RAMPAGE. 
 
Tables 
T1 Summary of monoclonal antibodies used in FACS analysis. 
T2 Primers used in CDR3 spectratyping analysis 
T3 Flow cytometric analysis of TCR Vβ usage on naïve and SMX-NO specific 
memory T-cells. 
T4 CDR3 size distribution of TCR Vβ subtypes on naïve and SMX-NO specific 
memory T-cells. 
T5 Correspondence between the nomenclatures of TCR Vβ monoclonal 
antibodies and TCR Vβ primers. 
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Figure F1: Self-presenting CD4+ (A) and CD8+ (B) T-cell clones reactive to CBZ. 
T-cell clones were cultured with CBZ (25μg/ml) in the absence and presence of autologous B-
LCL. Proliferation was determined by [3H]-thymidine uptake. Data represent mean cpm ± SEM 
of n clones. 
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A) HLA-A*31:01 
 
 
Figure F2: Ramachandran plots of 3D-model structures of HLA-A*31:01 (A) and HLA-
B*15:02 (B) generated by RAMPAGE. 
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B) HLA-B*15:02 
 
 
Figure F2 (continued): Ramachandran plots of 3D-model structures of HLA-A*31:01 
(A) and HLA-B*15:02 (B) generated by RAMPAGE. 
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Table T1: Summary of monoclonal antibodies used in FACS analysis. 
Monoclonal 
antibody 
Fluorochrome Clone ID Supplier 
CD phenotyping 
anti-CD4 PE RPA-T4 BD Pharmingen 
anti-CD8 FITC HIT8a BD Pharmingen 
Intracellular cytokine staining assay 
anti-CD3 PerCP SP34-2 BD Pharmingen 
anti-CD4 APC-Cy7 RPA-T4 BD Pharmingen 
anti-TNF α PE-Cy7 MAb11 BD Pharmingen 
anti-IFN γ Pacific Blue 4S.B3 Biolegend 
anti-granzyme 
B 
Alexa Fluor 700 GB11 BD Pharmingen 
anti-IL 4 APC 8D4-8 eBioscience 
In vitro T-cell priming assay 
anti-CD14 FITC M5E2 BD Pharmingen 
anti-CD3 APC UCHT1 BD Pharmingen 
anti-CD25 PE 4E3 Miltenyi Biotech 
anti-CD45RA FITC HI100 BD Pharmingen 
anti-CD45RO Cy5 UCHL1 BD Pharmingen 
anti-CD4 FITC RPA-T4 BD Pharmingen 
anti-CD8 PE RPA-T8 BD Pharmingen 
APC= Allophycocyanin; Cy= cyanine; FITC= Fluorescein isocyanate; PE= 
Phosphatidylethanolamine; PerCP= Peridinin chlorophyll protein 
  
  Appendix 
183 
 
Table T2: List of primers used in TCR Vβ CDR3 spectratyping  analysis 
Sequence Name Sequence  (‘5-‘3) 
humTCR-VB1 CCG CAC AAC AGT TCC CTG ACT TGC 
humTCR-VB2 ACA TAC GAG CAA GGC GTC GA 
humTCR-VB3 CGC TTC TCC CTG ATT CTG GAG TCC 
humTCR-VB4 CAT CAG CCG CCC AAA CCT AA 
humTCR-VB5 GAT CAA AAC GAG AGG ACA GC 
humTCR-VB6 A GAT CCA ATT TCA GGT CAT ACT G 
humTCR-VB6 B CAG GGS CCA GAG TTT CTG AC 
humTCR-VB6 C CAG GGT TCA GAG GTT CTG AC 
humTCR-VB7 CAA GTC GCT TCT CAC CTG AAT GC 
humTCR-VB8 GGT ACA GAC AGA CCA TGA TGC 
humTCR-VB9 TTC CCT GGA GCT TGG TGA CTC TGC 
humTCR-VB11 GTC AAC AGT CTC CAG AAT AAG 
humTCR-VB12 TCC TCC TCA CTC TGG AGT C 
humTCR-VB13 A GGT ATC GAC AAG ACC CAG GCA 
humTCR-VB13 B AGG CTC ATC CAT TAT TCA AAT AC 
humTCR-VB14 GGG CTG GGC TTA AGG CAG ATC TAC  
humTCR-VB15 CAG GCA CAG GCT AAA TTC TCC CTG 
humTCR-VB16 GCC TGC AGA ACT GGA GGA TTC TGG 
humTCR-VB17 TGT GAC ATC GGC CCA AAA GAA 
humTCR-VB18 CAA AGA GGG CCC CAG CAT 
humTCR-VB20 TGC CCC AGA ATC TCT CAG CCT CCA 
humTCR-VB21 GGA GTA GAC TCC ACT CTC AAG 
humTCR-VB22 GAT CCG GTC CAC AAA GCT GG 
humTCR-VB23 ATT CTG AAC TGA ACA TGA GCT CCT 
humTCR-VB24 GAC ATC CGC TCA CCA GGC CTG 
  
humTCR-CB1 (use with TCR-VB 5, 6B/C, 20) GGG TGT GGG AGA TCT CTG C 
humTCR-CB2RO (run-off PCR) FAM-ACA CAG CGA CCT CGG GTG GG 
humTCR-CB3 CCT TTT GGG TGT GGG AGA TCT C 
 
 
  
 
1
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Table T3: Flow cytometric analysis of TCR Vβ usage on naïve and SMX-NO specific memory T-cells. 
 Day 0- % naïve T-cells  Day 11- % SMX-NO spec. memory T-cells 
TCR S1 S2 S3 S4 S5 S6 
Mean day0 
(exclud.S1) 
SD 
mean 
-3SD 
mean 
+3SD 
S1 S2 S3 S4 S5 S6 
Vb 1 4.06 4.66 3.96 4.28 3.69 3.76 4.07 0.40 2.87 5.27 6.40 3.17 1.28 1.82 1.93 5.59 
Vb 2 6.94 7.12 8.49 6.65 7.29 5.34 6.98 1.14 3.57 10.39 10.66 18.12 0.88 0.62 1.30 9.89 
Vb 3 4.19 0.67 0.43 10.64 4.60 6.39 4.55 4.26 -8.23 17.32 3.21 1.24 0.57 6.81 3.57 4.11 
Vb 4 0.94 0.21 0.07 0.09 0.53 0.03 0.18 0.20 -0.42 0.79 0.10 2.85 3.27 3.37 5.24 3.92 
Vb 5.1 11.67 4.53 8.54 6.82 6.88 4.44 6.24 1.75 1.01 11.48 9.15 5.34 0.86 0.41 0.30 3.32 
Vb 5.2 0.98 0.77 0.80 0.33 0.61 0.91 0.68 0.23 0.01 1.36 0.11 0.73 10.65 7.88 12.22 1.00 
Vb 5.3 2.08 0.78 0.26 0.21 0.40 0.77 0.48 0.27 -0.33 1.30 0.16 1.16 3.88 4.25 2.88 0.82 
Vb 7.1 3.47 2.91 1.95 1.04 2.59 1.62 2.02 0.75 -0.22 4.26 3.56 5.36 0.70 0.73 1.12 1.64 
Vb 7.2 0.90 2.53 0.60 0.06 0.35 0.03 0.71 1.04 -2.42 3.85 0.14 3.11 1.98 1.00 1.47 0.00 
Vb 8 1.17 3.55 1.76 2.34 1.92 3.52 2.62 0.86 0.03 5.21 3.02 3.72 5.00 3.89 3.30 3.74 
Vb 9 1.35 0.18 0.22 0.15 0.15 0.07 0.15 0.05 -0.01 0.32 0.43 3.84 3.45 4.47 6.85 2.27 
Vb 11 0.78 0.75 0.87 0.77 0.73 0.58 0.74 0.10 0.43 1.05 0.09 1.18 4.69 5.66 2.92 0.65 
Vb 12 1.08 1.17 1.64 1.32 1.22 0.68 1.21 0.34 0.18 2.24 1.20 1.52 1.78 2.32 1.61 1.10 
Vb 13.1 2.36 3.27 4.27 2.84 3.27 3.57 3.45 0.53 1.86 5.03 5.20 4.62 3.35 2.81 3.66 5.03 
Vb 13.2 1.49 3.91 2.34 0.97 1.73 0.60 1.91 1.31 -2.01 5.83 1.37 3.92 0.49 0.57 0.51 0.42 
Vb 13.6 1.88 1.57 1.62 1.29 1.79 1.61 1.58 0.18 1.03 2.13 1.02 1.45 6.02 2.75 2.93 2.59 
Vb 14 0.38 2.19 0.89 2.47 0.85 0.89 1.46 0.80 -0.95 3.86 3.66 6.05 4.83 6.59 5.44 3.70 
Vb 16 1.07 0.55 0.86 0.75 0.82 1.09 0.81 0.19 0.23 1.39 0.17 0.38 1.37 0.69 1.15 0.62 
Vb 17 1.76 6.90 3.45 6.20 6.44 4.68 5.54 1.43 1.24 9.83 2.03 8.00 1.64 1.91 1.06 4.97 
Vb 18 1.26 0.52 0.11 0.17 0.12 0.39 0.26 0.18 -0.28 0.81 0.31 0.49 10.40 7.89 8.05 1.02 
Vb 20 5.16 1.33 2.18 0.96 2.14 1.43 1.61 0.54 0.00 3.22 2.05 2.68 2.35 0.67 1.93 2.25 
Vb 21.3 1.86 1.63 2.54 2.67 2.46 1.82 2.22 0.47 0.82 3.63 1.10 1.72 1.55 1.69 1.93 1.70 
Vb 22 2.02 3.10 3.47 4.02 1.79 4.00 3.27 0.92 0.52 6.03 6.40 1.88 1.14 1.56 0.65 3.87 
Vb 23 1.72 0.79 0.67 0.29 0.57 1.30 0.72 0.37 -0.39 1.84 3.81 0.54 5.65 0.37 4.21 0.85 
total Vb 60.60 55.59 51.95 57.33 52.95 49.52        65.33 83.08 77.79 70.72 76.23 65.09 
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Table T4: CDR3 size distribution of TCR Vβ subtypes on naïve and SMX-NO specific memory T-cells. 
  S1   S2   S3   S4   S5   S6   
TCR Vβ Naive Memory Naive Memory Naive Memory Naive Memory Naive Memory Naive Memory 
1 P O P O P P P P P O P O 
2 X X X X P P S/P P X X X X 
3 P O X P P P X O P S P O 
4 X X X X X X X X X S S/P X 
5 O O P P P S P O P O P O 
6A P O O O S O P P P P P O 
6B/C P O P O S S P S/P P P P O 
7 P O P O P P O O P O P P 
8 O O O O P O O O S O O O 
9 P O P O P P P O P P S/P O 
11 O O O O O O O O S O S/O X 
12 P X P S/O P P S/P O P P S/P P 
13A P O P P P P S/P O P O S/P O 
13B O O O S/O P O P S/O P O P O 
14 O O P P P P P O O O P O 
15 P O P P P P P O P P P P 
16 O O P P P P O O P O P O 
17 O O O O P O O O S S P O 
18 P O P O P O P O P O P O 
20 P O O O P O P S/X P P S/X P 
21 S/P P S/O O P P X X X X X X 
22 P O O O P O P P P P P O 
23 S/P O S/O O P P S/O S/O S S P O 
24 O O O P P S O O O S P O 
P= polyclonal (Gaussian-like distribution, ≥ 5 peaks); O= oligoclonal (skewed Gaussian profile, at least 1 dominant peak); X= undetectable (fluorescence intensity of profile below 250); S= no 
sizing data (no spectratype profile shown) 
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Table T5: Correspondence between the nomenclatures of TCR Vβ monoclonal 
antibodies and TCR Vβ primers. 
TCR Vβ primers 
(Pannetier et al. 1998) 
IMGT nomenclature 
(Lefranc et al. 1999) 
TCR Vβ mAB 
(Wei, S. et al. 1994) 
1 9 1 
2 20 2 
3 28 3 
4 29 4 
5 5(1,3-8) 5.1, 5.2, 5.3 
6A 7(2-3) - 
6B/C 7(4,6,8,9) - 
7 4(1-3) 7.1, 7.2 
8 12(3-5) 8 
9 3(1-2) 9 
11 25 11 
12 10-3 12 
13A 6(1-3,5-9) 13.1, 13.2, 13.6 
13B 6-4 - 
14 27 14 
15 24-1 - 
16 14 16 
17 19 17 
18 18 18 
20 30 20 
21 11(1-3) 21.3 
22 2 22 
23 13 23 
24 15 - 
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